UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the fiscal year ended April 30, 2000
Commission File Number: 0-28666

AMERICAN BIO MEDICA CORPORATION
(Name of Small Business Issuer in its charter)

          New York                                     14-1702188
(State or other jurisdiction of             (IRS Employer Identification No.)
 incorporation or organization)

       122 Smith Road                                                 12106
   Kinderhook, New York                                             (Zip Code)
(Address of principal executive offices)

Issuer's telephone number (800) 227-1243

Securities registered pursuant to Section 12(b) of the Exchange Act: None

Securities registered pursuant to Section 12(g) of the Exchange Act: Common
Shares, $.01 par value per share

Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
[X] Yes [ ] No

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. [X]

State issuer's revenues for its most recent fiscal year. $7,653,000.

The aggregate market value of 11,559,444 voting Common Shares held by non-affiliates of the issuer was approximately $18,067,411 based on the last reported sale price of the issuer's Common Shares, $.01 par value, as reported on the Nasdaq SmallCap Market on July 12, 2000.

The Proxy Statement for the Annual Meeting of Shareholders for the 2001 Fiscal Year has been incorporated herein by reference to the extent indicated herein in Part III of this Form 10-KSB.

As of July 12, 2000, the issuer had outstanding 18,045,548 Common Shares, $.01 par value.

Traditional Small Business Disclosure Format: [ ] [X] No


PART I

ITEM 1. DESCRIPTION OF BUSINESS

Summary

American Bio Medica Corporation (the "Company") is primarily engaged in acquiring, developing, manufacturing and marketing biomedical technologies and products. The Company owns a technology, for which patents have been granted, for screening drugs of abuse, using the adopted trademark the "Rapid Drug Screen". The Company's common shares ("Common Shares") trade on the Nasdaq SmallCap Market under the trading symbol "ABMC".

The Company produces several versions of a drugs of abuse screening test, called the "Rapid Drug Screen" at its manufacturing facility in Columbia County, New York. The Rapid Drug Screen is a one-step test that allows a small urine sample to be tested for the presence or absence of up to nine drugs of abuse (cocaine, THC (marijuana), opiates, amphetamine, PCP, benzodiazepines, methamphetamine, barbiturates, and tricyclic antidepressants) simultaneously.

The competitively priced test is self-contained, thereby preventing exposure of the test administrator to the urine sample. In the opinion of the Company's management ("Management"), the Rapid Drug Screen, which requires no mixing of reagents, pipetting, or manipulation of the test, is easier to use than any other competitive product. In addition, hundreds of controlled tests conducted by independent laboratories compared the Rapid Drug Screen with results produced by EMIT II, a standard laboratory test, and found a 100% correlation of both positive and negative test results. As a result, Management believes that the Rapid Drug Screen is as accurate as that laboratory test.

Versions of the Rapid Drug Screen include two-two panel tests, three-three panel tests, two-five panel tests, an eight panel test, and a nine panel test. Additional versions of the Rapid Drug Screen can be produced by the Company, on special order, for any quantity (from two - nine) or configuration of drugs. The three, five, eight, and nine panel tests have received 510(k) clearance from the Federal Drug Administration (the "FDA") and can thus be sold in clinical as well as non-clinical markets. The Company has developed 10 tests trademarked "Rapid One", each of which detects one drug of abuse (cocaine, THC, opiates, amphetamine, PCP, benzodiazepines, methamphetamines, barbiturates, tricicyclic antidepressants, and methadone). The Company has received 510(k) clearance on the cocaine, THC, opiates, amphetamine, barbiturates, and benzodiazepine Rapid One tests.

In January 2000, the Company acquired the exclusive rights for distribution and marketing of a patented onsite drug detection system in North and South America. The Company has adopted the trademark the "Drug Detector" for this product. The Drug Detector tests for the presence or absence of residue on surfaces from marijuana, cocaine, heroin, or methamphetamines without the need for urine, hair, or saliva samples.


The Company owns a patented low cost method for producing keratin proteins. The Company has no intention of developing or marketing its keratin technology at this time, but intends to concentrate on the production and marketing of its drug screen tests and pursuing development and acquisition strategies related to onsite diagnostic testing markets. The Company may develop or acquire additional biomedical technologies or products in the future unrelated to substance abuse testing.

Since its inception to April 30, 2000, the Company has an accumulated deficit of $11,643,000 (see Financial Statements - Balance Sheet). Management believes that the Company's accumulated deficit is the result of the on-going development, marketing, and distribution of its Rapid Drug Screen test. During the year ended April 30, 2000, the Company sustained a net loss from operations of $2,136,000 and used net cash of $846,000 in operating activities. The Company is in the process of taking a number of steps to improve its financial prospects including focusing its efforts on sales of existing products, implementing certain cost reductions and production efficiencies and taking other measures to enhance profit margins.

Design

The Company has developed and markets its trademarked "Rapid Drug Screen" a test for one, two, three, five, eight, and nine drugs of abuse, which can be used in all situations where an immediate test result is required. The product consists of a credit-card size test card divided into two, three, five, eight, or nine lengthwise strips, or sections. The card contains an identification and date area. The person being tested urinates into a test cup, puts on the lid and hands it to the person administering the test. The test administrator inserts the card into a pre-punched slit in the lid without the danger of spilling, touching, or contaminating the urine specimen. Thus, the test administrator is not exposed to the urine sample nor does he or she have to mix reagents. Within five to eight minutes the results can be read on the inserted card through the side of the cup. A single line in the test area of the Rapid Drug Screen card indicates the sample is positive for the presence of tested drug(s) of abuse. A double line in the test area of the Rapid Drug Screen card indicates that the sample is negative for the presence of tested drug(s) of abuse.

The Company has designed two-two panel tests, three-three panel tests, two-five panel tests, an eight panel test, and a nine panel test and can produce, on special order or if a market demands, tests which can screen for any quantity (from two - nine) or configuration of drugs of abuse. The two-two panel tests, designed for the correction and education markets, screens only for cocaine and THC/methamphetamine and THC. The three-three panel tests, designed for various non-clinical markets, screens for THC, cocaine, and opiates/THC, cocaine, and amphetamine/THC, cocaine, and methamphetamine. The two-five panel tests, designed for the workplace (industry) market, screens for the "SAMHSA 5" ( SAMHSA stands for the Substance Abuse and Mental Health Services Administration); cocaine, THC, opiates, PCP, and amphetamine (the additional version of this test consists of methamphetamine replacing PCP). The Drug Free Workplace Act (the "Act"), designated drugs of abuse to be tested for in most federally regulated drug-testing programs. The eight panel test, designed for the clinical market; primarily to hospitals and physicians, includes the "SAMHSA
5 (listed above), benzodiazepines,

2

methamphetamine, and barbiturates. The nine panel test, also designed for the clinical market, includes all drugs of abuse from an eight panel in addition to tricyclic antidepressants (TCA). These additional tests are combined in a single card so that one sample can be tested simultaneously for nine drugs of abuse.

In July 1998, the Company began marketing the "Rapid One", a line of 10 drug tests, each of which screens for the presence or absence of a substance of abuse (cocaine, marijuana(THC), opiates, PCP, amphetamine, benzodiazepines, methamphetamine, barbiturates, tricyclic antidepressants (TCA), and methadone). Rapid One utilizes the same technology as the Rapid Drug Screen. It includes a single dip platform, and identification and date area, and does not require the use of pipettes or reagents. Rapid One is designed for correctional facilities and other markets where the person subject to substance abuse testing is known to abuse a specific drug. It can also be used to enhance a two, three, five, eight, nine panel, or any special order test, by means of allowing screening of an additional drug.

One of the problems which may occur in on-site drug testing is that of fraud or evasion practiced by the person being tested. The most prevalent method of avoiding adverse test results is the substitution, by the person being tested, of a hidden "clean" urine sample, which he or she brings to the test. As a consequence, each of the Company's drug screens contains a temperature sensor, which helps prevent the substitution of another urine sample. The premise is that the substituted sample would be of a lower temperature than a sample produced from the body on the spot. In addition, the Rapid Drug Screen contains a control line, designed to assure the test administrator that the test is working properly. Should the control line not appear, the administrator is instructed to void the test and re-test the individual by obtaining another urine sample. It is suggested, and sometimes mandated, that a positive result be confirmed by method of GC/MS (Gas chromatography/Mass spectrometry).

The Company markets the "Drug Detector", an on-site drug detection system which tests for the presence or absence of residue on surfaces from marijuana, crack/cocaine, heroin, or methamphetamines. The Drug Detector consists of an aerosol spray for either of the previously listed drugs, special collection papers, and instructions. The Company is currently marketing the retail (over-the-counter) version which contains enough collection papers to perform 10 tests. The Drug Detector for crack/cocaine and the Drug Detector for marijuana are the two versions being offered for sale initially in the over-the-counter market. The remaining two Drug Detector tests may be available for over-the-counter sale at a later date. It is the Company's intention to offer an "industrial" version of the product, which would contain collection papers to perform either 50 or 100 tests and a larger aerosol can. All four tests as mentioned above would be available in this industrial Drug Detector. The test can be performed with or without the knowledge of the person whom you believe has come in contact with the surface. The Company feels this is of great benefit in avoiding confrontation with a suspected drug abuser. You simply wipe the surface with the special collection paper and spray the collection paper with the aerosol can. Within seconds, a color change will occur if the presence of the drug is detected. No color change will occur if the drug is not detected.

3

"FDA" Approval

Although FDA clearance is not required for non-clinical markets (i.e. industry, corrections, etc.), it is required for clinical markets (i.e. hospitals, physicians, etc.), which Management anticipates will become a major marketplace for the Company's drug testing product(s). FDA 510(k) clearances have been granted for Company's three panel (cocaine, THC, and opiates), two five panels (cocaine, THC, opiates, amphetamines, PCP and cocaine, THC, opiates, amphetamines, methamphetamines), eight panel (cocaine, THC, opiates, amphetamines, methamphetamines, PCP, benzodiazepines, barbiturates), eight panel-low volume (eight panel as above requiring only 2 ml specimens), and nine panel (eight panel with tricyclic antidepressants (TCA) added). The Company has applied to the FDA for clearance of its Rapid One tests which, although they use the same methodology and chemistries as the Rapid Drug Screen, employ a different delivery device. The Company has received clearance on the THC, cocaine, opiates, amphetamines, barbiturates, and benzodiazepines Rapid One tests. The Company's Drug Detector does not require FDA approval for sale.

Patents and Trademarks

The Company, to date, has been granted six patents relating to the Rapid Drug Screen including a design patent on the multiple drug test card issued in January 1999 and a utility patent on the drug abuse test kit issued in November 1999. The Company has registered "ABM" and its logo in the United States, Canada, Chile, and Mexico and has registered "Rapid Drug Screen" in Mexico and Canada. The Company has additional trademark applications pending in the United States, Russia, Philippines, and in 15 European countries. The Company's trademark counsel, has opined that there are no similar marks and, as a consequence, the Company feels confident that such trademarks will be registered. The Company has applied for various additional patents directly in numerous countries, including the United States, Canada, Austria, Russia, Switzerland, Hong Kong, Australia, Argentina, Brazil, China, Japan, Germany, Mexico, Philippines, and Poland. Stan Cipkowski, Chairman of the Board of Directors, President and CEO, has assigned to the Company for no consideration, his application for a utility and design patent in the United States and Canada on the drug screen kit as an entity. The Company's patent counsel has opined that a search has revealed no competing patented products. However, there can be no assurance that patents will be granted or that, if granted, they will withstand challenge. (See "Risk Factors - Patents and Trademarks").

Research and Development

Research and Development ("R&D") efforts of the Company have been focused on methods to reduce the costs of the drug testing delivery system. A program of in-house strip manufacturing was embarked upon in Fiscal 1999. In Fiscal 2000, the Company continued to make a significant investment in this program. The Company currently manufactures nearly all of its required individual drug testing strips. In Fiscal 2000, a considerable effort and expense was also invested in development and production of the drug testing strip for tricyclic antidepressants ("TCA"). The Company's nine panel version of the Rapid Drug Screen includes this testing strip. This nine panel version is essential for the Company to achieve success in the clinical market. The Company is of the belief that it is one of very few companies who can offer

4

this product in the clinical market. Additionally, the Company's R&D efforts have been focused on enhancing strip performance thereby allowing the Company to offer, in its opinion, the most reliable on-site drugs of abuse test on the market today.

Sales and Marketing

The Company advertises through trade journals and direct mail campaigns, and its representatives attend trade shows. The Company sells primarily to distributors in the industrial market, which then resell in the various marketplaces and the Company sells directly in the over-the-counter market. The Company employs a Vice-President of Sales and Marketing, Director of Sales for Mexico and Latin America, National Sales Manager, OTC National Sales Manager, U.S. Marketing Manager, six regional sales managers, and additional sales and marketing support positions. In September of 1999, the Company closed a Sales and Marketing Office in Boca Raton, Florida and consolidated the Company's operations at its current facility in New York State.

The Company has divided its marketplace into the following categories:

Corporate/Industry

The Company has developed a nationwide network of distributors and administrators of workplace drug testing programs to sell its Rapid Drug Screen testing kit. The Company's National Sales Manager and its six regional sales managers oversee this market. The Company believes that the market for pre-employment and random/employee testing is immense and expanding. The economic and human costs of drug and alcohol use are astounding. In fact, the National Institute of Health reported that alcohol and drug abuse cost the economy $246 billion in 1992, the most recent year for which economic data is available. The number of businesses using drug testing to screen job applicants and employees has increased significantly in the last several years. According to the Drug Free Workplace Act, Congress found that 74% of adults who use illegal drugs are employed; absenteeism is 66% higher among drug users than those who do not use drugs; health benefit utilization is 300% higher among drug users; 47% of workplace accidents are drug-related; disciplinary actions are 90% higher among drug users; and employee turnover is significantly higher among drug users. According to a national survey conducted by the Hazelden Foundation, more than 60% of adults know people who have gone to work under the influence of drugs or alcohol. Most employers recognize not only the financial benefits of drug testing, but also realize a drug-free environment is also a safer one. Incentives encourage employers to adopt Drug Free Workplace Programs; they include, in some states, workman's compensation and unemployment insurance premium reductions; tax deductions; and other incentives. The Act requires employers receiving federal contracts of $100,000 or more (the Federal Acquisition Streamlining Act of 1994 (FASA) raised the threshold of contracts covered by the Drug-Free Workplace Act of 1988 from $25,000 to those exceeding $100,000) to enact a Drug Free Workplace Program.

The Company's Drug Detector is not yet available for sale in the Corporate/Industry market. The Company does intend to introduce the "industrial" Drug Detector in Fiscal 2001. (See "Description of Business - Design").

5

Government, Corrections, and Law Enforcement

This market includes federal, state, and county level agencies, including correctional facilities, pretrial agencies, probation, drug courts and parole departments at the federal and state levels, and juvenile correctional facilities. As of June 1998, there were more than 1.8 million inmates nationally: 1.2 million in state and federal prisons and 600,000 in local jails. In 1985, our incarceration rate was 313 per 100,000 population. In 1998, it was 645 per 100,000, which is three to 10 times higher than rates of the other modern democratic societies. The largest single factor contributing to this imprisonment wave is an eight-fold rise in drug arrests. In the Survey of Inmates in State Correctional Facilities conducted for the Bureau of Justice Statistics, it was found that rates of use among convicted inmates was substantially higher than the household population. This survey collected information on the use of drugs in the month prior to the offense for convicted inmates. Under the Uniform Crime Reporting System, the FBI maintains estimates of arrests for drug abuse violations. Arrests for drug abuse violations are at their highest levels ever for adults and juveniles. The Rapid Drug Screen is ideal for this use. The Company employs a Regional Sales Manager who has extensive experience in this market. In addition, the Company exhibits at the trade shows of the American Corrections Association and other related organizations. The Company has shipped orders to several agencies included in this market. The "industrial" Drug Detector would also be of use in this market and the Company intends to introduce the product in Fiscal 2001. (See "Description of Business - Design").

Rehabilitation Centers

This market for the Rapid Drug Screen includes people in treatment for substance abuse. This does not include rehabilitation centers that are affiliated with hospitals. The importance of this market relates to the high frequency of testing. For example, in many residence programs, patients are tested each time they leave the facility and each time they return. In outpatient programs, patients are generally tested on a weekly basis.

International Markets

The Company has entered into distribution agreements with companies in several countries and is pursuing a course of multinational distribution of its products through both clinical and non-clinical distribution companies. As of July, 2000, the Company has 24 distributors in 31 various countries throughout the world.

Clinics, Physicians, and Hospitals

The Company is actively pursuing the hospital and physician markets for its entire Rapid Drug Screen product line. In December 1998, the Company entered into a four-year, exclusive, worldwide distribution agreement with Abbott Laboratories (NYSE:ABT) to market the Rapid Drug Screen product line to hospitals, physicians, and occupational health clinics throughout the world. The Company had initially entered into a distribution agreement with Murex International Technologies Corp. ("Murex"). Abbott Laboratories acquired Murex in April 1998 and the Company negotiated with Abbott Laboratories to expand and extend the contract. In May 2000,

6

the distribution agreement between the Company and Abbott Laboratories was re-negotiated to a non-exclusive two year contract. The Company currently utilizes the services of a nationwide network of independent commissioned sales representatives to sell the nine panel Rapid Drug Screen. The Company believes that this market could yield a significant beneficial impact on its business. The Company does not feel the Drug Detector would be of use in this market and does not intend to actively market the product.

Consumer and Over-the-Counter ("OTC")

The Rapid Drug Screen product line is ideal for consumer use as it produces immediate and accurate results, is unrivaled for its ease-of-use, and its design is such that the person utilizing the product will not come in contact with the specimen. In September 1998, the FDA approved the class of on-site diagnostic kits for drugs of abuse. The Company submitted its application to the FDA for over-the-counter approval in May 2000. Its target for launching its retail product is the end of Fiscal 2001. However, there can be no assurance that such approval will be obtained. (See "Risk Factors - Possible Changes in Regulatory Framework")

In June 2000, the Company debuted its over-the-counter version of the Drug Detector at the National Association of Chain Drug Stores tradeshow. The Company is establishing the market framework for sales and intends to leverage these costs when the Rapid Drug Screen is available. It is the belief of the Company that the Drug Detector is ideal for use by consumers such as persons who are concerned about the welfare of their child/spouse and suspect drug abuse but who are hesitant to confront their child/spouse without just cause. The Drug Detector will allow them to obtain this just cause without confrontation, as the person being tested does not need to be present at the time of the test. The Company feels sales in this market could have a significant beneficial impact on its business

Educational Market

The Company believes that this is a potentially large market as testing becomes more prevalent in this area. It consists of the testing of student athletes, and in some states, all students involved in extra-curricular activities. Private schools can begin testing all of their students as an admission requirement. A 1995 Supreme Court decision in the case of Acton vs. Vernonia, in which the Justices voted 6 to 3 to overturn a lower court decision and allow testing of student athletes. Since that decision, the Seventh Circuit Court of Appeals made a decision enabling a Rush County School District to test not only student athletes but students involved in extra curricular activities as well. In this case, the Supreme Court refused to hear the appeal therefore allowing the lower court ruling to stand. These ground-breaking decisions have opened the door for all schools, both public and private, to enact drug testing programs within their schools.

The Company currently sells its Rapid Drug Screen to over 100 schools across the United States. The Company feels the Rapid Drug Screen could be an integral part of helping schools test due to its ease of use and immediate, accurate results. The Drug Detector would also be useful in this market and the Company intends to

7

introduce the "industrial" version of the Drug Detector into this market when available.

Additional Markets

The Company believes that the Department of Transportation ("DOT") could be a future market for its Rapid Drug Screen. Presently, the DOT market is not available to any on-site drug of abuse testing device. Law requires that anyone with a commercial driving license be randomly tested for use of drugs of abuse. Federal law requires that certified laboratories be used in these testing situations. The Company feels that the potential for this market is enormous when or if the law is changed. The Company actively pursues such change.

Competition

Competition to the Rapid Drug Screen comes from on-site tests developed by companies including, but not limited to, Roche Diagnostics, Medtox Scientific, Inc. and Biosite Diagnostics. In all cases that the Company is aware of, competitive products use a collection or delivery method different than the Rapid Drug Screen. Management believes the Rapid Drug Screen provides an easier option to the user. There is no pipetting of the specimen, adding or mixing of reagents, and no other manipulation of the device by the user. Other competitive products for the Rapid Drug Screen are on-site tests with platforms utilizing saliva instead of urine. It is the Company's opinion that such tests are limited in their use as the time frames in which drugs can be detected are much less than that of urine, which remains to be the industry standard.

Other available drug testing options, aside from on-site tests offering immediate results, include traditional laboratory testing where a urine sample is sent to a laboratory for analysis and hair testing where a hair sample is sent to a laboratory for analysis. These forms of drug testing are more expensive and take longer to produce results than the Rapid Drug Screen. (See "Risk Factors - Competition in the Drug Testing Market; Technological Obsolescence").

Manufacturing

In September 1999, the Company moved into a 30,000 square foot facility in Kinderhook, New York, which houses assembly and packaging of the Rapid Drug Screen and Drug Detector in addition to administration. The Company continues to contract out the printing and manufacture of specimen cup components of the Rapid Drug Screen. The Drug Detector components are not manufactured by the Company. Due to the unavailability of qualified technical personnel, the Company leased a laboratory facility in Bridgeport, New Jersey in August 1999. This facility houses research and development and bulk strip manufacturing. (See Item
2. Description of Property)

The Company's Plan of Operations

The Company intends to continue to establish a network of distributors, which service customers in the non-clinical markets (i.e. workplace/industry,

8

government/corrections/law enforcement, education, etc.) and to market its Rapid Drug Screen product line in the clinical market (i.e. hospitals, physicians, etc.) through Abbott Laboratories and a nationwide network of independent commissioned sales representatives. The Company intends to market the Rapid Drug Screen in the over-the-counter market (pending FDA approval), and to market its Drug Detector in both the over-the-counter market and non-clinical markets. It also intends to continue research and development on additional biomedical products.

The Company has entered into national and international non-exclusive, non-clinical market distribution agreements with a number of distributors. These agreements permit the distributors to sell the non-competitive products of other manufacturers and permits the Company to sell its test kits to other distributors within and outside the territory of each distributor. The agreements are cancelable by either the Company or the distributor upon 30 days written notice.

The Company has retained a Director of Sales for Latin America and Mexico, a National Sales Manager, six regional sales managers (in Florida, Pennsylvania, Wisconsin, Oregon, Europe, and Puerto Rico). These representatives call on non-clinical accounts, such as corporations, correctional facilities, directly and support the Company's worldwide distribution network. The Company intends to continue its direct mail campaign and its participation in national and regional trade shows.

The Company's present manufacturing equipment is sufficient to produce 200,000 drug test kits per month, assuming one shift per day, five days per week. The Company's facility in Kinderhook would allow it to increase its capacity for production when/if additional personnel were hired and equipment was installed assuming the same one shift per day, five days per week. The Company would expect to add additional assembly/packaging personnel and/or equipment when/if production needs of either or both the Rapid Drug Screen and Drug Detector increases. (See "Business - Manufacturing" and Item 2. Description of Property)

In Fiscal 2000, the Company completed its in-house strip manufacturing program to reduce costs and improve earnings. However, there can be no guarantee that the Company will be able to operate profitably. (See "Risk Factors - Limited Operations History")

Government Regulations

The development, testing, manufacture, and sale of the Company's Rapid Drug Screen and possible additional biomedical products are subject to regulation by the United States and foreign regulatory agencies. Pursuant to the Federal Food, Drug, and Cosmetic Act, and the regulations promulgated thereunder, the FDA regulates the pre-clinical and clinical testing, manufacture, labeling, distribution, and promotion of medical devices. If the Company fails to comply with applicable requirements it may be subject to fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, failure of the government to grant pre-market clearance or pre-market approval for devices, withdrawal of marketing clearances or approvals and criminal prosecution.

9

Risk Factors

Limited Operating History

Although the Company was formed in 1986, as far as the development, manufacture, and sale of drug testing kits are concerned, it has limited operational history upon which investors may base an evaluation of its performance of any assumption as to the likelihood that the Company will be profitable. (See " Business -- Summary and Company's Plan of Operations"). The Company's prospects must be considered in the light of the risks, expenses, delays, problems, and difficulties frequently encountered in the establishment of a business, the development and commercialization of products based on innovative technology and the competitive environment in which the Company operates. Since the Company's entry into the biomedical business, the Company has generated increased revenues. There can be no assurance that the Company will be able to generate continued increased revenues or achieve profitable operations. (See "Management's Discussion and Analysis of Financial Condition and Results of Operations" and Financial Statements.)

Technological Factors; Uncertainty of Product Development; Unproven Technology

Although the Company's development efforts relating to the technological aspects of the Rapid Drug Screen are completed, the Company is continually seeking to refine and improve its design and performance. The Company's efforts remain subject to all of the risks inherent in product development, including unanticipated technical, regulatory, or other problems which could result in material delays in product development or commercialization or significantly increase costs. The Company may be required to commit considerable additional efforts, time, and resources to develop production versions of additional products. The Company's success will depend upon such products meeting targeted product costs and performance, and may also depend upon their timely introduction into the marketplace. There can be no assurance that development of the Company's proposed products will be successfully completed on as timely basis, if at all, that they will meet projected price and performance objectives, satisfactorily perform all of the functions for which they are being designed, or prove to be sufficiently reliable in widespread commercial application. Moreover, there can be no assurance that unanticipated problems will not arise with respect to technologies incorporated into its test kits or that product defects will not become apparent after commercial introduction of its additional test kits. In the event that the Company is required to remedy defects in any of its products after commercial introduction, the costs to the Company could be significant, which could have a material adverse effect on the Company revenues or earnings.

Uncertainty of Continued Market Acceptance

The Company's Rapid Drug Screen product line and Rapid One have been well received by customers, including, but not limited to, industry, distributors and correctional institutions. Achieving continued market acceptance for its drug tests will require substantial marketing efforts and expenditure of significant funds to inform potential distributors and customers of the distinctive characteristics, benefits, and advantages of its test kits. There can be no assurance that its Rapid Drug Screen

10

product line and Rapid One will continue to be accepted or that the Company's efforts will result in successful product commercialization or continued market acceptance. The Company's Drug Detector has just recently been introduced into the over-the-counter market and its industrial version has yet to be launched. The Company has no history upon which to base market or customer acceptance of the product. Introduction of the Drug Detector will also require substantial marketing efforts and expenditure of funds. There can be no guarantee of such market acceptance in response to the Company's efforts. (See "Business - Sales and Marketing and Company's Plan of Operations")

Competition in the Drug Testing Market; Technological Obsolescence

The Company faces competition from other manufacturers of drug test kits. Some of its competitors are well known and have far greater financial resources than that of the Company. To the best of Management's knowledge, and in its opinion, no competitors have introduced products which equal the ease of use combined with the accuracy of the Company's Rapid Drug Screen product line and Rapid One. (See "Business - Competition"). The markets for drug test kits and related products are highly competitive. There can be no assurance that other companies will not attempt to develop or market competing products directly competitive with the Company's Rapid Drug Screen product line or Rapid One. Despite protections, which are available to the Company under its patents, the Company expects other companies to attempt to develop technologies or products which will compete with the Company's products. (See " Business - Competition and Patents and Trademarks")

Possible Inability to Find and Attract Qualified Personnel

The Company currently has sufficient management expertise and depth to develop its business. However, it will need additional skilled, technical and production personnel in the near future. There is no guarantee that the Company can retain its present staff or that capable personnel with relevant skills will be available. (See Item 9. and "Business - Manufacturing")

Dependence on Management

The Company is dependent on the expertise and experience of Stan Cipkowski, President and CEO, Jay Bendis, Vice President Sales and Marketing, and Douglas Casterlin, Vice President Operations for its operations. The loss of Messrs. Cipkowski, Bendis, and/or Casterlin, will seriously inhibit the Company's operations. The Company does not maintain key man insurance for any of its management employees. (See Item 9).

Possible Adverse Changes in Regulatory Framework

Approval from the FDA is not required for the sale of the Rapid Drug Screen in the non-clinical market, but it is required for the clinical and over-the-counter markets. The Company has received 510(k) clearances from the FDA for its three, five, eight, and nine panels of the Rapid Drug Screen and six of its ten Rapid One tests. The Company has submitted its application to the FDA for over-the-counter approval of the Rapid Drug Screen. However, regulatory standards may change in the future

11

and there is no assurance that if and when the Company applies for additional approvals from the FDA they will be granted. FDA approval is not required for the Drug Detector. (See "Business - FDA Approval and Government Regulations")

Patents and Trademarks

The Company to date has been granted six patents relating to its Rapid Drug Screen. The Company has applied for additional patents on its Rapid Drug Screen and for certain trademarks in the United States, South and Central America, European Common Market, and Japan. Certain trademarks have been registered and others are pending (See "Business - Patent and Trademarks"). Although its patent/trademark counsel has opined that there are no competing designs or marks, there is no assurance that the additional patents will be granted or that additional trademarks will be registered. (See "Business - Patent and Trademarks" and "Risks -Competition in the Drug Testing Market")

Protection of Intellectual Property Rights

The Company's success depends in part on its ability to maintain and enforce its patents and other proprietary rights. The Company relies on a combination of patents, trademarks, trade secrets, know-how and confidentiality agreements to protect the proprietary aspects of its technology. These measures afford only limited protection and competitors may gain access to the Company's intellectual property and proprietary information. The patent positions of biomedical product companies are generally uncertain and involve complex legal and technical issues. Litigation may be necessary to enforce the Company's intellectual property rights, to protect its trade secrets and to determine the validity and scope of its proprietary rights. Any litigation could be costly and divert the Company's attention from the growth of the business. (See "Item 3. Legal Proceedings"). The Company cannot assure investors that its patents and other proprietary rights will not be successfully challenged, or that others will not independently develop substantially equivalent information and technology or otherwise gain access to the Company's proprietary technology. The Company may be sued by third parties which claim that the Company's products infringe on their intellectual property rights.

Dilution as a Result of Potential Issuance and Exercise of New Warrants and Exercise of Outstanding Warrants

As part of the sale by the Company of 1,408,450 Common Shares for $2,000,000 ($1.41 per share) in a private placement to Seaside Partners, LLC ("Seaside") on April 28, 2000, the Company agreed under certain circumstances to issue a five-year warrant to Seaside (the "Seaside Warrant") to purchase up to 1,877,934 Common Shares. The specific number of Common Shares, if any, to be subject to the Seaside Warrant will be determined pursuant to a formula based partially on the average of the closing prices of the Common Shares on the Nasdaq SmallCap Market as reported by the Nasdaq Stock Market on the 10 consecutive trading days immediately preceding the date of the six-month anniversary of the closing date (the "Anniversary Date") of the Seaside private placement (the "Anniversary Price"). If the Anniversary Price is $2.13 or more per share, the Company will not be obligated to issue the Seaside Warrant. If the Anniversary Price is less than

12

$2.13 per share, the specific number of Common Shares to be subject to the Seaside Warrant will be determined pursuant to the formula based partially on the Anniversary Price. The exercise price per share for the Common Shares subject to the Seaside Warrant will be the Anniversary Price. For example, if the Anniversary Price is $1.25 per share, 872,535 Common Shares would be subject to the Seaside Warrant with an exercise price of $1.25 per share.

As of July 12, 2000, the Company also had warrants outstanding to purchase 107,355 Common Shares at a price of $4.81 per share (the "Outstanding Warrants").

The issuance and exercise of the Seaside Warrant and the sale of such Common Shares and/or the exercise of the Outstanding Warrants and the sale of such Common Shares could have a significant negative impact on the market price of the Common Shares and could materially impair the Company's ability to raise capital through the future sale of equity securities.

Resale of Restricted Securities

7,426,455 Common Shares presently issued and outstanding as of the date hereof are "restricted securities" as that term is defined under the Securities Act of 1933, as amended, (the "Securities Act") and in the future may be sold in compliance with Rule 144 of the Securities Act, or pursuant to a Registration Statement filed under the Securities Act. Rule 144 provides, in essence, that a person holding restricted securities for a period of one year or more may sell those securities in unsolicited brokerage transactions or in transactions with a market maker, in an amount equal to one percent of the Company's outstanding Common Shares every three months. Sales of unrestricted shares by affiliates of the Company are also subject to the same limitation upon the number of shares that may be sold in any three month period. Such information is deemed available if the issuer satisfies the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 (the "Securities Exchange Act") or of Rule 15c2-11 thereunder. Rule 144(k) also permits the termination of certain restrictions on sales of restricted securities by persons who are not affiliates of the Company at the time of the sale and have not been affiliates in the preceding three months. Such persons must satisfy a two-year holding period. There is no limitation on such sales and there is no requirement regarding adequate current public information. Investors should be aware that sales under Rule 144 or 144(k), or pursuant to a registration statement filed under the Act, may have a depressive act on the market price of the Company's securities in any market which may develop for such shares.

Preferred Shares

The Company has the authority to issue up to 5,000,000 Preferred Shares with such designations, rights, and preferences as may be determined by the Board of Directors. The Company is empowered, without further shareholder approval, to issue Preferred Shares with dividend, liquidation, conversion, voting or other rights which could adversely affect the voting power or other rights of the holders of Common Shares. No Preferred Shares were outstanding as of July 12, 2000.

13

Need for Additional Financing

The Company expects that its cash on hand will be sufficient to fund the Company's proposed operations for at least 12 months. This estimate is based on certain assumptions and there can be no assurance that unanticipated un-budgeted costs will not be incurred. Future events, including the problems, delays, expenses, and difficulties which may be encountered in establishing and maintaining a substantial market for the Company's Rapid Drug Screen product line and Rapid One could make cash on hand insufficient to fund the Company's proposed operations. There can be no assurance that the Company will be able to obtain any necessary additional financing on terms acceptable to it, if at all. In addition, financing may result in further dilution to the Company's then existing shareholders. The Company has no established borrowing arrangements or available lines of credit. (See "Management's Discussion and Analysis of Financial Condition and Results of Operations")

No Dividends

The payment of dividends rests within the discretion of the Company's Board of Directors. No dividends have been paid on the Common Shares and the Company does not anticipate the payment of cash dividends in the foreseeable future. If the operations of the Company become profitable, it is anticipated that, for the foreseeable future, any income received therefrom would be devoted to the Company's future operations and that cash dividends would not be paid to the Company's shareholders.

Ability to Retain and Attract Market Makers

The Common Shares trade on the Nasdaq SmallCap Market under the symbol "ABMC". In the event that the market makers cease to function as such, public trading in the Company's Common Shares will be adversely affected or may cease entirely. Presently, market makers for the Company's Common Shares include Knight Securities L.P., Herzog, Heine & Geduld, Inc., M.H. Meyerson & Co., Hill, Thompson. Magid, & Co., J.W. Genesis Clearing Corp., Sharpe Capital Inc., Brean Murray Foster Securities Inc., Wein Securities Corp., Schwab Capital Markets, and Wien Securities Group.

Anti-Takeover Provision in Certificate of Incorporation

The Company's certificate of incorporation authorizes the issuance of 5,000,000 Preferred Shares. The Board of Directors has the authority, without further action by the Common Shareholders, to issue Preferred Shares from time to time in one or more classes or series, to fix the number of shares constituting any class or series and the stated value thereof, if different from the par value, and to fix the terms of any such series or class, including dividend right, dividend rates, conversion or exchange rights, voting rights, rights and terms of redemption (including sinking fund provisions), the redemption price and the liquidation preference of such class or series. Thus, the Board of Directors, in order to avoid a hostile takeover, could issue Preferred Shares with super-voting rights, conversion rights into Common Shares, liquidation or a combination of rights and preferences which could inhibit success of such attempt.

14

No Assurance of Continued Public Market for Common Shares

Although the Common Shares trade on the Nasdaq SmallCap Market, there is no assurance that an active trading market will be sustained.

ITEM 2. DESCRIPTION OF PROPERTY

In September 1999, the Company re-located to a new 30,000 square foot facility in Kinderhook, New York. This new facility houses administrative offices, assembly and packaging, quality control/quality assurance, and sales and marketing (See "Business - Sales and Marketing"). The Company has entered into a Lease/Purchase Agreement with a non-affiliate. The purchase of the building is contingent upon a permanent zoning change that the Company is confident it will receive from the town. However, there can be no guarantee that this permanent zoning change will occur. In such case, the Company will lease the facility through December, 2001. At that time, the lease would be required to be re-negotiated.

In August 1999, the Company began leasing a 3,900 square foot laboratory facility in Bridgeport, New Jersey. This facility is leased for a period of three years at which time the Company has the option to re-new the lease. (See " Manufacturing")

ITEM 3. LEGAL PROCEEDINGS

"Patent, Trademark, and Unfair Competition Litigation"

On January 26, 1999, the Company was granted a U.S. Patent for the design of the Multiple Test Card, known as the Rapid Drug Screen. On April 7, 1999, the Company filed suit in the federal court in Delaware against Phamatech, Inc. of California. Phamatech, Inc. of California was a former supplier of the Company and in that capacity acquired proprietary information on the Company's Rapid Drug Screen that it used to "knock off" the Company's product. This case was transferred from Delaware to California. In July 2000, the California Court granted ABMC's motion to add Tuan Pham, President of Phamatech, as an individual defendant in the suit. The Court also ordered that Wolfe & Associates (aka Wolfe Data) and James Wolfe, Elite Health Services, LLC and John Polanco (former distributors now selling the alleged infringing product) be joined as defendants. Peninsula Drug Analysis Co., Inc. and James Ramsey (former distributor selling a private label knock off believed by the Company to be manufactured by Phamatech), and Dipro Diagnostics of North America (another party selling the private label knock off (believed to be manufactured by Phamatech) are already parties. The Company is alleging patent infringement, violation of trademark rights, and unfair competition against all parties.

On April 8, 1999, one day after the Company filed its Delaware suit, Phamatech, Inc. filed suit in the federal court in San Diego, California asking for a declaration that the Company's patent is invalid. It also claimed breach of contract damages for an alleged non-payment of invoices by the Company. The Company's transferred Delaware case and Phamatech's California case have been placed on the same trial docket in San Diego. By Order dated July 24, 2000, the Court ordered the competing California based suits be consolidated in one case. In a recent motion, Phamatech sought summary judgment on its declaratory judgment on the Company's

15

patent claims. The trial court denied the motion declaring that the designs "are visually similar....", and "[t]he accused device [is] visually similar to the design patent." The opinion states: "Simply, visually comparing the design patent and the accused devices, they appear substantially similar." Opinion of June 7, 2000 @ p.12. Since the ABMC trademark had not been registered, even though the petition for trademark is on appeal within the United States Patent and Trademark Office ("PTO"), the trial court denied the Company's trademark claim. However, the Court did not deal with the Company's trade dress claim. Phamatech has now moved for partial summary judgment on ABMC's trade dress claim even though ABMC's application for trademark protection of its trade dress is still pending before the examiner at the PTO.

In October 1999, the Company sued Larry Hartselle, Drug Detection Devices, and Gulf Supply for patent infringement, trademark dilution, and unfair competition. It is alleged that they are also selling the Phamatech knock off. Drug Detection Devices is alleged to be selling yet another private label manufactured by Phamatech. Larry Hartselle d/b/a Instant Drug Detection is a former distributor who was selling the Phamatech knock-off. Gulf Supply is alleged to be selling the private label knock off sold by Drug Detection Devices. The claims against Hartselle and 3DL have been settled by the parties. The terms are confidential. By the time of release of this report, an injunction is anticipated to have been entered against Hartselle prohibiting further infringement by him. The remaining defendant is engaged in settlement negotiations with the Company.

"Friedenberg-related Litigation"

In February 1994, Robert Friedenberg, as former owner of the two medical technology companies, MDI and Gendex, acquired by the Company, in the name of these corporations, filed for a declaratory judgment in Maryland that a Share Exchange Agreement had been rescinded. In order to make a claim for damages, the Company filed a third-party claim against Dr. Friedenberg for breach of the Share Exchange Agreement and fraud. In November 1995, after a trial, the court denied Dr. Friedenberg's request for a declaration of rescission and allowed the Company's third-party claim to proceed to trial. In September 1996, Dr. Friedenberg died.

The Company's third party claim was decided by a jury on May 5, 1997. The verdict determined that Dr. Friedenberg breached the Share Exchange Agreement when he failed to deliver drug screening know how technology to the Company. The jury also found in favor of the Company on two of three fraud claims against Dr. Friedenberg and awarded the Company approximately $321,000 in damages. Dr. Friedenberg's estate, just prior to the jury trial, filed a supplemental claim for the shares of the Company which he would have received under the Share Exchange Agreement. The trial judge on July 17, 1998, ruled that the estate of Dr. Friedenberg was entitled to 5,907,154 common shares of the Company. The Company appealed that ruling and on September 15, 1999, the Court of Special Appeals in Maryland ruled in favor of the Company and reversed a Maryland circuit court's ruling that the estate of Dr. Robert Friedenberg was entitled to 5,907,154 common shares of the Company. The case was remanded to the circuit court with directions to enter a judgment for the Company. The Friedenberg estate petitioned the Court of Appeals, Maryland's highest court, to consider the case. The Company opposed any further proceeding.

16

On December 21, 1999, the Court of Appeals denied the Friedenberg estate's petition to review the decision of the Court of Special Appeals.

In June 1995, the Company filed a lawsuit against Jackson Morris, the lawyer who was in charge of drafting and advising it on the Share Exchange Agreement. Mr. Morris, who had been recommended to the Company by Dr. Robert Friedenberg and whose fees were paid by the Company, is alleged to have breached his fiduciary duty to the Company in several ways, including by later advising Dr. Friedenberg, individually, on how to rescind the Share Exchange Agreement as well as testifying for Dr. Friedenberg over the Company's objections and in violation of this obligations to the Company. Mr. Morris is also charged with negligence in drafting the Share Exchange Agreement. The Company's lawsuit demands damages in the amount of $1,000,000. Mr. Morris has counterclaimed as a party to the Share Exchange Agreement and seeks common shares. Whatever claim Mr. Morris has comes from the Friedenberg claim. No trial date has been set. The Company is vigorously contesting the Morris claim.

In June 1999, an individual, Richard Davidson, filed suit in New York claiming that two placement memoranda dated respectively September 15, 1992 and February 5, 1993, obligated the Company to issue him 1,555,601 common shares of the Company. The claim is that he is entitled to the common shares in consideration of brokering the acquisitions subject to the Share Exchange Agreement with Dr. Robert Friedenberg. In addition, the individual is claiming a finder's fee of five percent of the funds raised by the September 1992 private placement. He alleges that a sum of one million dollars was raised. Finally, he claims that he is entitled to a consulting fee of $24,000. Management denies the claims and is vigorously contesting the suit. It is scheduled for a jury trial in the fourth calendar quarter of 2000.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

PART II

ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

The table below sets forth the range of high and low sale prices for the fiscal years 1999 and 2000 on the Nasdaq SmallCap Market. As of July 12, 2000 there were approximately 4,000 holders of Common Shares.

Fiscal Year Ending April 30, 2000            High          Low
---------------------------------            ----          ---

     Fourth Quarter                          $4.25         $1.31
     Third Quarter                           $2.50         $1.06
     Second Quarter                          $2.25         $1.25
     First Quarter                           $1.96         $1.25

17

Fiscal Year Ending April 30, 1999            High          Low
---------------------------------            ----          ---

     Fourth Quarter                          $1.87         $1.75
     Third Quarter                           $2.87         $2.75
     Second Quarter                          $3.00         $2.62
     First Quarter                           $3.53         $3.31

As of July 12, 2000 there were outstanding 18,045,548 Common Shares. The Company has not declared any dividends on the Common Shares and does not expect to do so in the foreseeable future.

ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that except for the description of historical facts contained herein, this Form 10-KSB contains certain forward-looking statements that involve risks and uncertainties as detailed herein and from time to time in the Company's filings with the Securities and Exchange Commission and elsewhere. Such statements are based on Management's current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. These factors include, among others: (a) the Company's fluctuations in sales and operating results, risks associated with international operations and regulatory, competitive and contractual risks and product development; (b) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; and (c) acquisitions.

RESULTS OF OPERATIONS FOR THE FISCAL YEAR ENDED APRIL 30, 2000 (THE "2000 FISCAL YEAR") COMPARED TO THE FISCAL YEAR ENDED APRIL 30, 1999 (THE "1999 FISCAL YEAR")

Net sales were $7,653,000 for the 2000 Fiscal Year as compared to $7,038,000 for the 1999 Fiscal Year, representing an increase of $615,000 or 8.7%. During the 2000 Fiscal Year, the Company continued its extensive program to market and distribute its primary product, the Rapid Drug Screen((TM)). The Company believes that sales from drug test kits will continue to grow steadily.

Cost of goods sold for the 2000 Fiscal Year was $3,602,000 or 47.1% of net sales as compared to $3,356,000 or 47.7% of net sales for the 1999 Fiscal Year. Based on the extensive cost reduction program aimed specifically at its in-place production process undertaken by the Company and the commencement of its in-house manufacturing of drug test strips, the Company believes that it can continue to decrease the cost of goods sold as a percentage of net sales.

18

Although net sales of drug test kits in the 2000 Fiscal Year increased 17.8% compared to the 1999 Fiscal Year, the 2000 Fiscal Year percentage increase in net sales was significantly less than the 226.4% increase in the 1999 Fiscal Year compared to the 1998 Fiscal Year. Management believes that the Company's net sales were significantly impacted by the production and sale of a "knock-off" product by a former supplier. Certain of the Company's former distributors also began selling the knock-off product in the 2000 Fiscal Year. The Company has filed a lawsuit against the former supplier and certain of the former distributors alleging patent infringement, trademark dilution and unfair competition. As of July 31, 2000, the Company has settled the claims against two former distributors and is in the final stages of settlement negotiations with a third former distributor. See "Item 3. Legal Proceedings". Management believes that as the Company successfully settles these lawsuits or the courts rule in favor of the Company following the trial of these lawsuits, the Company's net sales will significantly increase.

While revenues increased 8.7% in the 2000 Fiscal Year, selling, general and administrative costs increased $183,000 or 3.6% to $5,223,000 for the 2000 Fiscal Year compared to $5,040,000 for the 1999 Fiscal Year.

The following table sets forth the percentage relationship of selling, general and administrative costs to net sales for both years:

                                                   2000           Percent           1999           Percent
                                                Fiscal Year       of Sales       Fiscal Year      of Sales
                                                -----------       --------       -----------      --------
Sales salaries and commissions                    $1,033,000        13.5%          $1,047,000        14.9%
Sales travel                                         439,000         5.7              496,000         7.0
Consulting and other selling
 expenses                                            936,000        12.2              441,000         6.3
Marketing and promotion                              265,000         3.5              883,000        12.5
Investor relations costs                             225,000         3.0              138,000         2.0
Legal fees                                           951,000        12.4              489,000         6.9
Accounting fees                                       80,000         1.1               81,000         1.2
Office salaries                                      667,000         8.7              507,000         7.2
Payroll taxes and insurance                          174,000         2.3              187,000         2.7
Telephone                                            139,000         1.8              100,000         1.4
Insurance                                             49,000         0.6               43,000         0.6
Bad debts                                             79,000         1.0               13,000         0.2
Other administrative costs                           186,000         2.4              615,000         8.7
                                                 -----------       ------     -------------          ------
Total selling, general and administrative         $5,223,000        68.2%          $5,040,000        71.6%
costs

Management believes that the amount of selling, general and administrative costs will increase as the Company continues to create the necessary infrastructure to meet the Company's worldwide drug test marketing and production goals. These costs will also increase as the Company increases its marketing efforts relating to over-the-counter sales of the Drug Detector and increases its direct selling efforts in connection with all of the Company's products. As a result of increasing sales, the Company expects selling, general and administrative costs to continue to decline as a percentage of net sales

19

As a result of relocating its marketing department to New York, marketing and promotion costs (included in selling, general and administrative costs) decreased $618,000 or 8.1% of net sales to $265,000 for the 2000 Fiscal Year compared to $883,000 for the 1999 Fiscal Year.

Legal fees for the 2000 Fiscal Year were $951,000 or 12.4% of net sales, an increase of $462,000 compared to legal fees of $489,000 or 6.9% of net sales for the 1999 Fiscal Year. This increase in legal fees is primarily due to the substantial legal fees incurred in connection with the lawsuits filed against a former supplier and certain former distributors in connection with the production and sale of a knock-off product. Management believes that the Company's successful prosecution of these lawsuits will result in a significant increase in the Company's sales revenue.

During the 2000 Fiscal Year, the Company issued 300,000 Common Shares and granted options to purchase 297,250 Common Shares as compensation for consulting and professional services resulting in a non-cash compensation charge of $367,000 or 4.8% of net sales. The non-cash compensation charge incurred in the 1999 Fiscal Year was $91,000.

Research and development expenses for the 2000 Fiscal Year were $799,000 compared to $336,000 for the 1999 Fiscal Year. This increase represents a continuation of the Company's efforts to develop improved methods to reduce the cost of manufacturing its drug test kits and to develop and produce the drug testing strip for TCA included in the Company's nine panel version of the Rapid Drug Screen.

Net loss from operations increased to $(2,136,000) for the 2000 Fiscal Year compared to $(1,691,000) for the 1999 Fiscal Year.

LIQUIDITY AND CAPITAL RESOURCES AS OF APRIL 30, 2000

The Company had working capital of $2,016,000 at April 30, 2000 as compared to working capital of $2,387,000 at April 30, 1999. The Company has historically satisfied its working capital requirements principally through proceeds from private placements of equity securities with institutional investors. The Company has never paid any dividends on its Common Shares. The Company anticipates that all future earnings, if any, will be retained for use in the Company's business and it does not anticipate paying any cash dividends.

Net cash used in operating activities was $846,000 for the 2000 Fiscal Year compared to net cash used in operating activities of $2,008,000 for the 1999 Fiscal Year. The net cash used in operating activities in the 2000 Fiscal Year was primarily due to the net loss of $2,136,000 offset by a reduction of inventory of $356,000, issuance of compensatory stock and stock options of $367,000 and an increase in accounts payable and accrued expenses of $535,000. The net cash used in operating activities in the 1999 Fiscal Year was primarily due to the net loss of $1,691,000 and increases in accounts receivable and inventory of $339,000 and $843,000 respectively, offset by an increase in accounts payable and accrued expenses of $663,000.

20

Net cash provided by investing activities was $64,000 for the 2000 Fiscal Year compared to net cash used in investing activities of $1,092,000 for the 1999 Fiscal Year. The net cash provided from investing activities for the 2000 Fiscal Year was primarily due to sales and maturity of investments of $571,000 offset by a purchase of investments of $73,000, a $280,000 loan to BioSys, Inc. and purchases of plant, property and equipment of $145,000. The net cash used in investing activities in the 1999 Fiscal Year was primarily due to a purchase of investments of $1,812,000 offset by sales and maturities of investments of $969,000.

Net cash provided by financing activities was $1,858,000 for the 2000 Fiscal Year compared to net cash used in financing activities of $8,000 for the 1999 Fiscal Year. The net cash provided by financing activities in the 2000 Fiscal Year was primarily due to the sale by the Company of 1,408,405 Common Shares for $2,000,000 in a private placement to Seaside Partners, LLC on April 28, 2000 offset by repayment of note payable to stockholder of $130,000.

At April 30, 2000 the Company had cash and cash equivalents of $1,207,000.

The Company's primary short-term needs are to increase its manufacturing and production capabilities, decrease current inventory levels and continue to support its research and development programs, finance its patent infringement litigation and to increase its direct sales force. The Company currently plans to expend approximately $100,000 for the expansion and development of its manufacturing facilities in addition to its marketing and general administrative programs.

The Company expects its capital requirements to increase over the next several years as it expands its research and development efforts, sales and administration infrastructure, manufacturing capabilities and facilities and, if the required contingencies are resolved purchases the Kinderhook, New York facility. The Company's future liquidity and capital funding requirements will depend on numerous factors, including the extent to which the Company's products under development are successfully developed and gain market acceptance, the timing of regulatory actions regarding the Company's potential products, the costs and timing of expansion of sales, marketing and manufacturing activities, facilities expansion needs, procurement and enforcement of patents important to the Company's business, results of clinical investigations and competition.

The Company believes that its available cash and cash from operations will be sufficient to satisfy its funding needs through April 30, 2001. Thereafter, if cash generated from operations is insufficient to satisfy the Company's working capital and capital expenditure requirements, the Company may be required to sell additional equity or debt securities or obtain additional credit facilities. There can be no assurance that such financing, if required, will be available on satisfactory terms, if at all.

ITEM 7. FINANCIAL STATEMENTS.

The Company's Financial Statements are set forth beginning on page F-1.

21

ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

PART III

ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS, AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT

Directors, Executive Officers, and Senior Officers

The following sets forth the names of the Company's directors, executive officers, and senior officers. Directors of the Company are elected annually by the shareholders and the officers are appointed annually by the Board of Directors. Karen Russo resigned from the Board of Directors in April 2000 due to schedule conflicts and John Murray, the Company's CFO, resigned from the Board of Directors in May 2000 in an effort to increase the number of independent directors. Robert Aromando and Denis O'Donnell, M.D. were appointed by the Board to fill those vacancies.

Name                                    Age        Position                                          Since
----                                    ---        --------                                          -----
Stan Cipkowski                          52         Chairman of the Board of Directors, President     1986
                                                   and Chief Executive Officer
Edmund Jaskiewicz                       77         Secretary                                         1992
Jay Bendis                              53         Vice President-Sales and Marketing,  Director     1995
John F. Murray                          56         Chief Financial Officer                           1997
Douglas Casterlin                       53         Vice President-Operations                         1997
Robert Aromando                         44         Director                                          2000
Gerald Moore                            62         Director                                          1999
Denis O'Donnell, M.D.                   46         Director                                          2000
Henry J. Wells, Ph.D.                   68         Vice President-Scientific Development             1995
Martin Gould                            49         Vice President-Technology                         1998

Stan Cipkowski founded the predecessor of the Company in 1982 and has been an executive officer and director of the Company since its incorporation in April 1986. From 1982 to 1986, he was sole proprietor of American Micro Media, the predecessor, which was acquired by the Company. In addition, from 1983 to 1987, Mr. Cipkowski was a general partner of Florida Micro Media, a Fort Lauderdale-based marketer of educational software and was a principal shareholder and Chief Financial Officer of Southeast Communications Group, Inc., a publisher of direct response media. In 1982, he was a consultant to Dialogue Systems, Inc., a New York-based developer of training and communications materials, where he served as Vice-President of Sales and Marketing. From 1977 to 1982, he was employed by Prentice-Hall Publishing

22

Company, reaching the position of National Sales Manager. Prior to 1977 he was employed as an accountant for the New Seabury Corporation and as Mid-West Area Manager for the Howard Johnson Company.

Edmund Jaskiewicz is a lawyer-engineer. He has practiced international patent and corporate law as a sole practitioner since 1963 and served as Chairman of the Board of Directors from 1992 until 1999. He currently serves as Secretary of the Company. From 1953 to 1963, Mr. Jaskiewicz was associated with Toulmin and Toulmin, Attorneys-at-Law, Washington, D.C. From 1960 to 1962, he resided in Frankfurt, Germany managing that firm's local office. From 1952 to 1953 he was with the Patent Section of the Bureau of Ordinance of the Department of the Navy working on patent infringement and licensing matters. He received his J.D. in 1952 from George Washington University Law School and his B.S. in Engineering from the University of Connecticut in 1947.

Jay Bendis was an independent consultant to biomedical companies from 1990 until 1995, specializing in commercializing new concept products in both domestic and international markets. From 1990 to 1992, he was a principal and served as Vice-President of Sales and Marketing for Scientific Imaging Instruments. From 1985 to 1990, Mr. Bendis served as National Sales Manager of the XANAR Laser Corp., a division of Johnson & Johnson, where he directed its national sales force and developed its marketing strategy for integrating high power lasers into the hospital market. From 1979 to 1984, he was the Eastern Area Sales and Marketing Manager for the IVAC Corp., a division of Eli Lilly. Prior to 1979, Mr. Bendis held sales management positions with Xerox Corporation and A.M. International. Mr. Bendis earned his B.A. in Marketing/Management from Kent State University and is currently a member of the Edison BioTechnology Center Advisory Council for the State of Ohio.

John F. Murray served as Chief Financial Officer of Federal Supply, Inc., Pompano Beach, Florida from April, 1994 to 1998. From 1988 to 1994, Mr. Murray served as Controller for Bio Therapeutics, Inc., Woodbridge, New Jersey. He also was Controller of Shortline, a group of transportation companies, from 1982 to 1988 and, from 1974 to 1982, of Kleber Tire & Rubber Corp. Mr. Murray was Director of Accounting for Western Union Telegraph Company from 1972 to 1974 and Senior Accountant for S.D. Leidesdorf & Co (now Ernst & Young) from 1969 to 1972. Mr. Murray received his B.B.A. in Accounting from the Baruch School of the City University of New York in 1968 and became a Certified Public Accountant in the State of New York in 1974.

Douglas Casterlin was General Manager of Coarc, Inc., the Company's product assembling, packaging and shipping contractor, from 1979 to 1997. In that capacity, he developed a contract manufacturing business involving plastic injection molding and clean room assembly and packaging of FDA - regulated medical products. He also negotiated a joint venture with a major German healthcare product manufacture to establish its United States operations and established a professional-format videocassette re-manufacturing business serving the television broadcast industry. Mr. Casterlin was Workshop Director, Putnam Industries, Inc., from 1976 to 1979 and Production Manager, from 1973 to 1976, of Occupatics, Inc. From 1966 to 1970, Mr. Casterlin served as an Air Force Intelligence Officer and was honorably discharged as Sergeant. He studied Engineering at Lehigh University from 1965 to 1966 and

23

received his B.A. degree in Psychology in 1973 from the State University of New York at New Paltz.

Robert Aromando is currently the Director of Global Marketing of Covance, Inc., a global clinical research organization. He has over 20 years experience in sales and marketing. Aromando was Director of Global Marketing of Roche Diagnostics from 1992 until 1999. In this capacity, he had the responsibility for the business development and marketing for Roche Diagnostics' global on-site drugs of abuse business. From 1988 until 1992 he was Product Manager for American Home Products where he organized a new infectious disease business unit. From 1984 to 1988, he was Director of Sales and Marketing at Diagnostic Technology Inc. where he reorganized the hematology sales and marketing department. From 1978 to 1984, he was a Regional Sales Manager for Litton Bionetics, responsible for a field sales district.

Gerald Moore currently serves as President and CEO of Med-Ox Diagnostics of Canada and BioSys, Inc. Mr. Moore was President of UNIPATH (North America) from 1990 to 1998 when he reached parent-company Unilever's mandatory retirement age. Brooke Bond, Inc took a majority equity position in MED-OX in 1978 and renamed it Oxoid. In 1980, Mr. Moore opened Oxoid US in Columbus, Maryland and was appointed President and Chief Executive Officer of both Oxoid CANADA and Oxoid USA. Unilever acquired all of Oxoid International's holdings and subsidiaries in 1984 and changed its name to UNIPATH in 1990. Mr. Moore is a member of the Board of Directors of the Canadian Assoc. of Clinical Microbiology and Infectious Diseases (CACMID); a Director of the Canadian Clinical Standards Organization, serves on the National Committee for Clinical Laboratory Standards (NCCLS), a member of the NCCLS Committee for Antimicrobial Susceptibility testing and Veterinary Diagnostics, is an advisor to the NCCLS Committee on Culture Media, is a liaison to the Board of Exhibitors of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) of the American Society of Microbiology. Mr. Moore received his degree in chemistry and mathematics from Strathclyde University in Glascow, Scotland in 1961.

Denis O'Donnell, M.D. is currently a Managing Director of Seaside Partners, L.P., the firm which purchased $2,000,000 of Common Shares in a private placement on April 28, 2000. Since 1986, Dr. O'Donnell has been a Clinical Instructor of Health Science at Northeastern University. From 1984 to 1985 he was a Resident in Surgery at Tufts New England Medical Center. From 1986 to 1991 he served a Director of the Clinical Research Center of Medical and Technical Research Associates, Inc. From 1991 through 1995 he was Vice President of IGI, Inc. From 1995 until 1997 he was President of Novavax, Inc., a company in which he still holds the seat of Chairman of the Board. In addition to the Novavax, Inc. board seat, Dr. O'Donnell is currently a director of ELXSI Corporation (NASDAQ:ELXS), Columbia Laboratories, Inc. (AMEX:COB), Ampersand Medical Corporation (NASDAQ:AMPM), and is also a member of the Associates of Clinical Pharmacology Scientific Advisory Board. He has written and contributed to numerous medical manuscripts, abstracts, and papers. Dr. O'Donnell graduated from Harvard University (A.B./Biology) and from AUC Medical School (M.D.).

Henry Wells, Ph.D. has served since 1990 as a contract chemist with the title of Vice-President-Science and Technology for New Horizons Diagnostics, Inc. where he adapts immuno-chemical technologies for detection of infectious diseases. From 1989

24

to 1990, he was director of production for Espro, Inc., a producer of in-vivo pesticides. From 1985 to 1989, Dr. Wells was Vice-President-Science and Technology for Keystone Diagnostics, Inc. From 1984 to 1985, he was Director of Research and Development for Hill-Wells Research Corporation, a developer of diagnostics products. From 1981 to 1984, he was Vice-President-Research and Development of Hematec Corporation. From 1979 to 1981, Dr. Wells was Director of Biochemistry for Helena Laboratories. From 1973 to 1979, he was Manager of Chemical Chemistry at Smith Kline Diagnostics. Dr. Wells earned his Ph.D. in Biochemistry from the University of Pittsburgh, his M.A. from University of Pennsylvania and his B.S. in Chemistry from the University of Pittsburgh.

Martin Gould is a biomedical scientist with more than 24 years of experience in the diagnostic and chemical fields. He has an extensive background in research and development, manufacturing, quality control/assurance, as well as business development, sales and marketing. His experience is in the areas of clinical chemistry, serology, immunology, hematology, dyes and stains, chromatography, reagent chemical and food diagnostics, specifically rapid microbiological testing. From 1973 to 1987, Mr. Gould worked for E. Merck, Inc. in various positions of increasing responsibilities within the product management, research and development, and quality assurance/control departments. In 1987, he founded Ampcor Diagnostics, Inc. which he grew until 1994 when it was acquired by Neogen Corp. (NASDAQ:NEOG). Mr. Gould continued to serve as Vice President and General Manager of Neogen Corp. until 1997. Mr. Gould was an independent consultant after leaving Neogen Corp. in 1997 until joining the Company in 1998. Mr. Gould is an accomplished researcher with numerous publications in a variety of fields, including rapid immunoassay tests to detect food pathogens such as e-coli, salmonella, listeria, shigella, and campylobacter. He has a master's in biomedical science and engineering and a bachelor's in animal science/chemistry. Mr. Gould established a patent in composition for stabilization of diagnostics reagents, three separate patents for immunoassay diagnostics kits, as well as a patent concerning a growth media that resuscitates injured bacteria, such as salmonella, that was recently issued.

ITEM 10. EXECUTIVE COMPENSATION

See Proxy Statement for the Annual Meeting of Shareholders for Fiscal Year 2001.

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth as of July 12, 2000, the number and percentage of shares of the common stock of the Company owned of record and beneficially by each executive officer and director of the Company and by any other person owning more than 5% of the outstanding Common Shares and by all executive officers and directors as a group.

25

                                                                 Number of
Beneficial Owner                                               Common Shares            Percent of Total
----------------                                               -------------            ----------------
Stan Cipkowski                                                  2,693,000  (1)                  14.6%
122 Smith Road
Kinderhook, New York 12106

Edmund Jaskiewicz                                               2,148,155  (2)                  11.8%
1730 M Street, NW
Washington, DC  20036

Jay Bendis                                                        774,999  (3)                   4.2%

John F. Murray                                                    221,666  (4)                   1.2%

Douglas Casterlin                                                 289,500  (5)                   1.6%

Robert Aromando                                                         0                        *

Gerald Moore                                                       20,000  (6)                   *

Denis O'Donnell, M.D.                                                   0  (7)                   *

Seaside Partners, L.P.                                          1,408,450                        7.8%
623 Ocean Avenue
Sea Girt, NJ 08750

Directors  and  executive  officers  as a  group  (8
persons)                                                        6,147,320  (8)                  32.0%


* Less than one percent (1%).

(1) Includes 363,500 Common Shares subject to stock options exercisable within 60 days of July 12, 2000.
(2) Includes 161,500 Common Shares subject to stock options exercisable within 60 days of July 12, 2000.
(3) Includes 219,000 Common Shares subject to stock options exercisable within 60 days of July 12, 2000.
(4) Includes 221,666 Common Shares subject to stock options exercisable within 60 days of July 12, 2000.
(5) Includes 175,000 Common Shares subject to stock options exercisable within 60 days of July 12, 2000.
(6) Includes 20,000 Common Shares subject to stock options exercisable within 60 days of July 12, 2000.
(7) Dr. O'Donnell may be deemed to indirectly beneficially own 1,408,450 Common Shares because he is a member of Seaside Advisors, LLC which is the general partner of Seaside Partners, L.P. Dr. O'Donnell specifically disclaims beneficial ownership of these securities.
(8) Includes an aggregate of 1,160,666 Common Shares subject to stock options exercisable within 60 days of July 12, 2000. Does not include the 1,408,450 Common Shares beneficially owned by Seaside Partners, L.P. which Dr. O'Donnell may be deemed to indirectly beneficially own.

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

See Proxy Statement for the Annual Meeting of Shareholders for Fiscal Year 2001.

26

ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits

See Exhibit Index on page E-1, incorporated herein by reference.

(b) Reports on Form 8-K

There were no reports on Form 8-K during the fourth quarter of Fiscal Year 2000.

27

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMERICAN BIO MEDICA CORPORATION

                                           By /s/ Stan Cipkowski
                                             ----------------------------------
                                             Stan Cipkowski, Chairman of the
                                             Board of Directors, President and
                                             Chief Executive Officer

Date:  August 9, 2000

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on August 9, 2000:

/s/ Stan Cipkowski                      Chairman of the Board of Directors,
-------------------------------         President and Chief Executive Officer
Stan Cipkowski


/s/ Edmund Jaskiewicz                   Director
-------------------------------
Edmund Jaskiewicz


/s/ Jay Bendis                          Director
-------------------------------
Jay Bendis


/s/ Gerald Moore                        Director
-------------------------------
Gerald Moore


/s/ Robert Aromando                     Director
-------------------------------
Robert Aromando


/s/ Denis O'Donnell, M.D.               Director
-------------------------------
Denis O'Donnell, M.D.


/s/ John F. Murray                      Chief Financial Officer
-------------------------------         (Principal Financial Officer)
John F. Murray

S-1

AMERICAN BIO MEDICA CORPORATION

FINANCIAL STATEMENTS

APRIL 30, 2000


AMERICAN BIO MEDICA CORPORATION

CONTENTS
                                                                                                                       PAGE
                                                                                                                       ----
FINANCIAL STATEMENTS

   Independent auditors' report                                                                                        F-2

   Balance sheet as of April 30, 2000                                                                                  F-3

   Statements of operations for the years ended April 30, 2000 and 1999                                                F-4

   Statements of changes in stockholders' equity for the years ended April 30, 2000 and 1999                           F-5

   Statements of cash flows for the years ended April 30, 2000 and 1999                                                F-6

   Notes to financial statements                                                                                       F-7

F-1

INDEPENDENT AUDITORS' REPORT

To the Stockholders and Board of Directors of American Bio Medica Corporation
Kinderhook, New York

We have audited the accompanying balance sheet of American Bio Medica Corporation as of April 30, 2000 and the related statements of operations, changes in stockholders' equity and cash flows for each of the years in the two-year period ended April 30, 2000. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining on a test basis evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements enumerated above present fairly, in all material respects, the financial position of American Bio Medica Corporation as of April 30, 2000 and the results of its operations and its cash flows for each of the years in the two-year period ended April 30, 2000, in conformity with generally accepted accounting principles.

Richard A. Eisner & Company, LLP

New York, New York
June 9, 2000

With respect to the last paragraph of Note G, July 20, 2000

With respect to the first and third paragraphs of Note K[4](d), July 24, 2000

With respect to the last paragraph of Note E, August 2, 2000

F-2

AMERICAN BIO MEDICA CORPORATION

BALANCE SHEET
APRIL 30, 2000

ASSETS
Current assets:
   Cash and cash equivalents                                                                 $  1,207,000
   Investments                                                                                     74,000
   Accounts receivable - net of allowance for doubtful accounts of $81,000                      1,150,000
   Inventory                                                                                    1,332,000
   Prepaid expenses and other current assets                                                       46,000
                                                                                             ------------

      Total current assets                                                                      3,809,000

Property, plant and equipment, net                                                                388,000
Due from director/stockholder                                                                     335,000
Restricted cash                                                                                   112,000
Other assets                                                                                      114,000
Loan receivable - BioSys, Inc.                                                                    280,000
                                                                                             ------------

                                                                                             $  5,038,000
                                                                                             ============

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
   Accounts payable and accrued expenses                                                     $  1,655,000
   Note payable - stockholder                                                                     125,000
   Current portion of capital lease obligations                                                    13,000
                                                                                             ------------

      Total current liabilities                                                                 1,793,000

Long-term portion of capital lease obligations                                                     34,000
                                                                                             ------------

      Total liabilities                                                                         1,827,000
                                                                                             ------------

Commitments and contingencies

Stockholders' equity:
   Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued
      and outstanding
   Common stock; par value $.01 per share; 30,000,000 shares authorized; 18,045,548 shares
      issued and outstanding                                                                      180,000
   Additional paid-in capital                                                                  15,210,000
   Subscription receivable                                                                         (5,000)
   Unearned portion of compensatory options                                                      (454,000)
   Unrealized loss on investments available for sale                                              (77,000)
   Accumulated deficit                                                                        (11,643,000)
                                                                                             ------------

                                                                                                3,211,000
                                                                                             ------------

                                                                                             $  5,038,000
                                                                                             ============

See notes to financial statements

F-3

AMERICAN BIO MEDICA CORPORATION

STATEMENTS OF OPERATIONS

                                                                                  YEAR ENDED APRIL 30,
                                                                              -----------------------------
                                                                                  2000            1999
                                                                              -----------------------------
Net sales                                                                     $  7,653,000    $  7,038,000
Cost of goods sold                                                               3,602,000       3,356,000
                                                                              ------------    ------------

Gross profit                                                                     4,051,000       3,682,000
                                                                              ------------    ------------

Operating expenses:
   Selling, general and administrative (including equity related charges of
      $367,000 in 2000 and $91,000 in 1999)                                      5,223,000       5,040,000
   Depreciation and amortization                                                   106,000          25,000
   Research and development                                                        799,000         336,000
                                                                              ------------    ------------

                                                                                 6,128,000       5,401,000
                                                                              ------------    ------------
Operating loss                                                                  (2,077,000)     (1,719,000)
                                                                              ------------    ------------

Other income (loss):
   Loss on sale of marketable securities                                          (122,000)        (68,000)
   Interest income                                                                  84,000         103,000
   Interest expense                                                                (21,000)         (7,000)
                                                                              ------------    ------------

                                                                                   (59,000)         28,000
                                                                              ------------    ------------

NET LOSS                                                                        (2,136,000)     (1,691,000)

Adjustments:
   Preferred stock beneficial conversion feature                                   (57,000)       (123,000)
   Preferred stock dividends (including late penalty in 1999)                      (82,000)       (391,000)
                                                                              ------------    ------------

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS                                  $ (2,275,000)   $ (2,205,000)
                                                                              ============    ============

BASIC AND DILUTED LOSS PER COMMON SHARE                                       $       (.15)   $       (.15)
                                                                              ============    ============

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED               15,480,790      14,557,000
                                                                              ============    ============

See notes to financial statements

F-4

AMERICAN BIO MEDICA CORPORATION

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

                                                        PREFERRED          COMMON STOCK             ADDITIONAL
                                                          STOCK         -----------------------      PAID-IN        SUBSCRIPTION
                                                          SHARES         SHARES         AMOUNT       CAPITAL         RECEIVABLE
                                                       -------------    -----------------------   --------------    -------------
BALANCE - APRIL 30, 1998                                   2,500        14,282,989     $143,000     $12,102,000      $ (9,000)
Proceeds from exercise of options                                            2,000                        6,000
Preferred "D" shares converted to common shares           (1,093)          588,032        6,000          (6,000)
Dividend paid to holders of Preferred "D" shares:
   Preferred shares                                          129                                        128,000
   Cash
   Common shares                                                             2,169                        5,000
Settlement of registration rights agreement
Value assigned to compensatory stock options                                                             91,000
Amortization of compensatory stock options
Net loss
Other comprehensive loss:
   Unrealized loss on securities available for sale

Comprehensive loss
                                                    ------------      ------------      --------    -----------      --------

BALANCE - APRIL 30, 1999                                   1,536        14,875,190      149,000      12,326,000        (9,000)
Preferred "D" shares converted to common shares           (1,647)        1,445,759       14,000         (14,000)
Dividends paid to holders of Preferred "D" shares:
   Preferred shares                                          111                                        112,000
   Cash
Fair value of compensatory stock options                                                                 83,000
Common shares issued in a private
   placement                                                             1,408,450       14,000       1,986,000
Exercise of common stock options                                            17,649
Common stock and common stock options issued
   to consultants, net of amortization                                     300,000        3,000         721,000
Cancellation of common stock                                                (1,500)                      (4,000)        4,000
Amortization of compensatory stock options
Net loss
Other comprehensive loss:
   Unrealized loss on securities available for sale

Comprehensive loss
                                                    ------------      ------------     --------     -----------      --------
BALANCE - APRIL 30, 2000                                       0        18,045,548     $180,000     $15,210,000      $ (5,000)
                                                    ============      ============     ========     ===========      ========


                                                                                          ACCUMULATED
                                                                                           OTHER
                                                    COMPREHENSIVE        UNEARNED      COMPREHENSIVE    ACCUMULATED
                                                        LOSS           COMPENSATION        LOSS           DEFICIT         TOTAL
                                                    -------------     --------------   -------------   -------------    -----------
BALANCE - APRIL 30, 1998                                               $  (24,000)                     $ (7,342,000)    $ 4,870,000
Proceeds from exercise of options                                                                                             6,000
Preferred "D" shares converted to common shares                                                                                   0
Dividend paid to holders of Preferred "D" shares:
   Preferred shares                                                                                        (158,000)        (30,000)
   Cash                                                                                                      (3,000)         (3,000)
   Common shares                                                                                             (5,000)              0
Settlement of registration rights agreement                                                                (225,000)       (225,000)
Value assigned to compensatory stock options                                                                                 91,000
Amortization of compensatory stock options                                 11,000                                            11,000
Net loss                                             $(1,691,000)                                        (1,691,000)     (1,691,000)
Other comprehensive loss:
   Unrealized loss on securities
    available for sale                                   (56,000)                      $ (56,000)                           (56,000)
                                                     -----------
Comprehensive loss                                   $(1,747,000)
                                                     ===========       ----------      ---------        -----------      ----------
BALANCE - APRIL 30, 1999                                                  (13,000)       (56,000)        (9,424,000)      2,973,000
Preferred "D" shares converted to common shares                                                                                   0
Dividends paid to holders of Preferred "D" shares:
   Preferred shares                                                                                         (82,000)         30,000
   Cash                                                                                                      (1,000)         (1,000)
Fair value of compensatory stock options                                                                                     83,000
Common shares issued in a private
   placement                                                                                                              2,000,000
Exercise of common stock options                                                                                                  0
Common stock and common stock options issued
   to consultants, net of amortization                                   (452,000)                                          272,000
Cancellation of common stock                                                                                                      0
Amortization of compensatory stock options                                 11,000                                            11,000
Net loss                                             $(2,136,000)                                        (2,136,000)     (2,136,000)
Other comprehensive loss:
   Unrealized loss on securities available for sale      (21,000)                        (21,000)                           (21,000)
                                                     -----------
Comprehensive loss                                   $(2,157,000)
                                                     ===========       ----------      ---------       ------------     -----------
BALANCE - APRIL 30, 2000                                               $ (454,000)     $ (77,000)      $(11,643,000)    $ 3,211,000
                                                                       ==========      =========       ============     ===========

See notes to financial statements

F-5

AMERICAN BIO MEDICA CORPORATION

STATEMENTS OF CASH FLOWS

                                                                                                    YEAR ENDED APRIL 30,
                                                                                              ---------------------------------
                                                                                                  2000              1999
                                                                                              ---------------------------------
CASH FLOWS FROM OPERATING ACTIVITIES:
   Net loss                                                                                   $   (2,136,000)  $   (1,691,000)
   Adjustments to reconcile net loss to net cash used in operating activities:
      Amortization and depreciation                                                                  106,000           78,000
      Loss on disposal of property                                                                                      7,000
      Allowance for note receivable, net                                                             105,000
      Provision for bad debts                                                                         11,000           30,000
      Issuance of compensatory stock and stock options                                               367,000          102,000
      Accrued interest                                                                               (23,000)         (16,000)
      Loss on sale of marketable securities                                                           14,000           68,000
      Changes in:
        Accounts receivable                                                                         (197,000)        (339,000)
        Inventory                                                                                    356,000         (843,000)
        Prepaid expenses and other current assets                                                     51,000          (73,000)
        Other assets                                                                                 (35,000)           6,000
        Accounts payable and accrued expenses                                                        535,000          663,000
                                                                                              --------------   --------------

           Net cash used in operating activities                                                    (846,000)      (2,008,000)
                                                                                              --------------   --------------

CASH FLOWS FROM INVESTING ACTIVITIES:
   Purchase of property, plant and equipment                                                        (145,000)        (220,000)
   Purchase of investments                                                                           (73,000)      (1,812,000)
   Sales and maturity of investments                                                                 571,000          969,000
   Collections on note receivable                                                                     23,000
   Loan to BioSys, Inc.                                                                             (280,000)
   Loans to director/stockholder                                                                     (32,000)         (29,000)
                                                                                              --------------   --------------

           Net cash provided by (used in) investing activities                                        64,000       (1,092,000)
                                                                                              --------------   --------------

CASH FLOWS FROM FINANCING ACTIVITIES:
   Repayment of capital lease obligations                                                            (11,000)         (11,000)
   Proceeds from private placement                                                                 2,000,000
   Proceeds from exercise of options                                                                                    6,000
   Cash dividends paid                                                                                (1,000)          (3,000)
   Repayment of note payable to stockholder                                                         (130,000)
                                                                                              --------------   --------------

           Net cash provided by (used in) financing activities                                     1,858,000           (8,000)
                                                                                              --------------   --------------

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                                               1,076,000       (3,108,000)
Cash and cash equivalents - beginning of year                                                        131,000        3,239,000
                                                                                              --------------   --------------

CASH AND CASH EQUIVALENTS - END OF YEAR                                                       $    1,207,000   $      131,000
                                                                                              ==============   ==============

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
      Cash paid during the year for:
      Interest                                                                                $        8,000   $        8,000
      Income taxes                                                                                             $        6,000

NONCASH ACTIVITIES:
   Common stock issued in connection with stock dividends to holders of
      preferred stock                                                                         $      111,000   $      133,000
   Dividend accrued not yet paid                                                                               $       30,000
   Acquisition of property under capital leases                                                                $       69,000
   Settlement of registration rights agreement                                                                 $      225,000
   Sale of book business and related assets for a note receivable                             $      205,000
   Cancellation of common stock                                                               $        4,000
   Preferred stock converted to common stock                                                  $    1,647,000   $    1,093,000

See notes to financial statements

F-6

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE A - THE COMPANY AND ITS SIGNIFICANT ACCOUNTING POLICIES

American Bio Medica Corporation (the "Company") was formed under the laws of the state of New York on April 10, 1986 and is in the business of manufacturing, developing and marketing biomedical technologies and products. The Company currently owns two technologies for screening drugs of abuse, a workplace screening test and a preliminary test for use by laboratories. The Company was involved in marketing educational books and software to schools and municipal libraries and audio-visual educational packages to corporations throughout the United States, which constitute less than 10% of net sales. (See Note F).

During the year ended April 30, 2000 the Company sustained a net loss of $2,136,000 and had net cash outflows from operating activities of $846,000. The Company has taken a number of steps to improve its financial prospects including entering into national and international distribution agreements with a number of distributors, completed an in-house strip manufacturing program to reduce costs and other measures to enhance profit margins. In addition, on April 28, 2000 the Company raised $2,000,000 pursuant to a common stock purchase agreement (see Note J[2]).

[1] CASH EQUIVALENTS:

The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.

[2] INVENTORY:

Inventory is stated at the lower of cost or market; cost is determined by the first-in-first-out method.

[3] INCOME TAXES:

The Company accounts for income taxes in accordance with Statements of Financial Accounting Standards ("SFAS") No. 109, "Accounting for Income Taxes". Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted laws and tax rates that will be in effect when the differences are expected to reverse. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.

[4] DEPRECIATION AND AMORTIZATION:

Property, equipment and capitalized lease assets are depreciated on the straight-line method over their estimated useful lives. Leasehold improvements are amortized by the straight-line method over the shorter of their estimated useful lives or the term of the lease.

[5] REVENUE RECOGNITION:

The Company recognizes revenue when products are shipped or services are rendered.

[6] RESEARCH AND DEVELOPMENT:

Research and development costs are charged to operations when incurred.

[7] LOSS PER COMMON SHARE:

Basic loss per share is calculated by dividing net loss by the weighted average number of outstanding common shares during the period. No effect has been given to potential issuances of common stock including outstanding options and warrants in the diluted computation as their effect would be antidilutive.

F-7

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE A - THE COMPANY AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[7] LOSS PER COMMON SHARE: (CONTINUED)

When preferred stock is convertible to common stock at a conversion rate that is the lower of a rate fixed at issuance or a fixed discount from the common stock market price at the time of conversion, the discounted amount is an assured incremental yield. This "beneficial conversion feature", to the preferred stockholders is accounted for as an embedded dividend to preferred shareholders. As such, the loss per common share was adjusted for this feature.

[8] USE OF ESTIMATES:

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that effect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

[9] IMPAIRMENT OF LONG-LIVED ASSETS:

       The Company adopted SFAS No. 121, "Accounting for the Impairment of
       Long-Lived Assets and for Long-Lived Assets to be Disposed Of " during
       the year ended April 30, 1999. SFAS No. 121 establishes accounting
       standards for the impairment of long-lived assets, certain identifiable
       assets, and goodwill related to those assets. There was no effect of the
       adoption of SFAS No. 121 on the financial statements.

[10]   FINANCIAL INSTRUMENTS:

       The carrying amounts of cash and cash equivalents, accounts receivable -
       net, due from director/stockholder, loan receivable - BioSys, Inc.,
       accounts payable and accrued expenses and note payable approximate their
       fair value based on the nature of those items.

       Estimated fair value of financial instruments are determined using
       available market information. In evaluating the fair value information,
       considerable judgment is required to interpret the market data used to
       develop the estimates. The use of different market assumptions and/or
       different valuation techniques may have a material effect on the
       estimated fair value amounts. Accordingly, the estimates of fair value
       presented herein may not be indicative of the amounts that could be
       realized in a current market exchange.

[11]   ACCOUNTING FOR STOCK-BASED COMPENSATION:

       The Company accounts for its stock-based compensation plans under
       Accounting Principles Board Opinion ("APB") No. 25, "Accounting for Stock
       Issued to Employees" and related interpretations. In October 1995, the
       Financial Accounting Standards Board issued Statement No. 123,
       "Accounting for Stock-Based Compensation" ("SFAS No. 123"), which
       establishes a fair value-based method of accounting for stock-based
       compensation plans. The Company has adopted the disclosure-only
       alternative under SFAS No. 123, which requires disclosure of the pro
       forma effects on net loss and net loss per share as if stock-based
       employee compensation was measured under SFAS No. 123, as well as certain
       other information. The Company accounts for stock-based compensation to
       nonemployees using the fair value method in accordance with SFAS No. 123
       and Emerging Issues Task Force (EITF) 96-18. The Company has recognized
       deferred stock compensation related to certain stock option grants (see
       Note J).

F-8

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE A - THE COMPANY AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[12] CONCENTRATION OF CREDIT RISK:

       The Company sells its drug testing products primarily to United States
       distributors. Credit is extended based on an evaluation of the customer's
       financial condition, and generally collateral is not required. The
       Company establishes an allowance for doubtful accounts based on factors
       surrounding the credit risk of specific customers and other information.

       The Company maintains certain cash balances at a financial institution
       that is federally insured and at times the Company's balance have
       exceeded federally insured limits.

[13]   REPORTING COMPREHENSIVE LOSS:

       During fiscal 1999, the Company adopted Statement of Financial Accounting
       Standards No. 130, "Reporting Comprehensive Income" (SFAS No. 130"). The
       provisions for SFAS No. 130 require the Company to report the change in
       the Company's equity during the period from transactions and events other
       than those resulting from investments by and distributions to the
       shareholders.

[14]   RECLASSIFICATIONS:

       Certain items have been reclassified to conform with the current year
       presentation.

NOTE B - INVESTMENTS AND RESTRICTED CASH

The Company's investments are classified as available-for-sale and are carried at fair value with the unrealized gains and losses included in stockholders' equity. Investments at April 30, 2000 consist of the following:

                                                                            FAIR        UNREALIZED
                                                            COST            VALUE          LOSS
                                                       ---------------  ------------    ----------
Certificates of deposit - maturity
   less than one year                                  $        32,000  $     32,000
Marketable equity securities - common stock                    119,000        42,000    $(77,000)
                                                       ---------------  ------------    --------

                                                       $       151,000  $     74,000    $(77,000)
                                                       ===============  ============    ========

Certificate of deposit - restricted (Note K[5])        $       112,000  $    112,000
                                                       ===============  ============

During the year ended April 30, 1999, the Company used equity instruments as collateral for certain borrowings under a margin account, which were repaid.

NOTE C - INVENTORY

Inventory is comprised of the following:

Drug screening tests:
   Raw materials                                       $     713,000
   Work in process                                           397,000
   Finished goods                                            222,000
                                                       -------------

Total                                                  $   1,332,000
                                                       =============

F-9

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE D - PLANT AND EQUIPMENT

Plant and equipment, at cost, are as follows:

Office equipment, including $46,000 under capital leases     $    246,000
Manufacturing and warehouse equipment, including $23,000
   under capital lease                                            365,000
                                                             ------------

                                                                  611,000
Less accumulated depreciation                                     223,000
                                                             ------------

                                                             $    388,000
                                                             ============

NOTE E - LOAN RECEIVABLE - BIOSYS, INC.

BioSys, Inc. is a development stage company focusing on developing, manufacturing, marketing and selling proprietary new products for the industrial microbiology testing market. BioSys, Inc. has developed patented methodologies, a computerized instrument and disposable vials for accurate rapid microbiological testing.

The Company advanced $280,000 to BioSys, Inc., (the President of BioSys is a director of the Company). The loan is convertible into common stock of BioSys, Inc. based on the percentage of funds provided by the Company compared to the total amount of capital obtained by BioSys, Inc. within a two-year period commencing July 14, 1999, limited to a maximum of 20% in exchange for an aggregate contribution of $400,000. The agreement provides for the Company to select two individuals to serve on the board of directors of BioSys, Inc.

During May 2000, the Company advanced an additional $100,000 pursuant to the aforementioned terms.

In August 2000, BioSys, Inc. began to more fully exploit its technology and will display its testing equipment at trade shows and otherwise commercialize its products.

NOTE F - OTHER ASSETS

On September 1, 1999, the Company sold its book sales business including all inventories and accounts receivable (see Note A) to an entity in exchange for a $250,000 five year secured promissory note. During the year ended April 30, 2000, the Company repossessed certain assets, upon the default of the note and collected $23,000 through April 30, 2000. In addition, the Company recorded an allowance of $150,000 and is carrying the repossessed assets at its estimated realizable value of $77,000.

NOTE G - DUE FROM DIRECTORY/STOCKHOLDER

At April 30, 2000, the Company has a note receivable from an director/stockholder for $335,000. The note bears interest at 11.5% per annum and is payable on demand.

During the years ended April 30, 2000 and 1999, the Company advanced $32,000 and $29,000, respectively to the director/stockholder. Interest income in connection with the note receivable for the years ended April 30, 2000 and 1999 was $23,000 and $16,000, respectively.

During May 2000, the Company advanced an additional $80,000 to this director/stockholder pursuant to the same terms, as stated above.

The Company's Board of Directors is currently evaluating forms of repayments of the director/stockholder's loan. The forms of repayment may include cash or noncash assets in the form of Company common shares owned by the director/ stockholder. The director/stockholder has agreed to provide 1,500,000 common shares as collateral for the loan.

F-10

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE H - CAPITAL LEASE OBLIGATIONS

The Company leases certain equipment under a capital lease. As of April 30, 2000, minimum future lease payments on the capital leases are as follows:

YEAR ENDING
APRIL 30,

      2001                                             $    19,000
      2002                                                  19,000
      2003                                                  19,000
      2004                                                   1,000
                                                       -----------

Total future minimum loan payments                          58,000
Less amount representing interest                          (11,000)
                                                       -----------

Present value of minimum lease payments                     47,000
Less current portion of capital lease payments             (13,000)
                                                       -----------

Long-term portion of capital lease obligations         $    34,000
                                                       ===========

NOTE I - INCOME TAXES

At April 30, 2000, the Company has approximately $8,500,000 of net operating loss carryforwards expiring through 2019.

At April 30, 2000, the Company has a deferred tax asset of approximately $3,500,000 representing the benefits of its net operating loss carryforward and certain expenses not currently deductible. The Company's deferred tax asset has been fully reserved by a valuation allowance since realization of its benefit is uncertain. The difference between the statutory tax rate of 34% and the Company's effective tax rate of 0% is substantially due to the increase in the valuation allowance of $900,000 and $716,000 for the years ended April 30, 2000 and 1999, respectively. The Company's ability to utilize its net operating loss carryforwards may be subject to an annual limitation in future periods pursuant to Section 382 of the Internal Revenue Code of 1986, as amended.

NOTE J - STOCKHOLDERS' EQUITY

[1] PREFERRED STOCK:

In October 1996, the Company amended its certificate of incorporation authorizing the issuance of 5,000,000 Preferred Shares. The board of directors of the Company has the authority, without further action by the holders of the outstanding common shares, to issue preferred shares from time to time in one or more classes or series, to fix the number of shares constituting any class or series and the stated value thereof, if different from the par value, and to fix the terms of any such series or class, including dividend rights, dividend rates, conversion or exchange rights, voting rights, rights and terms of redemption (including sinking fund provisions,) the redemption price and the liquidation preference of such class or series.

F-11

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE J - STOCKHOLDERS' EQUITY (CONTINUED)

[1] PREFERRED STOCK: (CONTINUED)

During April 1998, the Company completed a private placement in which it netted proceed of approximately $2,312,000 through the sale of 2,500 shares of 8% Series D Convertible Preferred Shares with a stated value of $1,000 per share. Each Preferred Share is convertible at the lesser of
(i) 95% of the average of the closing bid prices of the common shares over any three trading days selected by the holder of the Preferred Shares in the 20 trading days immediately preceding the date of conversion or (ii) $4.625 based on a formula as provided. Dividends are payable in cash or additional Preferred Shares at the Company's option.

Pursuant to a Registration Rights Agreement dated April 24, 1998 (the "Registration Rights Agreement"), the Company agreed to register the resale of the Company's common stock issuable upon conversion of the Company's Series D Preferred Stock and upon exercise of certain stock purchase warrants. Pursuant to the Registration Rights Agreement, if a registration statement covering the resale of such shares of Common Stock was not declared effective by July 23, 1998 or once declared effective sales could not be made thereunder for any reason (a "Registration Statement Deficiency"), the Company agreed to pay a late registration penalty. The Registration Statement filed by the Company was not declared effective until March 17, 1999, resulting in a penalty. In the fourth quarter of fiscal 1999, the Series D preferred stockholders (the "holders") communicated to the Company that they were willing to accept $250,000 in cash in settlement of the penalty. On May 28, 1999, the Company entered into a definitive Agreement as of April 30, 1999 (the "1999 Agreement") to settle all claims against the Company, including the late registration penalty and certain other claims under the Securities Purchase Agreement dated April 24, 1998. Pursuant to the 1999 Agreement, the Company gave as consideration $225,000 on June 1, 1999 ($100,000 in cash and a one-year promissory note in the principal amount of $125,000 accruing interest at the rate of 14% annually), which was subsequently repaid.

The preferred dividend payable of $30,000 at April 30, 1999 was paid through the issuance of 29 Series D Preferred Shares and $1,000 in cash.

On January 27, 2000, the Company entered into an agreement with the holders of The Series D Preferred shares to convert all of their outstanding Series D Preferred shares. Pursuant to this agreement certain preferred shares were converted at a price of $1.078646 resulting in an additional preferred dividend of approximately $57,000 for the difference between the original conversion rate and the adjusted conversion price. During the year ended April 30, 2000, the Company issued 1,445,759 common shares to convert all of the outstanding Series D Preferred shares and to pay accrued dividends of approximately $111,000.

[2] COMMON STOCK PURCHASE AGREEMENT:

On April 28, 2000, the Company entered into an agreement with an investor group ("Investor") to issue and sell 1,408,450 common shares at a per share price of $1.42 (the "closing price") for a total of $2 million.

In conjunction with the agreement, the Company has agreed to issue a five-year warrant to the investor to purchase up to 1,877,934 common shares pursuant to a formula based on the Company's stock price on the ten consecutive tradings prior to the six-month anniversary of the closing date. If the six-month anniversary price per share is $2.13 or more per share, the Company will not be required to issue any warrants. If it is less than $2.13 per share, the Company will be required to issue warrants exercisable at the anniversary price into a number of common shares based on a formula.

F-12

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE J - STOCKHOLDERS' EQUITY (CONTINUED)

[3] STOCK OPTION PLANS:

The Company adopted the Fiscal 1997 Nonstatutory Stock Option Plan (the "1997 Plan"), the Fiscal 1998 Nonstatutory Plan (the "1998 Plan") and the Fiscal 2000 Nonstatutory Stock Option Plan (the "2000 Plan"). The 1997 Plan provides for the granting of options to purchase up to 2,000,000 shares of common stock, the 1998 Plan provides for the granting of options to purchase 1,000,000 common shares and the 2000 Plan provides for the granting of options to purchase up to 1,000,000 common shares. These Plans are administered by the Option Committee of the Board of Directors, which determines the terms of options exercised, including the exercise price, the number of shares subject to the option and the terms and conditions of exercise.

[4] OTHER STOCK OPTIONS:

During March 1996, the Company entered into an agreement with a public relations and communications firm to serve as the Company's liaison and spokesman to the financial and investment community. In connection therewith, the Company also granted 500,000 options exercisable at $1.00 through March 15, 1999 and 500,000 options exercisable at $2.00 through March 15, 1999. During March 1998, the Company purchased from the public relations firm 75,000 options exercisable at $1.00 per common share and 75,000 options exercisable at $2.00 per common share for $225,000.

At April 30, 1999, the options had expired.

[5] STOCK OPTIONS:

Stock option activity is summarized as follows:

                                                          YEAR ENDED APRIL 30,
                                            -----------------------------------------------------
                                                  2000                           1999
                                            -----------------------     -------------------------
                                                           WEIGHTED                     WEIGHTED
                                                           AVERAGE                       AVERAGE
                                                           EXERCISE                      EXERCISE
                                             SHARES          PRICE         SHARES         PRICE
                                            ---------      --------     ------------    ---------
Options outstanding at beginning of year    1,976,000        $3.02        2,510,000          $2.55
Granted                                     1,858,000         2.45          468,000           2.81
Exercised                                     (67,000)        2.96           (2,000)          3.00
Cancelled/expired                            (777,000)        3.00       (1,000,000)          3.02
                                            ----------                   ----------

Options outstanding at end of year          2,990,000         2.63        1,976,000           3.02
                                            ==========                   ==========

Options exercisable at end of year          2,558,000         2.67        1,558,000           2.98
                                            ==========                   ==========

F-13

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE J - STOCKHOLDERS' EQUITY (CONTINUED)

[5] STOCK OPTIONS: (CONTINUED)

In March 2000, 17,649 common shares were issued upon the cashless exercise of options to purchase 67,000 shares of the Company's common shares.

The following table presents information relating to stock options outstanding at April 30, 2000.

                                            OPTIONS OUTSTANDING                 OPTIONS EXERCISABLE
                                 -----------------------------------------      ----------------------
                                              WEIGHTED       WEIGHTED                         WEIGHTED
                                              AVERAGE        AVERAGE                          AVERAGE
                                              EXERCISE      REMAINING                         EXERCISE
RANGE OF EXERCISE PRICE            SHARES      PRICE       LIFE IN YEARS          SHARES       PRICE
-----------------------           ---------   ---------    -------------         --------     ---------
     $2.00 - $3.00                2,805,000      $2.57             6.44          2,373,000       $2.61
                                  =========                                      =========
        $3.50                       185,000       3.50             2.37            185,000        3.50
                                  =========                                      =========

As of April 30, 2000, 4,416 options are available for future grant under the 1997 Plan, 8,250 options are available for future grant under the 1998 Plan and 275,000 options are available for future grant under the 2000 Plan.

Through May 27, 1999, the Company granted 137,750 options. On July 1, 1999 the Company extended the term of approximately 852,000 options from 3 to 5 years.

[6] WARRANTS:

In connection with the Private Placement of the 8% Series D Convertible Preferred Shares, the Company granted 107,355 common share purchase warrants entitling the holder to purchase one common share at a price of $4.81 per share until April 24, 2001. 100,000 of the purchase warrants were issued to preferred stockholders and 7,355 of the purchase warrants were issued to the selling agent as additional compensation. The weighted average fair value of warrants granted during the year ended April 30, 1998 was $1.67 on the date of grant using the Black-Scholes pricing model using the following assumptions: dividend yield 0%; volatility of 59%, risk free rate of 5.61% and expected life of three years.

F-14

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE J - STOCKHOLDERS' EQUITY (CONTINUED)

[7] STOCK-BASED COMPENSATION:

The Company applies APB No. 25 in accounting for its employee stock option plans and, accordingly, recognizes employee compensation expense for the difference between the fair value of the underlying common shares and the exercise price of the option at the date of grant. The effect of applying SFAS No. 123 on pro forma net loss as stated above is not necessarily representative of the effects on reported net loss for future years due to, among other things (1) the vesting period of the stock options and (2) the fair value of additional stock options in future years. The weighted average fair value of options granted during 1999 and 2000 was approximately $1.21 and $1.06, respectively. The following pro forma information gives effect to fair value of the options on the date of grant using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, volatility of 79% and 85% for 1999 and 2000, respectively, risk free interest rates of ranging from 4.67% - 5.62% and 5.81% - 6.60% for 1999 and 2000, respectively and expected life of 3 years.

YEAR ENDED APRIL 30,

                                              2000              1999
                                              ----              ----
Net loss:
   As reported                          $ (2,136,000)   $ (1,691,000)
   Pro forma                              (3,684,000)     (1,967,000)

Basic and diluted loss per share:
   As reported                          $       (.15)   $       (.15)
   Pro forma                            $       (.24)   $       (.17)

During the year ended April 30, 1999, the Company granted 9,000 options to employees at exercise prices less than fair value of the underlying common shares at dates of grant. In addition, during the year ended April 30, 1999, the Company granted 33,500 options to consultants. In connection with these grants the Company recorded a one-time noncash charge of $51,000.

During year ended April 30, 1999, the Company implemented a stock option program pursuant to which distributors were granted stock options under the 1997 Plan based on annual sales for the year ended April 30, 1999. On June 10, 1999, the Company granted 56,000 options at an exercise price of $3.00 per common share exercisable through June 10, 2002 pursuant to the program. In connection therewith, the Company recorded a charge of $40,000 for the year ended April 30, 1999.

During December 1999, the Company entered into a one year consulting agreement with an individual knowledgeable in the medical diagnostic testing area. In connection therewith, the Company issued 300,000 common shares and granted options to purchase 200,000 common shares at $2 per share, vesting as of December 15, 2000. The Company has recorded an estimated charge of $272,000 for the fair value of the common shares and options issued. The actual cost of the options will be determined on December 15, 2000.

During the year ended April 30, 2000, the Company has granted various options to distributors and consultants to purchase 97,250 common shares. The options can be exercised through January 2005 at exercise prices ranging from $2.50 to $3.00 per share. In connection therewith, the Company recorded a charge of $84,000 for the year ended April 30, 2000.

F-15

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE K - COMMITMENTS, CONTINGENCIES AND OTHER MATTERS

[1] OPERATING LEASES:

The Company leases office and warehouse facilities under operating leases expiring through August 2003. At April 30, 2000, the future minimum rental payments under the operating lease are as follows:

2001                  $   101,000
2002                       41,000
2003                        9,000
                      -----------

                      $   151,000
                      ===========

Rent expense was $139,000 and $75,000 for the years ended April 30, 2000 and 1999, respectively.

[2] PURCHASE AGREEMENT:

On May 19, 1999, the Company entered into an agreement to acquire one of the leased facilities for $1,300,000 subject to zoning approval, environment assessment and structural inspection. The Company anticipates the purchase to be financed through a mortgage loan. At April 30, 2000, the Company has made a deposit of $20,000 towards this purchase.

[3] EMPLOYMENT AGREEMENTS:

On November 4, 1998, the Company entered into an employment agreement with its President providing for an annual salary of $96,000 which expired April 30, 2000.

On November 4, 1996, the Company entered into a employment agreement with its Vice-President of Marketing and Sales for an annual salary of $84,000 which expired April 30, 2000.

In addition, the above agreements provide for bonuses based on an aggregate of 2% of net sales.

During 1997, the Company entered into a three year employment agreement with its Vice-President/General Manager. The employment agreement provides for a base annual salary of $84,000 per annum and a bonus of 1% of net sales after gross revenue of $1,000,000 per fiscal year. This employment agreement expired May 25, 2000.

The Company is currently negotiating agreements with all of these individuals.

During the years ended April 30, 2000 and 1999, the Company recorded approximately $156,000 and $199,000, respectively in bonuses based on net sales in accordance with employment agreements.

[4] LITIGATION:

(a) Friedenberg Case

In February 1994, Robert Friedenberg, as former owner of the two medical technology companies, MDI and Gendex, acquired by the Company, in the name of these corporations, filed for a declaratory judgment in Maryland that a Share Exchange Agreement had been rescinded. In order to make a claim for damages, the Company filed a third-party claim against Dr. Friedenberg for breach of the Share Exchange Agreement and fraud. In November 1995, after a trial, the court denied Dr. Friedenberg's request for a declaration of rescission and allowed the Company's third-party claim to proceed to trial. In September 1996, Dr. Friedenberg died.

F-16

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE K - COMMITMENTS, CONTINGENCIES AND OTHER MATTERS (CONTINUED)

[4] LITIGATION: (CONTINUED)

(a) Friedenberg Case (continued)

The Company's third party claim was decided by a jury on May 5, 1997. The verdict determined that Dr. Friedenberg breached the Share Exchange Agreement when he failed to deliver drug screening know how technology to the Company. The jury also found in favor of the Company on two of three fraud claims against Dr. Friedenberg and awarded the Company approximately $321,000 in damages. Dr. Friedenberg's estate, just prior to the jury trial, filed a supplemental claim for the shares of the Company which he would have received under the Share Exchange Agreement. The trial judge on July 17, 1998, ruled that the estate of Dr. Friedenberg is entitled to 5,907,154 common shares of the Company. The Company appealed that ruling and on April 1, 1999, a hearing was held in the Court of Special Appeals in Maryland.

On September 15, 1999, the Court of Special Appeals in Maryland ruled in favor of the Company and reversed the circuit court's ruling that the estate of Dr. Friedenberg was entitled to 5,907,154 common shares of the Company. On December 21, 1999, the Court of Appeals denied the Friedenberg estate's petition to review the decision of the Court of Special Appeals. As a result of the aforementioned matters no accrual was required.

(b) Jackson Morris Case

In June 1995, the Company filed a lawsuit against Jackson Morris, the lawyer who was in charge of drafting and advising it on the Share Exchange Agreement (see Friedenberg Case). Mr. Morris, who had been recommended to the Company by Dr. Friedenberg, is alleged by the Company to have breached his fiduciary duty to the Company by later advising Dr. Friedenberg, individually, on how to rescind the Share Exchange Agreement. Mr. Morris is also charged with negligence in drafting the Share Exchange Agreement. The Company's lawsuit demands damages in the amount of $1,000,000. Mr. Morris has counterclaimed as a party to the Share Exchange Agreement and seeks common shares. No trial date has been set. The Company is vigorously contesting the Morris claim.

(c) Private Placement Claim

In June 1999, an individual filed suit in New York claiming that two private placement memoranda dated respectively September 15, 1992 and February 5, 1993, obligated the Company to issue him 1,555,601 common shares of the Company. The claim is that he is entitled to the common shares in consideration of brokering the acquisitions subject to the Share Exchange Agreement with Dr. Friedenberg. In addition, the individual is claiming a finder's fee of five percent of the funds raised by a September 1992 private placement. He alleges that a sum of one million dollars was raised. Finally, he claims that he is entitled to a consulting fee of $24,000. Management denies the claims and is vigorously contesting the suit. It is scheduled for a jury trial in the 4th calendar quarter of 2000.

(d) Phamatech Case

On January 26, 1999, the Company was granted a U.S. Patent for the design of the Multiple Test Card, known as the Rapid Drug Screen. On April 7, 1999, the Company filed suit in the federal court in Delaware against Phamatech, Inc. of California. Phamatech, Inc. of California was a former supplier of the Company and in that capacity acquired proprietary information on its Rapid Drug Screen that it allegedly used to "knock off" the Company's product. This case was transferred from Delaware to California. On July 24, 2000, the California court granted American Bio Medica Corporation's motion to

F-17

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE K - COMMITMENTS, CONTINGENCIES AND OTHER MATTERS (CONTINUED)

[4] LITIGATION: (CONTINUED)

(d) Phamatech Case (continued)

add Tuan Pham, President of Phamatech, as an individual defendant in the suit. The court also ordered that Wolfe & Associates (aka Wolfe Data) and James Wolfe, Elite Health Services, LLC and John Polanco (former distributors now selling the alleged infringing products) be joined as defendants. Peninsula Drug Analysis Co., Inc. and James Ramsey (former distributor selling an alleged private label knock off believed by the Company to be manufactured by Phamatech), and Dipro Diagnostics of North America (another party selling an alleged private label knock off believed to be manufactured by Phamatech) are already parties to the Phamatech suit. The Company is alleging patent infringement, violation of trademark rights and unfair competition against all parties.

On April 8, 1999, Phamatech Inc. filed suit in the federal court in San Diego, California asking for a declaration that the Company's patent is invalid. It also claimed breach of contract damages for an alleged nonpayment of invoices by the Company. The Company's transferred Delaware case and Phamatech's California case have been placed on the same trial docket in San Diego. By Order dated July 24, 2000, the Court ordered the competing California based suits be consolidated in one case. In a recent motion, Phamatech sought summary judgment. The trial court denied the motion as to Phamatech's declaratory judgment on the Company's patent claims. Since the Company's trademark had not been registered, even though the petition for trademark is on appeal within the United States Patent and Trademark Office ("PTO"), the trial court denied the Company's trademark claim. However, the Court did not deal with the Company's trade dress claim. Phamatech has now moved for partial summary judgment on the Company's trade dress claim even though the Company's application for trademark protection of its trade dress is still pending before the examiner at the PTO.

In October 1999, the Company sued Larry Hartselle, Drug Detection Devices, and Gulf Supply for patent infringement, trademark dilution, and unfair competition. It is alleged that they are also selling the Phamatech knock off. Drug Detection Devices is alleged to be selling yet another private label manufactured by Phamatech. Larry Hartselle d/b/a Instant Drug Detection is a former distributor now selling the alleged Phamatech knock-off. Gulf Supply is alleged to be selling the private label knock off sold by Drug Detection Devices. The claims against Hartselle and Drug Detection Devices have been settled by the parties. An injunction will issue against Larry Hartselle prohibiting further infringement. The remaining defendant, Gulf Supply, is in settlement negotiations with the Company.

[5] RESTRICTED CASH:

The Company collateralized a bank loan totalling $105,000 for the chairman of the board of directors/stockholder with a certificate of deposit in the bank amounting to $112,000.

[6] MAJOR CUSTOMER:

During the year ended April 30, 2000, there were no major customers representing 10% of sales. During the year ended April 30, 1999, one customer accounted for approximately 17% of net sales.

[7] 401(K) PLAN:

Effective January 1, 1999, the Company adopted a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company at its discretion may make certain contributions to the plan. No such contributions have been made through April 30, 2000.

F-18

AMERICAN BIO MEDICA CORPORATION

NOTES TO FINANCIAL STATEMENTS
APRIL 30, 2000

NOTE L - GEOGRAPHIC INFORMATION

Information concerning sales by principal geographic is as follows:

YEAR ENDED APRIL 30,

                                               2000             1999
                                          --------------   --------------

United States                             $    7,073,000   $    6,477,000
North America (not domestic)                     276,000           22,000
Europe                                           155,000           70,000
Asia/Pacific Run                                  11,000           34,000
South America                                    138,000          435,000
                                          --------------   --------------

                                          $    7,653,000   $    7,038,000
                                          ==============   ==============

F-19

AMERICAN BIO MEDICA CORPORATION

INDEX TO EXHIBITS

Number                              Description of Exhibits
------                              -----------------------

   3.5   Bylaws*

3.6 Fifth Amendment to Certificate of Incorporation (filed as exhibit 3.6 to the Company's Form SB-2 filed on November 21, 1996 and incorporated herein by reference)

4.6 Fiscal 1997 Nonstatutory Stock Option Plan (filed as part of the Company's Proxy Statement for its Fiscal 1997 Annual Meeting and incorporated herein by reference) (a)

4.14 Fiscal 1998 Nonstatutory Stock Option Plan (filed as part of the Company's Proxy Statement for its Fiscal 1998 Annual Meeting and incorporated herein by reference) (a)

4.15 Fiscal 2000 Nonstatutory Stock Option Plan (filed as part of the Company's Proxy Statement for its Fiscal 2000 Annual Meeting and incorporated herein by reference) (a)

4.16 Common Stock Purchase Agreement dated as of April 28, 2000 by and between the Company and Seaside Partners, L.P.

10.6 Contract of Sale dated May 19, 1999/Kinderhook, New York facility

10.7 Agreement of Lease dated May 13, 1999/Kinderhook, New York facility

10.8 Lease dated August 1, 1999/New Jersey facility

23.1 Consent of Independent Auditors

27 Financial Data Schedule


Indicates an employee benefit plan, management contract or compensatory plan or arrangement in which a named executive officer participates.

* Filed as the exhibit number listed to the Company's Form 10-SB filed on November 21, 1996 and incorporated herein by reference.

E-1

EXHIBIT 4.16

COMMON STOCK PURCHASE AGREEMENT

This Common Stock Purchase Agreement (this "AGREEMENT" ) is made as of this 28th day of April, 2000 by and between American Bio Medica Corporation, a New York corporation (the "COMPANY"), and Seaside Partners, L.P., a Delaware limited partnership (the "INVESTOR").

THE PARTIES HEREBY AGREE AS FOLLOWS:

1. PURCHASE AND SALE OF CONVERTIBLE PREFERRED STOCK.

1.1 Investment by the Investor. Subject to the terms and conditions of this Agreement, at the Closing (as defined below), the Company will issue and sell to the Investor, and the Investor will purchase from the Company, an aggregate of 1,408,450 common shares, par value $0.01 per share, of the Company (the "COMMON STOCK") at a purchase price per share equal to $1.42 (the "CLOSING PRICE"), for an aggregate purchase price of $2,000,000 (the "INVESTMENT AMOUNT"). The Common Stock, together with the Warrants and the Warrant Shares (each as defined below) are collectively referred to as the "SECURITIES".

1.2 Closing. The purchase and sale of the Common Stock (the "CLOSING") shall take place at the offices of Buchanan Ingersoll Professional Corporation, 650 College Road East, Princeton, New Jersey 08540 at 10:00 a.m. on April 28, 2000, or such other date as the parties may mutually agree (the "CLOSING DATE").

1.3 Use of Proceeds. The Company will use the proceeds from the sale of the Common Stock solely for the purposes set forth on SCHEDULE 1.

2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company hereby represents and warrants to the Investor, except as disclosed on the Schedule of Exceptions attached hereto as SCHEDULE 2, such disclosures specifically identifying the subsection of this SECTION 2 that they modify, as follows:

2.1 Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of New York. The Company has all requisite power and authority to carry on its business as now conducted and as proposed to be conducted. The Company has all requisite power and authority to enter into and perform this Agreement and the transactions contemplated hereby and is duly qualified to transact business and is in good standing in each jurisdiction in which the failure so to qualify could have a material adverse effect on its business, properties, operations, earnings, assets, liabilities, condition (financial or otherwise) or prospects (collectively, "CONDITION").

2.2 Capitalization.

(a) After giving effect to the transactions contemplated by this Agreement, and immediately after the Closing, the capital stock of the Company, as authorized by its Certificate of Incorporation, will consist of: (i) an aggregate of 5,000,000 authorized 8% Series D Convertible Preferred Shares, $0.01 par value (the "SERIES D STOCK"), no shares of


which shares are issued and outstanding; (ii) an aggregate of 30,000,000 authorized common shares, par value $0.01 per share, of which (A) 18,045,548 shares will be validly issued and outstanding, (B) 1,263,142 shares will be reserved for future issuance to key employees, non-employee directors and consultants of the Company under the Company's Fiscal 1997 Non-Statutory Stock Option Plan; (C) 985,000 shares will be reserved for future issuance to key employees, non-employee directors and consultants of the Company under the Company's Fiscal 1998 Non-Statutory Stock Option Plan; (D) 1,000,000 shares will be reserved for future issuance to key employees, non-employee directors and consultants of the Company under the Company's Fiscal 2000 Non-Statutory Stock Option Plan; (E) 250,000 shares will be reserved for future issuance to Dr. Steiner under that certain Consulting Agreement dated December 31, 1999 between Dr. Steiner and the Company; (F) up to 2,134,016 shares (the "WARRANT SHARES") will be reserved for issuance upon exercise of the Warrants (as defined below) and (G) 309,342 shares will be reserved for future issuance upon exercise of certain other outstanding warrants. The rights, privileges and preferences of the Series D Stock and the Common Stock are as stated in the Company's Certificate of Incorporation.

(b) Except for Common Stock reserved for issuance as described in SECTION 2.2(a), as of the Closing, the Company will not (i) have outstanding any capital stock or other securities convertible into or exchangeable for any shares of its capital stock and, except as otherwise contained in the Certificate of Incorporation or pursuant to the terms of any of the Purchase Documents (as defined in SECTION 2.3), no person will have any right to subscribe for or to purchase (including conversion or preemptive rights), or any options for the purchase of, or any agreements providing for the issuance (contingent or otherwise) of, any calls, commitments or other claims of any character relating to, any capital stock or any stock or securities convertible into or exchangeable for any capital stock of the Company; (ii) have any capital stock, equity interests or other securities reserved for issuance for any purpose; or (iii) be subject to any obligation (contingent or otherwise) to repurchase or otherwise acquire or retire any shares of its capital stock or any convertible securities, rights or options of the type described in the preceding clause (i). All of the issued and outstanding shares of Common Stock and Series D Stock have been duly and validly issued and are fully paid and nonassessable and all of the shares of Conversion Stock and the Warrant Shares, when issued as contemplated hereby, will be validly issued, fully paid and nonassessable. To the best knowledge of the Company, there are no agreements among the Company's stockholders with respect to the voting or transfer of the Company's capital stock, other than the agreements contained herein. SCHEDULE 3 attached hereto includes a complete and correct list of the name of each of the Company's current or former officers, directors, employees or Persons that beneficially own in excess of 5.0% of the outstanding equity interest of the Company (each, a "PRINCIPAL OWNER") and the number of shares of Common Stock owned by each such Principal Owner as of the Closing Date.

2.3 Authority; Execution and Delivery; Requisite Consents; Nonviolation. The Company has, and as of the Closing will have, all requisite power and authority to execute, deliver and perform this Agreement and each other document or instrument executed by it, or any of its officers, in connection herewith or therewith or pursuant hereto or thereto (this Agreement, together with all of the foregoing documents and instruments, are sometimes collectively referred to herein as the "PURCHASE DOCUMENTS"), and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance of this Agreement and the other

-2-

Purchase Documents and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary action on the part of the Company. This Agreement and each of the other Purchase Documents that has been executed as of the date hereof are, and each of the Purchase Documents will be as of the Closing, duly executed and delivered by the Company and the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws affecting the enforceability of creditors' rights in general or by general principles of equity. The execution, delivery and performance of this Agreement and the other Purchase Documents, the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the offer, sale and delivery by the Company of the Securities) will not: (a) require the consent, license, permit, waiver, approval, authorization or other action of, by or with respect to, or registration, declaration or filing with, any court or governmental authority, department, commission, board, bureau, agency or instrumentality, domestic or foreign ("GOVERNMENTAL AUTHORITY") or any other individual, partnership, corporation, unincorporated organization or association, limited liability company, trust or other entity (collectively, a "PERSON"); (b) violate or conflict with any provision of the Certificate of Incorporation or the By-laws of the Company, complete and correct copies of which have been provided to counsel to the Investor; or (c) constitute a default (with or without the giving of notice or lapse of time or both) under, violate or conflict with, or give rise to a right of termination, cancellation or acceleration or to a loss of a material benefit under any Law (as defined in
SECTION 2.6), Permit (as defined in SECTION 2.6), Order (as defined in SECTION 2.5), or contract, agreement, arrangement or understanding, written or oral, to which the Company is or hereafter may be a party to or by which the Company or its properties are or hereafter may be bound.

2.4 Subsidiaries. The Company has no subsidiaries and does not, and prior to the Closing will not, own or control, directly or indirectly, any partnership interests, stock or other equity interests in any partnership, corporation or other entity or any voting rights or right to control the policies and direction of any partnership, corporation or other entity.

2.5 Litigation. There is no action, suit, proceeding, investigation or governmental approval process (collectively, "ACTIONS") pending or, to the best knowledge of the Company, threatened against it, or affecting any of its properties or assets (including, without limitation, any of its Permits) which individually or in the aggregate could have a material adverse effect on its Condition, nor is there any basis for any such Action. To the best knowledge of the Company, there is no Action against any of its directors, officers or employees in connection with its business which, in the event of an adverse judgment against any such Person, could have a material adverse effect on the Condition of the Company, nor is there any basis for any such Action. The foregoing includes, without limitation, any Action pending or, to the Company's best knowledge, threatened (or any basis therefor known to the Company) involving the prior employment of any employees of the Company, their use in connection with the business of the Company of any information or techniques allegedly proprietary to any of their former employers, or their obligations under any agreements with prior employers. Neither the Company nor any of its assets or properties, nor, in connection with its business, to the Company's best knowledge, any of its stockholders, directors, officers or employees, is subject to any order, judgment, writ, injunction, decree, ruling or decision (collectively, an "ORDER") of any

-3-

Governmental Authority which is material to the Condition of the Company. There is no Action by the Company currently pending or which the Company intends to initiate which is material to its Condition.

2.6 Compliance with Laws; Permits. Assuming the accuracy of the representations made by the Investor pursuant to SECTION 3, the offer and sale of the Securities to the Investor will be in compliance with all applicable federal and state securities laws. The Company has not violated or failed to comply with, in any material respect, any statute, law, ordinance, rule, regulation or policy of any Governmental Authority (collectively, "LAWS") to which it or any of its properties or assets is subject. The Company has all permits, licenses, orders, certificates, authorizations and approvals of any Governmental Authority (collectively, the "PERMITS") that are material to the conduct of its business as presently conducted and as proposed to be conducted; all such Permits are, and as of the Closing will be, in full force and effect; no violations or notices of failure to comply have been issued or recorded in respect of any such Permits; and the Company has no knowledge of any reason why such Permits may be revoked or suspended. All applications, reports, notices and other documents required to be filed by the Company with all Governmental Authorities have been timely filed and are complete and correct in all material respects as filed or as amended prior to the date hereof. With respect to any required Permits, applications for which are either pending or contemplated to be made pursuant to the business strategy of the Company, the Company knows of no reason why such Permits should not be approved and granted by the appropriate Governmental Authority. Neither the Company nor, to the Company's best knowledge, any of its officers, employees or agents has made any illegal or improper payments to, or provided any illegal or improper inducement for, any governmental official or other Person in an attempt to influence any such Person to take or to refrain from taking any action relating to the Company.

2.7 Absence of Certain Changes or Events. Since December 31, 1999, there has been no change in the Condition of the Company, except for changes in the ordinary course of business consistent with past practice which have not been, in the aggregate, materially adverse to the Company.

2.8 Title to Assets. The Company has good and marketable title to all of its assets and properties, free and clear of any liens, pledges, security interests, claims, encumbrances or other restrictions of any kind (collectively, "LIENS"). With respect to any assets or properties it leases, the Company holds a valid and subsisting leasehold interest therein, free and clear of any Liens, is in compliance, in all material respects, with the terms of the applicable lease, and enjoys peaceful and undisturbed possession under such lease. All of the assets and properties of the Company that are material to the conduct of business as presently conducted or as proposed to be conducted by it are in good operating condition and repair, subject to ordinary wear and tear. The inventory of the Company is in good and marketable condition, does not and will not include any material quantity of items which are obsolete, damaged or slow moving, and is salable (or may be leased) in the normal course of business as currently conducted by it, at current applicable prices and within normal inventory "turn" experience.

2.9 Contracts. True and correct copies of all contracts, agreements, notes, instruments, franchises, leases, licenses, commitments, arrangements or understanding, written or oral (collectively, "CONTRACTS") which are material to the Condition of the Company have been

-4-

made available to the Investor. All of the Contracts are in full force and effect and constitute legal, valid and binding obligations of the Company and, to the best knowledge of the Company, the other parties thereto; the Company and, to the best knowledge of the Company, each other party thereto, has performed in all material respects all obligations required to be performed by it under the Contracts, and no material violation or default exists in respect thereof, nor any event that with notice or lapse of time, or both, would constitute a default thereof, on the part of the Company or, to the best knowledge of the Company, any other party thereto; none of the Contracts is currently being renegotiated; and the validity, effectiveness and continuation of all Contracts will not be materially adversely affected by the transactions contemplated by this Agreement.

2.10 Intellectual Property. (a) (i) The Company owns, or has the right to use, all United States and foreign patents, trademarks, service marks, trade names, brand names, computer software and programs, franchises, technology, know-how and processes, and registered copyrights, and any applications for any of the foregoing (collectively, the "INTELLECTUAL PROPERTY") of any kind in which the Company has an interest or which is otherwise used in, or relates to its business. SCHEDULE 4 hereto contains a true, correct and complete list of all registered trademarks and service marks, all reserved trade names, all registered copyrights and all filed patent applications and issued patents that are used in the Company's business or are otherwise necessary for the conduct of its business as heretofore conducted and all licenses or agreements that in any way affect the rights of the Company to any of its Intellectual Property or any trade secret material (the "INTELLECTUAL PROPERTY LICENSES").

(ii) Subject to the limitations set forth in the Intellectual Property Licenses, the Company has all right, title and interest in all of the Intellectual Property, free and clear of all Liens. The Company owns or has the exclusive or non-exclusive right to use all Intellectual Property or trade secrets necessary to conduct its business as now being conducted or as proposed to be conducted. The Company owns or possesses sufficient licenses or other rights to use all Intellectual Property covered by its patents or patent applications necessary to conduct its business as now being conducted and as proposed to be conducted by the Company.

(iii) The Company has not disclosed, other than in the ordinary course of business and consistent with past practice and pursuant to the Intellectual Property Licenses, any proprietary information relating to the Intellectual Property or the Intellectual Property Licenses to any person other than the Investor and the previous investors in the Company. The Company has at all times maintained reasonable procedures to protect and has enforced all of its trade secrets. The Company has disclosed trade secrets to other Persons solely as required for the conduct of its business and solely under nondisclosure agreements that are enforceable by the Company. Other than pursuant to the Intellectual Property Licenses, the Company is not under any contractual or other obligation to disclose any proprietary information relating to the Intellectual Property, any trade secret material to the Company or the Intellectual Property Licenses, nor, to the best knowledge of the Company, is any other party to the Intellectual Property Licenses under any such obligation to disclose proprietary information included in or relating to the Intellectual Property, any trade secret material to the Company or the Intellectual Property Licenses to any Person, and no event has taken place, including the execution and delivery of this Agreement and the transactions contemplated hereby or any related change in the business activities of the Company, that would give rise to such obligation.

-5-

(iv) The consummation of the transactions contemplated hereby will not alter, adversely affect or impair the rights of the Company to any of the Intellectual Property, any trade secret material to it, or under any of the Intellectual Property Licenses.

(b) (i) No claim with respect to the Intellectual Property, any trade secret material to the Company, or any Intellectual Property License which would adversely affect the ability of the Company to conduct its business as presently conducted and as proposed to be conducted is currently pending or, to the best knowledge of the Company, has been asserted, or overtly threatened by any Person, nor does the Company know of any grounds for any claim against the Company: (A) to the effect that any operation or activity of the Company presently occurring or contemplated, including, among other things, the manufacture, use or sale of any product, device, instrument, or other material made or used according to the patents or patent applications included in the Intellectual Property or Intellectual Property Licenses, infringes or misappropriates any United States or foreign copyright, patent, trademark, service mark or trade secret; (B) to the effect that any other Person infringes on the Intellectual Property or misappropriates any trade secret or know-how or other proprietary rights material to the Company; (C) challenging the ownership, validity or effectiveness of any of the Intellectual Property or trade secret material of the Company; or (D) challenging the license of the Company or other legally enforceable right under, any Intellectual Property or the Intellectual Property Licenses.

(ii) The Company is not aware of any presently existing United States or foreign patents or any patent applications which if issued as patents would be infringed by any activity contemplated by the Company.

(c) (i) The United States and foreign patents and patent applications owned by the Company listed in SCHEDULE 5 hereto (the "PATENTS AND APPLICATIONS") as part of the Intellectual Property have been properly prepared and filed on behalf of the Company as named therein and are being diligently pursued by the Company. The inventions described in the Patents and Applications are assigned or licensed to the Company and no other entity or individual has any right or claim in any of the inventions, Patents and Applications or any patents to be issued therefrom, except as set forth in the Intellectual Property Licenses. To the Company's best knowledge, there are no defects in any of the Patents and Applications that would cause any of them to be held invalid or unenforceable. All relevant prior art of which the Company is aware has been filed in the Patents and Applications.

(ii) The Company has delivered to the Investor all information in its possession or of which it has knowledge concerning the Patents and Applications and has no knowledge of any objection or proceeding, pending or threatened, that would affect the validity of any patent issued pursuant thereto. The Company has furnished to the Investor all prior art, of which it presently has knowledge, that may be material to the validity or enforceability of the patent claims being prosecuted in the Patents and Applications.

(iii) Except in connection with the prosecution of the patent applications listed in SCHEDULE 5 hereto, there are no pending judicial or governmental proceedings, including but not limited to interferences and oppositions, relating to any of the Patents and Applications or any other proprietary information to which the Company is a party or

-6-

by which any property (including rights pursuant to licenses or options or other rights to acquire licenses) of the Company is subject, and no such proceedings are threatened or contemplated by Governmental Authorities or other Persons.

(d) Nothing has come to the attention of the Company that has caused it to believe that this SECTION 2.10, as of the date hereof and as of the Closing, contains any untrue statement of a material fact or omits to state a material fact required to be stated herein or necessary to make the statements herein not misleading.

2.11 Insurance. The Company has in full force and effect all insurance policies as are sufficient for compliance with all requirements of Law and applicable agreements.

2.12 Labor Union Activities; Employee Relations. No employee of the Company is represented by any labor union or covered by any collective bargaining agreement; nor, to the best knowledge of the Company, has any labor union sought to represent any of its employees of the Company. There is no strike or other labor dispute involving the Company pending, or to the best knowledge of the Company, threatened. To the best knowledge of the Company, no officer or key employee intends to terminate his employment with it. To the best knowledge of the Company, no officer or key employee of it is a party to or bound by any Contract, or subject to any restrictions (including, without limitation, any non-competition restriction), which would restrict the right of such person to participate in the affairs of the Company.

2.13 ERISA. The Company does not maintain (nor has it ever maintained) nor does it have (nor has it ever had) any obligation under (including, without limitation, any obligation to contribute to) an employee benefit plan as described in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended ("ERISA").

2.14 Taxes. All federal, state, city, county, local and foreign income, franchise, sales, use and value added tax returns and reports, and all other material tax returns and reports required to be filed by the Company in those or in any other jurisdiction (collectively, "RETURNS") have been timely filed. All such Returns are true, correct and complete in all material respects. All taxes, assessments, fees, interest, penalties and other charges with respect thereto (collectively, "TAXES") due or claimed to be due from the Company have been paid except to the extent reserved against on the Company's financial statements. No income tax return of the Company has been audited by the applicable Governmental Authority, and there are in effect no waivers of the applicable statute of limitations for Taxes in any jurisdiction for the Company for any period.

2.15 Environmental Matters. The business, assets and properties of the Company are and have been operated and maintained in compliance with all applicable federal, state, city, county and local environmental protection laws and regulations (collectively, the "ENVIRONMENTAL LAWS"). No event has occurred which, with or without the giving of notice or the passage of time or both, would constitute non-compliance by the Company with, or a violation by the Company of, the Environmental Laws. The Company has not caused or permitted to exist, as a result of an intentional or unintentional act or omission, a disposal, discharge or release of solid wastes, pollutants or hazardous substances, on or from any site

-7-

which currently is or formerly was owned, leased, occupied or used by it, except where such disposal, discharge or release was in compliance with the Environmental Laws.

2.16 Books and Records. The books of account, ledgers and records of the Company accurately and completely reflect in all material respects all information relating to its business, the nature, acquisition, maintenance, location and collection of its assets, and the nature of all transactions giving rise to its obligations or accounts receivable. The minute books of the Company fully set forth all action taken by its Board of Directors, stockholders and, if any, executive committee (or other committee thereof).

2.17 Transactions with Affiliates. Except for the loan from the Company to Stan Cipkowski reflected as "Due from Officers" on the Company's most recent balance sheet filed with the Securities and Exchange Commission (the "SEC"), the Company has not had any direct or indirect dealings with any Principal Owner or with any of such Principal Owner's Affiliates, associates or relatives and the Company has no obligation to or claim against any Principal Owner, or any of such Principal Owner's Affiliates, associates or relatives, and no such Person has any obligation to or claim against the Company. All products, services or benefits provided to the Company by any such Person, or provided by the Company to any such Person are provided at a charge equal to the fair market value of such products, services or benefits. No Principal Owner, nor to the Company's best knowledge any of such Principal Owner's Affiliates, associates or relatives, has any direct or indirect interest of any kind in any business or entity which is competitive with the Company. An "AFFILIATE" of a specified Person shall mean a person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the Person specified.

2.18 Registration Rights. Except for the registration rights granted to the Investor by this Agreement and the registration rights granted to the holders of outstanding Warrants, no Person has, and as of the Closing no Person shall have, demand, "piggy-back" or other rights to cause the Company to file any registration statement under the Securities Act of 1933, as amended (the "SECURITIES ACT"), relating to any of its securities or to participate in any such registration statement.

2.19 No Brokers or Finders. Neither the Company nor any of its respective Affiliates has entered or will enter into any agreement pursuant to which the Company or the Investor will be liable, as a result of the transactions contemplated by this Agreement or any of the Purchase Documents, for any claim of any person for any commission, fee or other compensation as finder or broker and the Company agrees to indemnify the Investor for any liability resulting from any such agreement.

2.20 Investment Company Act. The Company is not an "Investment Company" nor is the Company directly or indirectly controlled by or acting on behalf of any Person which is an "Investment Company" within the meaning of the Investment Company Act of 1940, as amended.

2.21 Business Plan. Any business information of the Company previously submitted to the Investor in any form, including the projections contained therein, was prepared by the senior management of the Company, is based on assumptions which are reasonable, and

-8-

reflects management's best judgment based on present circumstances of the most likely set of conditions and courses of action and most likely financial condition and results of operations, for the period(s) reflected therein. The Company is not aware of any fact or condition which could reasonably be expected to result in the Company not achieving the results described in such business plan.

2.22 Disclosure. In connection with the purchase of the Securities by the Investor as contemplated hereby, the Company has, to its knowledge, disclosed to the Investor all material facts and information concerning the Company, its Condition and the Securities, and has not, to its knowledge, made any untrue statement of a material fact or omitted to state any material fact necessary in order to make the statements contained herein or in any of the other Purchase Documents not misleading.

2.23 SEC Documents. The Company has filed, pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the "EXCHANGE ACT"), all SEC Documents (as defined below) required to be filed with respect to the business and operations of the Company under each of the Securities Act and Exchange Act, and the business and operations of the Company under each of the Securities Act and the Exchange Act, and the respective rules and regulations thereunder, and all of the SEC Documents complied in all material respects with all applicable requirements of the Securities Act or the Exchange Act, as the case may be, and the appropriate act and the rules and regulations thereunder in effect on the date each such report was filed. At the respective dates they were filed, none of the SEC Documents contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The consolidated financial statements of the Company included in the SEC Documents complied in all material respects with the applicable accounting requirements and the published rules and regulations of the Securities and Exchange Commission with respect thereto, have been prepared in accordance with GAAP consistently applied throughout the periods involved (except as may be indicated therein or in the notes thereto) and fairly present the consolidated financial position, results of operations and cash flows of the Company as of the dates and for the periods indicated therein, subject, in the case of the unaudited statements, to normal year-end adjustments and the absence of certain footnote disclosures. "SEC DOCUMENTS" means all material, forms, statements, reports and documents (including all exhibits, amendments and supplements thereto) required to be filed with respect to the business and operations of the Company under each of the Securities Act and the Exchange Act, and the respective rules and regulations thereunder.

3. REPRESENTATIONS AND WARRANTIES OF THE INVESTOR. The Investor hereby represents and warrants to, and agrees with, the Company as follows:

3.1 Organization. The Investor is, and as of the Closing will be, duly organized, validly existing and in good standing under the laws of its jurisdiction of organization.

3.2 Authorization. The Investor has, and as of the Closing will have, all requisite power and authority to execute, deliver and perform this Agreement and to consummate the transactions contemplated hereby. The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly and

-9-

validly authorized by all necessary action on the part of the Investor. This Agreement has been duly executed and delivered by the Investor and constitutes its legal, valid and binding obligation, enforceable against the Investor in accordance with its terms, except as its enforceability may be limited by bankruptcy, insolvency or other similar laws affecting the enforceability of creditors' rights in general or by general principles of equity.

3.3 No Legal Bar; Conflicts. Neither the execution and delivery of this Agreement, nor the consummation by the Investor of the transactions contemplated hereby, violates any law, statute, ordinance, regulation, order, judgment or decree of any court or governmental agency applicable to the Investor, or violates, or conflicts with, any contract, commitment, agreement, understanding or arrangement of any kind to which the Investor is a party or by which the Investor is bound.

3.4 No Litigation. No action, suit or proceeding against the Investor relating to the consummation of any of the transactions contemplated by this Agreement nor any governmental action against the Investor seeking to delay or enjoin any such transactions is pending or, to the Investor's knowledge, threatened.

3.5 Investment Intent. The Investor (i) is an accredited investor within the meaning of Rule 501(a) under the Securities Act, (ii) is aware of the limits on resale imposed by virtue of the nature of the transactions contemplated by this Agreement and is aware that the certificates representing the Investor's respective ownership of Common Stock will bear related restrictive legends and (iii) except as otherwise set forth herein, is acquiring the shares of the Company hereunder without registration under the Securities Act in reliance on the exemption from registration contained in Section 4(2) of the Securities Act, for investment for its own account, and not with a view toward, or for sale in connection with, any distribution thereof, nor with any present intention of distributing or selling such shares. The Investor has been given the opportunity to ask questions of, and receive answers from, the officers of the Company regarding the Company, its current and proposed business operations and the Common Stock, and the officers of the Company have made available to the Investor all documents and information that the Investor has requested relating to an investment in the Company. The Investor has been represented by competent legal counsel in connection with its purchase of the Common Stock and acknowledges that the Company has relied upon the Investor's representations in this SECTION 3 in offering and selling Common Stock to the Investor.

3.6 No Brokers or Finders. Neither the Investor nor any of its respective Affiliates has entered or will enter into any agreement pursuant to which the Investor or the Company will be liable, as a result of the transactions contemplated by this Agreement or any of the Purchase Documents, for any claim of any person for any commission, fee or other compensation as finder or broker and the Investor agrees to indemnify the Company for any liability resulting from any such agreement.

3.7 Economic Risk; Restricted Securities. The Investor recognizes that the investment in the Securities involves a number of significant risks. The foregoing, however, does not limit or modify the representations, warranties and agreements of the Company in SECTION 2 or the right of the Investor to rely thereon. The Investor is able to bear the economic

-10-

risks of an investment in the Securities for an indefinite period of time, has no need for liquidity in such investment and, at the present time, can afford a complete loss of such investment.

4. CONDITIONS TO THE INVESTOR'S OBLIGATION TO CLOSE. The obligation of the Investor to purchase the Securities to be purchased by it at the Closing is subject to the fulfillment, to the Investor's satisfaction, prior to or at the Closing, of each of the following conditions:

4.1 Representations and Warranties. The representations and warranties of the Company contained in this Agreement and the other Purchase Documents shall be true and correct in all material respects on and as of the Closing Date as if made on and as of such date.

4.2 Performance. The Company shall have performed and complied with all agreements and conditions required by this Agreement and the other Purchase Documents to be performed or complied with by it prior to or at the Closing.

4.3 Stock Certificates. Etc. At the Closing, the Company shall have tendered to the Investor a certificate representing the Investor's shares of Common Stock, all in form and substance satisfactory to the Investor and sufficient to transfer to, and vest in, the Investor good and valid title to the Common Stock, free and clear of any Lien.

4.4 Conduct of Business. The Company shall carry on its business diligently and shall not make or institute any unusual methods of management, accounting or operation, except as agreed to in writing by the Investor. All of the property of the Company shall be used, operated, repaired and maintained in a normal business manner consistent with past practice.

4.5 Compliance With Laws. The Company will comply in all material respects with all laws and regulations which are applicable to it, its ownership of its assets or to the conduct of its business and will perform and comply in all material respects with all contracts, commitments and obligations by which it is bound.

4.6 No Material Adverse Change. There shall not have occurred any material adverse change in the Condition of the Company.

4.7 Consents. The Company shall have obtained all consents, approvals or waivers from Governmental Authorities and third Persons necessary for the execution, delivery and performance of this Agreement, the other Purchase Documents and the transactions contemplated hereby and thereby, all without material cost or other adverse consequences to the Company. Without limiting the generality of the foregoing, if applicable, each of the Company's existing stockholders shall have waived any preemptive right or right of first offer any such stockholder may have to purchase any of the Securities.

4.8 No Litigation. There shall not be any Action of or before any Governmental Authority or other Person pending or threatened with respect to this Agreement, the other Purchase Documents or the transactions contemplated hereby or thereby or which might materially adversely affect the Condition of the Company.

4.9 Opinion of Counsel. The Investor shall have received from Hopkins & Sutter an opinion dated as of the Closing, in the form attached hereto as EXHIBIT A.

-11-

4.10 Compliance Certificate. The Investor shall have received a certificate dated as of the day of the Closing executed by the President of the Company certifying that the conditions specified in this SECTION 4 have been fulfilled.

4.11 Related Documents. The Purchase Documents shall have been executed and delivered by each of the parties thereto and be in full force and effect.

4.12 Due Diligence. The Investor shall have completed its business, financial and legal due diligence to its satisfaction, in its sole and unreviewable judgment.

4.13 Financing. The Investor shall have consummated on or before the Closing Date a financing on such terms, subject to such conditions and in such amount as are acceptable to the Investor, in its sole discretion.

4.14 Voting Agreement. The Investor, the Company and the holders of at least 5,000,000 of the outstanding common shares of the Company have entered into a voting agreement (the "VOTING AGREEMENT"), substantially in the form attached as EXHIBIT B.

4.15 Proceedings and Documents. All proceedings in connection with the transactions contemplated hereby and all documents and instruments incident to such transactions shall be satisfactory in substance and form to the Investor and its counsel, in all material respects, and the Investor shall have received all such counterpart originals or certified or other copies of such documents as the Investor may reasonably request.

If at the Closing the Company fails to tender to the Investor the documents specified herein which are required to be delivered to the Investor at the Closing or if at the Closing any of the conditions specified in this SECTION 4 shall not have been fulfilled to the Investor's reasonable satisfaction, the Investor shall, at its election, be relieved of all further obligations under this Agreement.

5. CONDITIONS OF THE COMPANY'S OBLIGATIONS AT CLOSING. The obligations of the Company to the Investor under this Agreement are subject to the fulfillment, prior to or at the Closing, of each of the following conditions:

5.1 Representations and Warranties. The representations and warranties of the Investor contained in this Agreement shall be true and correct in all material respects on and as of the Closing Date as if made on and as of such date.

5.2 Payment of Purchase Price. The Investor shall have delivered to the Company the Investment Amount.

5.3 No Litigation. There shall not be any Action of or before any Governmental Authority or other Person pending or threatened with respect to this Agreement or the transactions contemplated hereby.

5.4 Proceedings and Documents. All proceedings in connection with the transactions contemplated hereby and all documents and instruments incident to such transactions shall be satisfactory in substance and form to the Company and its counsel, and the

-12-

Company shall have received all such counterpart originals or certified or other copies of such documents as it may reasonably request.

If at the Closing the Investor fails to tender to the Company the payment or documents specified herein which are required to be delivered to the Company at the Closing or if at the Closing any of the conditions specified in this SECTION 5 shall not have been fulfilled to the Company's reasonable satisfaction, the Company shall, at its election, be relieved of all further obligations to the Investor under this Agreement.

6. CERTAIN POST-CLOSING COVENANTS OF THE COMPANY. The Company covenants and agrees with the Investor as follows:

6.1 Voting Agreement. If not delivered at the Closing, the Company shall enter into and deliver the Voting Agreement to the Investor within thirty
(30) days after the Closing.

6.2 Annual Meetings. The Company will hold an annual meeting of all shareholders at which information with respect to its business will be furnished and discussed.

6.3 Information. The Investor and its assignees shall be entitled to receive, and the Company agrees to provide to the Investor and its assignees, the following:

(a) Financial and Related Data.

(i) If not timely filed with the SEC, as soon as available, but in any event not later than forty-five (45) days after the end of each fiscal quarter, the unaudited balance sheet as at the end of such quarter of the Company and the related unaudited statements of operations, stockholders' equity and cash flows of such quarter and for the elapsed period of such fiscal year, all in reasonable detail and stating in comparative form the figures as of the end of and for the comparable period of the preceding fiscal year and budgeted figures for the period. All such financial statements shall be complete and correct in all material respects subject to year-end adjustments, and shall be accompanied by a certificate of the President or chief financial officer of the Company to such effect.

(ii) If not timely filed with the SEC, as soon as available, but in any event within 90 days after the end of each fiscal year of the Company, the audited balance sheet of the Company as at the end of such fiscal year and the related audited statements of operations, stockholders' equity and cash flows of the Company for such fiscal year, all in reasonable detail and stating in comparative form the figures as at the end of and for the previous fiscal year and budgeted figures for the fiscal year, accompanied by an opinion of an accounting firm of nationally recognized standing selected by the Company with respect to such financial statements, which opinion shall state that such accounting firm's audit was conducted in accordance with generally accepted auditing standards and, accordingly, included such tests of accounting records and such other auditing procedures as were considered necessary under the circumstances and which opinion shall not be subject to any qualification resulting from a limit on the scope of the examination of the financial statements or the underlying data or which could be eliminated by changes in the financial statements or the notes thereto or by the creation of or

-13-

increase in a reserve or a decreased carrying value of assets. All such financial statements shall be complete and correct in all material respects and prepared in reasonable detail and in accordance with GAAP applied, except as stated therein, on a consistent basis throughout the periods reflected therein.

(iii) As soon as available, but in any event not later than 30 days following the end of each fiscal year of the Company, the financial plan and business plan of the Company for the next succeeding fiscal year, including but not limited to cash flow and balance sheet projections and operating budget, calculated monthly, and any updates or revisions as soon as available.

(iv) If not timely filed with the SEC, promptly, but in any event within ten (10) days, after any distribution to its stockholders generally or to specific stockholders by agreement, to its directors, to prospective investors or to the financial community of an annual report, proxy statement, registration statement or other similar report or communication, a copy of each such report, proxy statement, registration statement or other similar report or communication; and promptly, but in any event within ten (10) days after any filing with the Securities and Exchange Commission or with any national securities exchange or with the National Association of Securities Dealers, Inc., of any publicly available annual or periodic or special report or proxy statement or registration statement, a copy of such report or statement; and promptly, but in any event within two (2) business days, after released, copies of all press releases and other statements made available generally by the Company to the public concerning material developments.

(v) From time to time, and promptly, such additional information and financial data regarding results of operations, financial condition, business, affairs or prospects of the Company, which the Investor may reasonably request.

(b) Access to Properties. The Company shall permit representatives designated by the Investor, upon reasonable prior notice to the Company, to visit and inspect each of the Company's properties, to examine its respective corporate and financial records (and make copies thereof or extracts therefrom), to discuss its respective affairs, finances and accounts with the Company's directors and officers, and, through the President or chief financial officer of the Company's, as the case may be, its key employees and accountants, all at such reasonable times as may be requested by the Investor.

6.4 Exemption from Investment Company Act. The Company shall conduct its business so that it shall not become an "investment company" within the meaning of the Investment Company Act of 1940, as amended.

6.5 Accounting and Reserves. The Company shall maintain a standard and uniform system of accounting and shall keep proper books and records and accounts in which full, true and correct entries shall be made of its transactions, all in accordance with GAAP applied on a consistent basis through all periods, and shall set aside on such books for each fiscal year all such proper reserves for depreciation, obsolescence, amortization, bad debts and other purposes in connection with its operations as are required by such principles so applied.

-14-

6.6 Transactions with Affiliates. Except for arrangements for development research involving aggregate amounts less than $50,000, the Company shall not, directly or indirectly, enter into any transaction or agreement with any stockholder of the Company or any Affiliate of the Company, unless the transaction or agreement is (i) reviewed and approved by a majority of Disinterested Directors (as defined below) and (ii) on terms no less favorable to the Company than those obtainable from a non-Affiliated Person. A "DISINTERESTED DIRECTOR" shall mean an individual who is not and who has not been an officer or employee of the Company and who is not a member of the family of, controlled by or under common control with, any such officer or employee.

6.7 Additional Covenants.

(a) The Company shall timely file all such SEC Documents required to be filed by it pursuant to the Exchange Act in order to permit sales under Rule 144 of the Securities Act.

(b) During any period in which the Company is not subject to
Section 13 or 15(d) of the Exchange Act, the Company shall make available information required to be provided by Rule 144A(d)(4), upon request.

(c) Upon the request of the Investor and the certification of the Investor that it qualifies under Rule 144(k) of the Securities Act, the Company shall, without further requirement, remove all restrictive legends from the Investor's Securities, insofar as such restrictions relate to the transfer of such securities under the Securities Act.

6.8 Issuance of Warrants. In the event that upon the six-month anniversary of the Closing Date (the "ANNIVERSARY DATE") the average of the closing prices of the Common Stock on the Nasdaq SmallCap Market (or such other quotation system or securities exchange upon which the Company's Common Stock is then traded) as reported by the Nasdaq Stock Market on the 10 consecutive trading days immediately preceding the Anniversary Date (the "ANNIVERSARY PRICE") is less than 1.5 times the Closing Price, the Company shall grant to the Investor five-year warrant (the "WARRANTS"), to purchase, at an exercise price equal to the Anniversary Price, such number of shares of the Common Stock as determined in accordance with the following formula:

W=(I/CP)x50%x((1.5 x CP)-AP) 0.50 x CP

where:

W = the number of Warrants issuable pursuant to this SECTION 6.8.

I = the Investment Amount.

CP = the Closing Price.

AP = the Anniversary Price.

-15-

Notwithstanding the foregoing, the number of Warrants issuable pursuant to this
SECTION 6.8 shall not exceed 2,134,016. The Warrants shall be substantially in the form attached hereto as EXHIBIT C.

6.9 Registration of Shares of Common Stock and the Warrant Shares.

(a) The Company agrees to register the shares of Common Stock by filing a registration Statement on Form S-3 (or any successor form thereto) with respect to the Common Stock and to have such registration statement declared effective on or prior to the Anniversary Date. The Company shall cause such registration statement to remain effective for (5) years following the Anniversary Date unless the Investor informs the Company that it has liquidated its position.

(b) The Company agrees to register the Warrant Shares by filing a registration statement on Form S-3 (or any successor form thereto) or, if permissible, by filing a post-effective amendment to the Form S-3 filed to register the shares of Conversion Stock, as soon as practicable after the Anniversary Date, but in no event later than sixty (60) days after the Anniversary Date, and using its best efforts to have such registration statement or post-effective amendment, as the case may be, become effective as soon as practicable, but in no event later than ninety (90) days after the Anniversary Date. The Company shall cause such registration statement to remain effective for five (5) years following the Anniversary Date unless the Investor informs the Company that it has liquidated its position.

(c) In the event the Company fails to satisfy its obligations to the Investor under this SECTION 6.9, the Company shall be obligated to pay to the Investor liquidated damages in an amount equal to five percent (5%) per month (or any part thereof), compounded monthly, on the Investment Amount pursuant to Section 6.9(a) or on the amount determined by multiplying the number of Warrants issuable pursuant to Section 6.8 by the Anniversary Date pursuant to
Section 6.9(b), until such time the Company is no longer in breach of this
SECTION 6.9. Any payments due to the Investor pursuant to this SECTION 6.9(C) shall be made no later than the fifteenth (15th) day of the month following the month in which such liquidated damages were incurred.

7. MISCELLANEOUS.

7.1 Hedging Activities. The Investor shall not engage in any hedging transactions (including short sales, put and call options, cashless collar transactions or other forms of derivative security transactions) with respect to the Common Stock that may have an impact on the market price of the Common Stock.

7.2 Expenses. The Company shall pay all of the Investor's legal fees relating to the preparation of this Agreement and all documents related hereto.

7.3 Publicity. Except as may be required by Law, or in connection with a public offering, the Company shall neither use the name of, nor make reference to, the Investor or

-16-

any of its Affiliates in any press release or in any public manner without the Investor's prior written consent.

7.4 Indemnification. The Company agrees to indemnify the Investor and each officer, director, employee, agent, partner, stockholder and Affiliate of the Investor (collectively, the "INDEMNIFIED PARTIES") for, and hold each Indemnified Party harmless from and against: (i) any and all damages, losses, claims and other liabilities of any and every kind, including, without limitation, judgments and costs of settlement, and (ii) any and all out-of-pocket costs and expenses of any and every kind, including, without limitation, reasonable fees and disbursements of counsel for such Indemnified Parties (all of which expenses periodically shall be reimbursed as incurred), in each case, arising out of or suffered or incurred in connection with any of the following: (a) any misrepresentation or any breach of any warranty made by the Company herein or in any of the other Purchase Documents, (b) any breach or non-fulfillment of any covenant or agreement made by the Company herein or in any of the other Purchase Documents, and (c) any claim relating to or arising out of a violation of applicable federal or state securities laws by the Company in connection with the sale of the Securities by the Company to the Investor.

7.5 Survival. All representations, warranties, covenants and agreements contained in or made pursuant to this Agreement or contained in any certificate delivered pursuant to this Agreement, shall remain operative and in full force and effect, regardless of any investigation made by or on behalf of any party hereto, and shall survive the transfer and payment for the Securities and the consummation of the transactions contemplated hereby.

7.6 Assignment. This Agreement and all the provisions hereof shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns, if any, except that neither this Agreement nor any rights or obligations hereunder shall be assigned or delegated by the Company without the prior written consent of the Investor. After the Closing, the Investor and its successors and assigns may, without the consent of the Company, assign this Agreement and/or any of the Investor's rights hereunder and under the other Purchase Documents (including, without limitation, any or all of the Securities), in whole or in part, to (i) any Affiliate of the Investor; (ii) any other transferee of at least 20% of the Securities acquired by the Investor; or (iii) in connection with an estate transfer, provided, however, that the Company shall not be required to permit such Assignment if such Assignment is in violation of federal securities regulations or relevant state "blue sky" laws.

7.7 Amendment; Waiver. Any term, covenant, agreement or condition of this Agreement may be amended, and compliance therewith may be waived (either generally or in a particular circumstance and either retroactively or prospectively), by one or more substantially concurrent written instruments signed by the Company and by the Investor. Any amendment or waiver effected in accordance with this paragraph shall be binding upon the Investor and the Company.

7.8 Applicable Law. The laws of the State of New Jersey shall govern the interpretation, validity and performance of the terms of this Agreement, regardless of the law that might be applied under principles of conflicts of law.

-17-

7.9 Judicial Proceedings. Any judicial proceeding involving any dispute, controversy or claim arising out of or relating to this Agreement or the rights or interests of the Investor or the Company or the breach or alleged breach of this Agreement, whether arising during or at or after the termination of this Agreement (each of the foregoing disputes, controversies and claims hereinafter referred to as an "AGREEMENT DISPUTE"), shall be brought only in a federal or state court located in the county, city and state of New Jersey, and each of the parties hereto (i) unconditionally accepts the exclusive jurisdiction of such courts and any related appellate court and irrevocably agrees to be bound by any judgment rendered thereby and (ii) irrevocably waives any objection such party may now have or hereafter has as to the venue of any such proceeding brought in such a court or that such court is an inconvenient forum. Each of the parties hereto hereby waives trial by jury in any judicial proceeding to which they are parties involving an agreement dispute.

7.10 Notices. All notices and other communications provided for herein shall be dated and in writing and shall be deemed to have been duly given (x) on the date of delivery, if delivered personally or by telecopier, receipt confirmed, (y) on the second following business day, if delivered by a recognized overnight courier service, or (z) seven days after mailing, if sent by registered or certified, return receipt requested, postage prepaid, in each case, to the party to whom it is directed at the following address (or at such other address as any party hereto shall hereafter specify by notice in writing to the other parties hereto):

(i) If to the Company, to it at the following address:

American Bio Medica Corporation 122 Smith Road
Kinderhook, New York 12106 Attention: President

(ii) If to the Investor, to it at the following address:

Seaside Partners, L.P.
623 Ocean Avenue
Sea Girt, New Jersey 08750 Attention: Managing Director

with a copy to:

Buchanan Ingersoll Professional Corporation 650 College Road East
Princeton, New Jersey 08540 Attention: David J. Sorin, Esq.

Telephone: (609) 987-6800

Telecopier: (609) 520-0360

7.11 Integration. This Agreement and the documents referred to herein or delivered pursuant hereto or pursuant to such documents, including all exhibits and schedules,

-18-

contain the entire understanding of the parties with respect to their subject matter and supersede all prior agreements and understandings between the parties with respect to their subject matter.

7.12 Severability. Each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

7.13 Descriptive Headings. The section and other headings contained in this Agreement are for convenience of reference only and shall not affect the meaning or interpretation of this Agreement. Unless otherwise stated, all references herein to "sections" shall be deemed to be references to sections or subsections, as appropriate, of this Agreement.

7.14 Counterparts. This Agreement may be executed in two or more counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.

[SIGNATURE PAGE FOLLOWS]

-19-

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

AMERICAN BIO MEDICA CORPORATION

By:

Name: Stan Cipkowski Title: President and CEO

SEASIDE PARTNERS, L.P.

By:

Name: William J. Ritger Title: Managing Director

-20-

Exhibit 10.6

CONTRACT OF SALE

CONTRACT OF SALE made as of May 19, 1999, between

AVOBA, INC., a domestic corporation
Address: Smith Road, Kinderhook, New York, 12106 Federal I.D. No:

hereinafter called "Seller", and

AMERICAN BIO MEDICA CORPORATION, a New York Corporation Address: 300 Fairview Avenue, Hudson, New York 12534 Federal I.D. No:

hereinafter called "Purchaser".

THE PARTIES HEREBY AGREE AS FOLLOWS:

1. PREMISES. Seller shall sell and convey and Purchaser shall purchase the property, together with all buildings and improvements thereon (collectively the "Premises"), more fully described on a separate map marked "Schedule A", annexed hereto and made a part hereof.

Together with Seller's ownership and rights, if any, to land lying in the bed of any street or highway, opened or proposed, adjoining the Premises to the center line thereof.

The deed of conveyance shall be drawn as per the survey description on said map.

2. PERSONAL PROPERTY. This sale also includes all fixtures, equipment and articles of personal property now attached or appurtenant to the Premises. This sale, for the same consideration, shall include all furnishings and furniture currently located in the premises all as set forth and generally identified on Schedule "B" annexed hereto and made a part hereof. The sum of Twenty Thousand ($20,000) shall be allocated to the purchase of the said items of personal property.

3. PURCHASE PRICE. The purchase price is One Million Three Hundred Thousand Dollars ($1,300,000) payable as follows:


(a) Twenty Thousand Dollars ($20,000) on the signing of this contract, by Purchaser's check payable to the Escrowee (as hereinafter defined), subject to collection, the receipt of which is hereby acknowledged, to be held in escrow pursuant to paragraph "4" of this contract (the "Downpayment");
(b) One Million Two Hundred Eighty Thousand Dollars ($1,280,000); balance at Closing in accordance with paragraph "5".

4. DOWNPAYMENT IN ESCROW. (a) Seller's attorney ("Escrowee") shall hold the Downpayment for Seller's account in escrow in a segregated bank account at until Closing or sooner termination of this contract and shall pay over and apply the Downpayment in accordance with the terms of this paragraph. Escrowee shall hold the Downpayment in an interest-bearing account for the benefit of the parties. Interest shall be paid to the party entitled to the Downpayment and the party receiving the interest shall pay any income taxes thereof. The Federal Identification numbers of the parties shall be furnished to Escrowee upon request. At Closing, the Downpayment shall be paid by Escrowee to Seller. If for any reason Closing does not occur and either party gives Notice (as defined in paragraph "21") to Escrowee demanding payment of the Downpayment, Escrowee shall give prompt Notice to the other party of such demand. If Escrowee does not receive Notice of objection from such other party to the proposed payment within ten (10) business days after the giving of such Notice, Escrowee is hereby authorized and directed to make such payment. If Escrowee does receive such Notice of objection within such ten (10) day period or if for any other reason Escrowee in good faith shall elect not to make such payment, Escrowee shall continue to hold such amount until otherwise directed by Notice from the parties to this contract or a final, nonappealable judgement, order or decree of a court. However, Escrowee shall have the right at any time to deposit the Downpayment and the interest thereon with the clerk of a court in the county in which the Premises are located and shall give Notice of such deposit to Seller and Purchaser. Upon such deposit or other disbursement in accordance with the terms of this paragraph, Escrowee shall be relieved and discharge of all further obligations and responsibilities hereunder.

5. ACCEPTABLE FUNDS. All money payable under this contract, unless otherwise specified, shall be paid by:
(a) Cash, but not over $1,000.;
(b) Good certified check of Purchaser drawn on or official check issued by any bank, savings bank, trust company or savings and loan association having a banking office in the State of New York, unendorsed and payable to the order of Seller, or as a Seller may otherwise direct upon not less than three (3) business days notice (by telephone or otherwise) to Purchaser;
(c) As to money other than the purchase price payable to Seller at Closing, uncertified check of Purchaser up to the amount of $5,000.; and


(d) As otherwise agreed to in writing by Seller or Seller's attorney.

6. MORTGAGE CONTINGENCY. This contract is contingent upon the purchaser, at its own cost and expense, obtaining Industrial Development Revenue Bond financing from the Columbia County Industrial Development Agency or some other appropriate agency or other lending institution at the purchaser's option. Such financing may include renovation and revisions to the building and the purchase of manufacturing equipment.

The contingency for said financing shall expire ninety (90) days following the amendment of the Zoning Ordinance of the Town of Stuyvesant as set for hereinafter in paragraph "19(b)". If said financing is not obtained, either party upon ten (10) days written notice to the other may rescind this agreement and upon the return of the deposit by the seller to the purchaser, all rights of the parties hereunder shall terminate.

7. PERMITTED EXCEPTIONS. The Premises are sold and shall be conveyed subject to:
(a) Subdivision laws and regulations, and landmark, historic or wetlands designation, provided that they are not violated by the existing buildings and improvements erected on the property or their use;
(b) Real estate taxes that are a lien, but are not yet due and payable; and
(c) The other matters, if any, including a survey exception, as set forth on Schedule "B" of the Certificate and Report of Title, Title No. P-14865, Items 5(a), (b), (c), (d) and (e) and Item 8; a copy of which is annexed hereto and made a part of this agreement, Exhibit "C".

8. GOVERNMENTAL VIOLATIONS AND ORDERS. (a) Seller shall comply with all notes or notices of violations of law or municipal ordinances, orders or requirements noted or issued as of the date hereof by any governmental department having authority as to lands, housing, buildings, fire, health, environmental and labor conditions affecting the Premises. The Premises shall be conveyed free of them at Closing. Seller shall furnish Purchaser with any authorizations necessary to make the searches that could disclose these matters.

9. SELLER'S REPRESENTATIONS. (a) Seller represents and warrants to Purchaser that:
(i) The Premises abut or have a right of access to a public road;
(ii) Seller is the sole owner of the Premises and has the full right, power and authority to sell, convey and transfer the same in accordance with the terms of this contract;
(iii) Seller is not a "foreign person", as that term is defined for purposes of the Foreign Investment in Real Property Tax Act, Internal Revenue Code ("IRC") Section 1445, as amended, and the regulations promulgated thereunder (collectively "FIRPTA");
(iv) The Premises are not affected by any exemptions or abatements of taxes; and
(b) Seller covenants and warrants that all of the representations and warranties set forth in this contract shall be true and correct at Closing.


(c) Except as otherwise expressly set forth in this contract, none of Seller's covenants, representations, warranties or other obligations contained in this contract shall survive Closing.

10. CONDITION OF PROPERTY.

(a) This sale is conditioned upon the results of a Phase I (and Phase II, if necessary) Environmental Site Assessment showing no evidence of adverse environmental impact due to past and present use of the premises or release of hazardous materials on the premises. The Environmental Site Assessment shall be performed at the sole cost and expense of the purchaser and completed no later than (10) days prior to the closing as identified in Paragraph 13. The seller consents to the taking of any samples deemed necessary or appropriate by the testing firm.

If the report shows evidence of adverse environmental impact, the purchaser may, cancel this agreement and upon the refund of the deposit, this agreement shall be of no further force or effect.

(b) Purchaser shall have until ten (10) days prior to the closing, as identified in Paragraph 13, to conduct an inspection of the improvements on the premises by a licensed architect or engineer for the purpose of determining that the premises are free from major structural defects. In the event that the inspection reveals a material defect in the structural condition of the premises, Purchaser may give notice to Seller of Purchaser's election to rescind this contract, whereupon the Seller shall return to the Purchaser the down payment made hereunder and on such payment this contract shall thereupon become null and void.

11. INSURABLE TITLE. Seller shall give and Purchaser shall accept such title as recognized New York State Title Insurance Company shall be willing to approve and insure in accordance with its standard form of title policy approved by the New York State Insurance Department, subject only to the matters provided for in this contract.


12. CLOSING, DEED, TITLE AND BILL OF SALE. (a) "Closing" means the settlement of the obligations of Seller and Purchaser to each other under this contract, including the payment of the purchase price to Seller, and the delivery to Purchaser of a Bargain and Sale with covenant against grantor's acts deed in proper statutory short form for record, duly executed and acknowledged, so as to convey to Purchaser fee simple title to the Premises, free of all encumbrances, except as otherwise herein stated. The deed shall contain a covenant by Seller as required by subd. 5 of Section 13 of the Lien Law.

(b) The Seller shall also deliver possession of all items of personal property as set forth on Schedule B, as well as a Bill of Sale conveying good title to the same, free of all liens and encumbrances.

13. CLOSING DATE AND PLACE. The Purchaser shall be obligated to proceed to closing at the Ganje Law Office, Two Tower Place, Albany, New York, or at a lending institution, within ninety (90) days after the time has expired to commence an Article 78 Proceeding against the Town of Stuyvesant modified Zoning Ordinance which would permit the industrial use of the subject premises as further defined in Paragraph "19(c)", provided, however, that no such proceedings have been commenced and are unresolved.

14. CONDITIONS OF CLOSING. This contract and Purchaser's obligation to purchase the Premises are also subject to and conditioned upon the fulfillment of the following conditions precedent:
(a) The accuracy, as of the date of Closing, of the representations and warranties of Seller made in this contract.
(b) The delivery by Seller to Purchaser of a duly executed Combined Real Estate Transfer Tax Return and Credit Line Mortgage Certificate (in form prescribed by law).
(c) The delivery by Seller to Purchaser of a certification stating that Seller is not a foreign person, which certification shall be in the form then required by FIRPTA.
(d) The delivery of the Premises and all building(s) and improvements comprising a part thereof, vacant and free of leases or tenancies.
(e) All plumbing (including water supply and septic systems), heating and air conditioning, electrical and mechanical systems, equipment and machinery in the building(s) located on the property and all appliances which are included in this sale being in working order as of the date of Closing. The Seller shall insure that the water supply system shall have easements to insure access to the water source located off premises.
(f) The delivery by the parties of any other affidavits required as a condition of recording the deed.


15. DEED TRANSFER AND RECORDING TAXES. At Closing, certified or official bank checks payable to the order of the appropriate State, City or County officer in the amount of any applicable transfer and/or recording tax payable by reason of the delivery or recording of the deed or mortgage, if any, shall be delivered by the party required by law or by this contract to pay such transfer and/or recording tax, together with any required tax returns duly executed and sworn to, and such party shall cause any such checks and returns to be delivered to the appropriate officer promptly after Closing. The obligation to pay any additional tax or deficiency and any interest or penalties thereon shall survive Closing.

16. APPORTIONMENTS AND OTHER ADJUSTMENTS. (a) To the extent applicable, the following shall be apportioned as of midnight of the day before the day of Closing:
(i) Taxes on the basis of the fiscal period for which assessed.
(b) If Closing shall occur before a new tax rate is fixed, the apportionment of taxes shall be upon the basis of the tax rate for the immediately preceding fiscal period applied to the latest assessed valuation.
(c) Any errors or omissions in computing apportionments or other adjustments at Closing shall be corrected within a reasonable time following Closing. This subparagraph shall survive Closing.

17. ALLOWANCE FOR UNPAID TAXES, ETC. Seller has the option to credit Purchaser as an adjustment to the purchase price with the amount of any unpaid taxes, assessments, water charges and sewer rents, together with any interest and penalties thereon to a date not less than five (5) business days after Closing, provided that official bills therefor computed to said date are produced at Closing.

18. AFFIDAVIT AS TO JUDGMENTS, BANKRUPTCIES, ETC. If a title examination discloses judgments, bankruptcies or other returns against persons having names the same as or similar to that of Seller, Seller shall deliver an affidavit at Closing showing that they are not against Seller.

19. ZONING.
(a) Seller represents to the Purchaser that the premises to be conveyed are located within a RR (Rural Recreational) Zoning District in the Town of Stuyvesant, Columbia County, New York. The Town of Stuyvesant Zoning Board of Appeals granted a Special Permit for the construction and use of the premises which are the subject of this agreement, dated August 27, 1987. The Special Permit was issued pursuant to Article 411 of the Zoning Ordinance. The Special Permit allowed for the construction and use of an industrial facility not to exceed 50,000 square feet for BioForce of America, Inc. to grow, process, store and ship herbs grown on the 175 acres of land which are the subject of this


agreement. The Seller acknowledges that the industrial facility was constructed and used to store, process and ship herbs and other agricultural products.

(b)Purchaser's obligation to purchase the premises are conditioned upon the Town Board of the Town of Stuyvesant amending the Zoning Ordinance of the Town of Stuyvesant to permit the use of the facility and at least fifteen
(15) acres adjacent lands which are the subject of this agreement for "industrial purposes" as a permitted use under the ordinance without restrictions other than the issuance of site plan approval. Upon closing, the Lease Agreement between the Seller and the Purchaser of even date herewith, shall terminate and all obligations thereunder cease with prorata adjustments of rent to the day of closing.

20. DEFAULTS AND REMEDIES.
(a)If Purchaser defaults hereunder, Seller's sole remedy shall be to receive and retain the Downpayment as liquidated damages, it being agreed that Seller's damages in case of Purchaser's default might be impossible to ascertain and that the Downpayment constitutes a fair and reasonable amount of damages under the circumstances and is not a penalty.
(b) If Seller defaults hereunder, Purchaser shall have such remedies as Purchaser shall be entitled to at law or in equity, including, but not limited to, specific performance.

21. NOTICES. Any notice or other communication ("Notice") shall be in writing and either (a) sent by either of the parties hereto or by their respective attorneys who are hereby authorized to do so on their behalf or by the Escrowee, by registered or certified mail, postage prepaid, or by facsimile to either parties counsel.

22. BROKER. Seller and Purchaser each represents and warrants to the other that it has not dealt with any broker in connection with this sale.

23. POSSESSION. Possession of the premises herein shall be delivered to Purchaser on the closing date.

24. AUTHORIZATION OF SALE. The Seller will provide a resolution of its board of directors authorizing the sale and delivery of the deed, and a certificate of the secretary or assistant secretary of the corporation certifying such resolution and setting forth facts showing that the transfer is in conformity with the requirements of Section 909 of the Business Corporation Law. The deed in such case shall contain a recital sufficient to establish compliance with that section.

25. MISCELLANEOUS. (a) All prior understandings, agreements, representations and warranties, oral or written, between Seller and Purchaser are merged in this contract; it completely expresses their full agreement and has been entered into after full investigation,


neither party relying upon any statement made by anyone else that is not set forth in this contract.
(b) Neither this contract nor any provision thereof may be waived, changed or cancelled except in writing. This contract shall also apply to and bind the heirs, distributees, legal representatives, successors and permitted assigns of the respective parties. The parties hereby authorize their respective attorneys to agree in writing to any changes in dates and time periods provided for in this contract.
(c) Any singular word or term herein shall also be read as in the plural and the neuter shall include the masculine and feminine gender, whenever the sense of this contract may require it.
(d) The captions in this contract are for convenience of reference only and in no way define, limit or describe the scope of this contract and shall not be considered in the interpretation of this contract or any provision hereof.
(e) This contract shall not be binding or effective until duly executed and delivered by Seller and Purchaser.
(f) Seller and Purchaser shall comply with IRC reporting requirements, if applicable. This subparagraph shall survive Closing.
(g) Each party shall, at any time and from time to time, execute, acknowledge where appropriate and deliver such further instruments and documents and take such other action as may be reasonably requested by the other in order to carry out the intent and purpose of this contract. This subparagraph shall survive Closing.
(h) This contract is intended for the exclusive benefit of the parties hereto and, except as otherwise expressly provided herein, shall not be for the benefit of, and shall not create any rights in, or be enforceable by, any other person or entity.

IN WITNESS WHEREOF, this contract has been duly executed by the parties hereto.

AVOBA, INC.

     /s/ David Ganje
---------------------------
David Ganje, Esq.   5/20/99             By:   /s/ A. Ruf       /s/ R. Baldinger
Escrowee                                   ----------------  -------------------
                                             A. Ruf            R. Baldinger
                                                               Seller

                                        Date:  May 18th, 1999

AMERICAN BIO MEDICA CORPORATION

By:   /s/
   -------------------------------------
                               Purchaser

OFFICIAL LEGALIZATION Back side


EXHIBIT 10.7

AGREEMENT OF LEASE

Agreement of Lease, made as of the 13th day of May 1999, between AVOBA, INC., a New York corporation maintaining its principal place of business at c/o Ganje Law Office, Two Tower Place, Albany, NY 12203 (hereinafter called "Landlord") and American BioMedica Corporation, a New York corporation maintaining its principal place of business at 300 Fairview Avenue, Hudson, New York 12534, (hereinafter called "Tenant").

WITNESSETH:

1. DEMISED PREMISES.

1.01 Landlord hereby leases to Tenant and Tenant hereby leases from Landlord, a building of approximately 26,000 square feet the premises (hereinafter referred to as the "Demised Premises") owned by Landlord at Smith Road, Kinderhook, New York as approximately outlined in red on the Drawing annexed hereto as Exhibit "A", with fixtures and improvements thereon, plus the grassed areas identified on Exhibit "A". This Lease includes the Tenant's right to use, the parking facilities in the areas outlined in blue on Exhibit "A". Tenant may have the use and possession of the adjoining fields and grasslands. Tenant shall maintain and mow the fields and grasslands.

2. TERM.

2.01 The term of this Lease shall be commence on the 1st of August, 1999 and end on December 31, 2000 unless sooner terminated as herein provided or by virtue of the purchase of the property.

3. RENT.

3.01 The minimum annual rental for the Demised Premises is $60,000.00, payable by Tenant monthly in advance in equal installments of $5,000.00 each on the first day of every month during this Lease term.

4. USE OF PREMISES.

3

4.01 Tenant may use and occupy the Demised Premises for all lawful purposes permitted by the use permit granted by the Stuyvesant Board of Appeals and may use and occupy the grassed areas of the Demised Premises for the purpose of agricultural and horticultural purposes and shall maintain same as provided in paragraph 1.01 herein.

4.02 Tenant will not, nor will it permit any other persons to do anything, or bring anything in or upon the Demised Premises or to be kept therein, which will in any way increase the rate of fire insurance on the Demised Premises, not use or permit the Demised Premises to be used for any purpose which would cause an increase in the rate of fire insurance on said Demised Premises.

5. TAXES.

5.01 In addition to the annual rental provided for in Article "3" hereof, Tenant agrees to pay to Landlord as additional rent of all real property taxes, water and sewer rents, rates, and charges, and assessments, which may be levied or assessed against the building of which Demised Premises forms a part by any lawful authority for the period of the term of this Lease. Should the State of New York or any political subdivision thereof or any governmental authority having jurisdiction thereover, impose a tax and/or assessment (other than a new income or franchise tax) upon or against the rental payable by a tenant in the Demised Premises to the Landlord, or any other tax which is intended in whole or in part as a substitute for the current method of real estate taxation, such tax and/or assessment shall be deemed to constitute a tax and/or assessment against the Demised Premises for the purposes of this Article.

5.02 Upon receipt of all tax bills and assessment bills attributable to any year during the term hereof, Landlord shall furnish Tenant with a written statement of the actual amount of the taxes and assessments for such year, and with a bill for the Tenant's payment thereof. Tenant shall pay to the Landlord the amount billed within ten (10) days of the receipt of the statement and bill. In the event the Landlord is required under a mortgage covering the Demised Premises to escrow real estate taxes, Landlord may require Tenant to pay said taxes and assessments during the term hereof in monthly installments on or before the first day of each calendar month, in advance, in an amount estimated by such mortgage. If the total amount paid by Tenant under this Article during the term of this Lease shall be less than the actual amount due from Tenant for

4

any year thereof, as shown on such statement, Tenant shall pay to Landlord the deficiency within ten (10) days after demand therefor by Landlord; and if the total amount paid by Tenant hereunder for any such year shall exceed such amount due from Tenant for such year, Tenant shall be entitled to offset the excess against payments next thereafter to become due under this Article. For the years in which this Lease commences and terminates, the provisions of this Article shall apply and Tenant's liability for taxes and assessments for any such year shall be subject to a pro rata adjustment based on the number of days of any such year during which the term of this Lease is in effect. A copy of a tax bill or assessment bill submitted by Landlord to Tenant shall at all times be sufficient evidence of the amount of taxes and/or assessments levied or assessed against the property to which such bill relates. Landlord's and Tenant's obligations under this Article shall survive the expiration of the term of this Lease.

5.03 Nothing herein contained is intended to make the Tenant responsible for franchise, corporate, or partnership taxes which are charged to the Landlord, including excise, inheritance, capital, levy, transfer or income, profits or revenue, upon income of Landlord except that, in the event of the passage of any statute, act or law as the result of which Landlord becomes obligated to pay any income tax or any other tax, charge, levy, assessment, or imposition, in lieu or in place of any school tax, or other real estate tax or assessment, which would otherwise be levied against and/or become a lien upon the Demised Premises, such tax, charge, levy, assessment, or imposition shall be payable by Tenant as provided for by this Article.

6. LIABILITY AND FIRE INSURANCE.

6.01 The Tenant shall maintain fire insurance coverage and other liability insurance as provided in this Lease for the entire building of which the Demised Premises forms a part and shall provide Landlord with proof of payment thereof and with proof of a valid insurance policy.

6.02 Tenant agrees to pay, during the term hereof the cost of insurance for fire, extended coverage, vandalism, malicious mischief, and such other hazards as Landlord or Landlord's first mortgagee may require, insuring the improvements located on the Demised Premises and all appurtenances thereto (excluding Tenant's merchandise, trade fixtures, furnishings, equipment, personal property, and Tenant's work) for not less than the full insurable

5

value thereof.

6.03 Tenant agrees to carry public liability insurance on the Demised Premises during the term hereof, covering both Tenant and Landlord as insureds, with the terms and companies reasonably satisfactory to Landlord, including coverage of Tenant's indemnity to Landlord contained in Article 17 of this Lease, for limits of not less than One Million ($1,000,000.00) Dollars for personal injury or death arising out of any one occurrence, and providing that Landlord and Tenant shall be given a minimum of thirty (30) days written notice by the insurance company prior to cancellation, termination, or change in such insurance. Tenant also agrees to carry property damage insurance in the amount of not less than Three Hundred Thousand ($300,000.00) Dollars for damage to property arising out of any one occurrence.

6.04 Tenant shall provide Landlord with copies of the policies or certificates evidencing that such insurance is in full force and effect and stating the terms thereof.

7. SIGNS, AWNINGS, FIXTURES, AND ALTERATIONS.

7.01 Tenant shall have the free right of alteration to the demised premises which alterations shall not affect the structural integrity of the demised premises provided advance notice is provided in writing to the Landlord. In the event that any proposed alteration will change the structural integrity of the premises, Tenant shall obtain prior written Landlord approval. Fixtures and equipment installed in premises by the Tenant shall be removable provided any damage to the premises shall be repaired at Tenant's cost and expense.

8. MAINTENANCE OF DEMISED PREMISES.

8.01 The Tenant shall take good care of the premises and shall at its own cost and expense make all repairs to the interior of the premises, other than structural repairs or mechanical capital repairs to the plumbing, heating or electrical systems. At the end or other expiration of the term, the Tenant shall deliver up the demised premises in good order and condition, damages by the elements excepted. Landlord shall be responsible for the maintenance of the well and septic system.

9. DAMAGE OR DESTRUCTION.

9.01 If all or any part of the Demised Premises is damaged or destroyed by fire or other casualty insured under the standard fire insurance policy with approved standard extended

6

coverage endorsement applicable to the demised Premises, the Landlord shall, except as otherwise provided herein, repair and rebuild the Demised Premises with reasonable diligence, and if there is a substantial interference with the operation of the Tenant's business in the demised Premises requiring the Tenant temporarily to close its business to the public, the minimum rental shall be equitably apportioned for the duration of such repairs in proportion to the extent to which there is interference with the operation of the Tenant's business. Notwithstanding the foregoing provisions, in the event the Demised Premises shall be damaged by fire or other insured casualty due to the fault or neglect of the Tenant, or the Tenant's servants, employees, contractors, agents, visitors, or licensees, then, without prejudice to any other rights and remedies of the Landlord, the damage shall be repaired by the Landlord, but there shall be no apportionment or abatement of any rent. Except to the extent provided for in this paragraph, neither the rent payable by the Tenant nor any of the Tenant's other obligations under any provision of this lease shall be affected by any damage to or destruction of the Demised Premises by any cause whatsoever.

10. UTILITIES.

10.01 The Landlord shall furnish heating and air conditioning systems to the Demised Premises. Landlord shall be responsible for maintenance of such systems and Tenant shall be responsible for the payment of all utilities servicing the Demised Premises.

11. ASSIGNMENT OF LEASE.

11.01 Tenant may not sublet or assign this Lease without the Landlord's consent, which consent will not be unreasonably withheld, provided, however, that Landlord shall not be liable for damages on any claim that landlord has unreasonably withheld such consent, Tenant's remedy being limited solely to an action to determine reasonableness of the withholding of such consent and to compel giving of same. It is further agreed that no assignment or sublease shall be effective unless the assignee or sublessee agrees directly with the Landlord to perform Tenant's obligations under this Lease. Notwithstanding any permitted assignment or subletting, not further assignment or subletting may be made without Landlord's consent and, in all events, Tenant shall remain fully and primarily liable for the payment of all rent, additional rent, and the performance of all the terms, covenants, and conditions contained herein jointly and severally

7

with such assignee or sublessee. Landlord's dealing with an assignee or sublessee shall not affect the continued liability of the Tenant under this Lease.

12. COMPLIANCE WITH TERMS.

12.01 Tenant shall comply with all laws, orders, and regulations of federal, state, county, and municipal authorities, and with any direction pursuant to laws of any public officer thereof, which shall impose any violation, order, or duty upon Landlord or Tenant resulting from the use and occupancy of the Demised Premises by Tenant. Tenant shall have the right, upon giving notice to the Landlord, to contest any obligation imposed upon Tenant pursuant to the provisions of this Article, and to deter compliance during the pendency of such contest, provided that the failure of Tenant to so comply will not subject Landlord to prosecution or criminal penalty. Landlord shall comply with any such laws, orders, regulations, directions, and rules other than those imposing an obligation upon Tenant as aforesaid, subject, however, to the right of Landlord similarly to contest as aforesaid and defer compliance during the pendency of such contest.

13. SUBORDINATION.

13.01 This instrument shall not be a lien against said Demised Premises in respect to any first mortgage that is now on or that hereafter may be placed against the Demised premises, and upon the recording of such mortgage or mortgages, the same shall have preference and precedence and be superior and prior in lien to this Lease, irrespective of the date of recording of the same and Tenant agrees to execute any such instrument, without cost, which may be deemed necessary to any such mortgage, and a refusal to execute such instrument shall entitle the Landlord, or the Landlord's assigns and legal representatives, to the option of canceling this Lease without incurring any expense or damage and the term hereby granted is expressly limited accordingly; provided, however, that a non-disturbance agreement shall have been first entered into in respect to such mortgage. The term "non-disturbance agreement" as used in this Article shall mean an agreement in recordable form between the Tenant and the holder of any subsequent mortgage lien, which shall provide, in substance, that the Tenant shall attorn to such mortgagee and that as long as Tenant is not in default under this Lease beyond any period given to Tenant to cure such default, such holder will not name or join Tenant to cure such default,

8

such holder will not name or join Tenant as a party defendant or otherwise in any suit, action, or proceeding not to enforce, nor will this Lease be terminated or otherwise affected by enforcement of, any rights given to such holder pursuant to the terms covenants, and conditions contained in such mortgage or mortgages, or any other documents held by such holder or any rights given to such holder as a matter of law.

13.02 With reference to any assignment by Landlord of Landlord's interest in this Lease, or the rents payable hereunder, conditional in nature or otherwise, which assignment is made to the holder of a mortgage on property which includes the Demised Premises, Tenant agrees:

(A) That the execution thereof by Landlord and the acceptance thereof by the holder of such mortgage shall never be treated as an assumption by such holder of such mortgage shall never be treated as an assumption by such holder of the obligations of the Landlord hereunder, unless and until such holder shall, by notice to Tenant, specifically otherwise elect; and

(B) Except as aforesaid, such holder shall be treated as having assumed Landlord's obligations hereunder only upon foreclosure of such holder's mortgage, the taking of possession of the Demised Premises, and such holder's acceptance of Tenant's attornment.

14. WAIVER OF REDEMPTION.

14.01 Tenant hereby expressly waives any and all rights of redemption granted by or under any present or future laws in the event of Tenant being dispossessed or removed from the Demised Premises because of default by Tenant pursuant to the covenants or agreements contained in this Lease.

15. DEFAULT.

15.01 A) It is expressly understood and agreed that in case the Demised Premises shall be deserted or vacated or if default be made in the payment of the rent or additional rent or any part thereof as herein specified, or if, without the consent of the Landlord, the Tenant shall sell, assign, or mortgage this Lease or if default be made in the performance of any of the covenants and agreements in this Lease contained on the part of Tenant to be kept and performed, or if the Tenant shall fail to comply with any requirements of the federal, state and local governments or of any and all their departments or bureaus, applicable to the Demised

9

Premises, or if the Tenant shall file or there shall be filed against Tenant a petition in bankruptcy or arrangement, or under any insolvency laws now or hereinafter enacted, or Tenant be adjudicated a bankrupt or make an assignment for the benefit of creditors to take advantage of any insolvency act, the Landlord may, if the Landlord so elects, and may at any time thereafter terminate this Lease and the term hereof, on giving to the Tenant forty-five
(45) days notice in writing to cure such default, other than a non-payment of rent, except in the case of a nonpayment of rent or additional rent, said notice shall require a cure within ten (10) days, and if such default is not so cured, this Lease and the term hereof shall expire and come to an end on the date fixed in such notice as if the said date were the date originally fixed in this Lease for the expiration thereof, or Landlord may dispossess or remove Tenant or any other occupant of the Demised Premises by summary proceedings or otherwise, and remove their effects and hold the demised Premises as if this Lease had not been made, but without prejudice to Landlord's remedies, on account thereof as set forth in paragraph (b) below. Such notice may be given by mail to the Tenant addressed to the Demised Premises.

B) In the event of such dispossession or removal and notwithstanding such action or the termination of this Lease (I) the Tenant shall be liable forthwith to pay the rent and additional rent and charges payable under this Lease up to the date of such dispossession, termination, or removal, (II) Landlord may relet the Demised Premises, or any part or parts thereof, either in the name of the Landlord or otherwise, for a term or terms which may, at the option of Landlord, be less than or exceed the period which would otherwise have constituted the balance of the term of this Lease and may grant concessions or free rent for a reasonable time, (III) Tenant shall pay to Landlord as liquidated damages for the failure of Tenant to observe and perform the covenants and agreements under this Lease, any deficiency between the rent and additional rent payable by Tenant under this Lease and the net amount, if any, of the rents collected on account of this Lease or leases of the Demised Premises for each month of the period which would otherwise have constituted the balance of the term of this Lease, (IV) amounts received by Landlord after reletting shall first be applied against Landlord's expenses incurred in any reletting, until the same are recovered, and until such recovery, tenant shall pay, as of each day when a payment would fall due under this Lease, the amount which Tenant is

10

obligated to pay under the terms of this Lease (Tenant's liability prior to any such reletting and such recovery not in any way to be diminished as a result of the fact that such reletting might be for a rent higher than the rent provided for in this Lease); when and if such expenses have been completely recovered, the amounts received from reletting by Landlord as have previously been applied shall be credited against Tenant's obligations as of each day when a payment would fall due under this Lease, and only the net amount thereof shall be payable by Tenant. Further, amounts received by Landlord from such reletting for any period shall be credited only against obligations of Tenant allocable to such period, nor shall any credit of any kind be due for any period after the date when the term of this Lease is scheduled to expire according to its terms, and (V) as an alternative, at the election of Landlord, Tenant will, upon such termination, pay to Landlord, as damages, such a sum as, at the time of such termination, represents the amount of the excess, if any, of the then value of the total rent and other benefits which would have accrued to Landlord under this Lease for the remainder of the Lease term if the Lease terms had been fully complied with by Tenant over and above the then cash rental value (in advance) of the Demised Premises for the balance of the term and upon payment of said sum, Tenant's further liability under the terms of the Lease would cease. Landlord may make such alterations, repairs, replacements, and decorations in the Demised Premises as Landlord considers advisable and necessary for the purpose of reletting the Demised Premises, and the making of such alterations and decorations shall not operate or be construed to release Tenant from liability under this Lease. The failure or refusal of Landlord to relet the Demised Premises or any part thereof shall not release or affect the liability of Tenant for damages under this Lease; however, Landlord will use its best efforts to relet the premises at a reasonable rent. Landlord shall in no event be liable in any way whatsoever for inability to relet the Demised Premises or, in the event that the Demised Premises or any part or parts thereof shall not release or affect the liability of Tenant for damages under this Lease.

C) If after default of payment of rent, or violation of any other provision of this Lease, or expiration thereof, the Tenant moves out or is dispossessed and fails to remove any trade fixture or other property prior to such said default, removal, expiration of Lease, or prior to the issuance of the final order or execution of the warrant, then in that event, the said fixtures and

11

properties shall be deemed abandoned by the said Tenant and shall become the property of the Landlord.

16. CURING DEFAULT.

16.01 If Tenant shall default in the observance or performance of any covenant or agreement of this Lease on the part of Tenant to be observed or performed, beyond any period given to Tenant to cure such default, Landlord may perform the same for the account of Tenant.

17. INDEMNIFICATION.

17.01 Tenant does hereby covenant and agree with Landlord that it will indemnify and save harmless Landlord from any and against all liability, damages, penalties, or judgments arising from injury to person or property sustained by anyone in and about the Demised Premises resulting from any act or acts of omission or commission of Tenant, or Tenant's officers, agents, servants, employees, contractors, or assignees. Tenant shall, at its own cost and expense, defend any and all suits or actions (just or unjust) which may be brought against Landlord or Landlord's officers, agents, servants, employees, assignees, or contractors. Landlord shall not be responsible or liable for any damage or injury to any property, fixtures, buildings, or other improvements, or to any person or persons, at any time on the Demised Premises, including any damage or injury to Tenant or to any of Tenant's officers, agents, servants, employees, contractors, customers, or assignees; except as may result from any act or acts of omission or commission of Landlord or Landlord's officers, agents, servants, employees, assignees, or contractors. Landlord shall not be responsible or liable for any damage or injury to any property, fixtures, buildings, or other improvements, or to any person or persons, at any time on the Demised Premises, including any damage or injury to Tenant or to any of Tenant's officers, agents, servants, employees, contractors, customers, or assignees; except as may result from any act of omission or commission of Landlord which continues after notice from tenant to Landlord of a condition for the cure or correction of which Landlord is liable, and the Landlord has failed, within a reasonable time after notice, to cure or correct such condition.

18. END OF TERM.

18.01 Upon expiration or other termination of the term of this Lease, Tenant shall quit and surrender to Landlord the Demised Premises, broom clean, in good order and condition,

12

reasonable wear and tear and damage by fire or other casualty excepted.

19. QUIET ENJOYMENT.

19.01 Landlord covenants and agrees that Tenant may peaceably and quietly enjoy the Demised Premises, subject, however, to the covenants and agreements contained in this Lease.

20. NO WAIVER.

20.01 The failure of Landlord to seek redress for violation of, or to insist upon the strict performance of, any covenant or agreement contained within this Lease shall not prevent a similar subsequent act from constituting a default under this Lease. This Lease contains the entire agreement between the parties, and cannot be changed, modified, or amended, unless such change, modification, or amendment is in writing and signed by the party against whom enforcement of such change, modification, or amendment is sought.

20.02 No payment by Tenant, or acceptance by Landlord, of a lesser amount than shall be due from Tenant to Landlord shall be treated otherwise than as a payment on account. The acceptance by Landlord of a check for a lesser amount with an endorsement or statement thereon, or upon nay letter accompanying such check, that such lesser amount is payment in full, shall be given no effect, and Landlord may accept such check without prejudice to any other rights or remedies which Landlord may have against Tenant.

21. WAIVER OF TRIAL BY JURY AND COUNTERCLAIMS.

21.01 Landlord and Tenant agree that they shall, and the hereby do, waive trial by jury in any action, proceeding, or counterclaim brought by either of the parties hereto against the other on any matters whatsoever arising out of, or in any way connected with, this Lease. Landlord and Tenant agree that any dispute in connection with this Lease be first brought before the American Arbitration Association in Albany, New York. If Landlord commences any summary proceeding for nonpayment of rent or additional rent, Tenant will not interpose any counterclaim in such proceeding unless such counterclaim arises out of, or is in any way connected with, this Lease.

22. MEMORANDUM OF LEASE.

22.01 Upon request of either party to this Lease, Landlord and Tenant agree to execute and deliver a memorandum of this Lease and memorandum of any modification of this Lease, in

13

recordable form, containing the information required by Section 291-c and
Section 291-cc of the Real Property Law of the State of New York.

23. INSPECTION OF PREMISES.

23.01 The Tenant agrees that the Landlord and its agents and/or representatives shall have the right to enter into and upon the Demised Premises, or any part thereof on prior notice and arrangement with Tenant for the purpose of examining the same, or making such repairs or alterations thereon as may be necessary for the safety and preservation thereof.

24. NOTICES.

24.01 Any notice or demand required to be given under this Lease, or pursuant to any law or governmental regulations, by Landlord to Tenant or by Tenant to Landlord shall be in writing. Unless otherwise required by law or governmental regulations, any such notice or demand shall be deemed given if sent by registered or certified mail, enclosed in a secure postpaid wrapper, addressed (I) to Landlord, at the address of Landlord first hereinabove set forth, or such other address as Landlord may designate by notice to Tenant, or
(II) to Tenant, at the address of Tenant first hereinabove set forth or such other address as Tenant may designate by notice to Landlord.

24.02 After receiving notice from any person, firm, or other entity that it holds a mortgage which includes the Demised Premises as part of the mortgaged premises, no notice from Tenant to Landlord shall be effective unless and until a copy of same is given to such holder, and the curing of any of Landlord's defaults by such holder shall be treated as performance by the Landlord.

25. CAPTIONS.

25.01 The captions preceding the Articles of this Lease are inserted only as matter of convenience and for reference and in no way define, limit, or describe the scope of this Lease nor the intent of any provision of this Lease.

26. SUCCESSORS OR ASSIGNS.

26.01 The covenants and agreements contained in this Lease shall bind and inure to the benefit of Landlord and the successors and assigns of Landlord, and Tenant and its successors and assigns.

14

27. BROKER'S COMMISSIONS.

27.01 Landlord shall hold the Tenant harmless from any and all broker's fees and commissions due in relation to this Lease.

28. MISCELLANEOUS.

28.01 If any term or provision of this Lease, or the application thereof to any person or circumstance shall, to any extent, be invalid or unenforceable, the remainder of this Lease, and the application of such term or provision to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby, and each term and provision of this Lease shall be valid and be enforced to the fullest extent permitted by law.

28.02 This Lease and the obligations of Tenant to pay rent and other charges or sums due hereunder and to perform all of the other covenants and agreements hereunder shall in no way be affected, impaired, or excused because Landlord is unable to perform any of the obligations of Landlord in this Lease where the inability to so perform is due to causes beyond Landlord's reasonable control.

IN WITNESS WHEREOF, the parties hereto have caused these presents to be signed by their duly authorized officers as of the date hereinabove set forth.

LANDLORD: AVOBA, INC.

Witness:                                 By:   /s/ A. Ruf     /s/ R. Baldinger
        -------------------------              ----------     ----------------
                                                 A. Ruf         R. Baldinger

TENANT:                                  American BioMedica Corporation


Witness:                                 By:
        -------------------------           --------------------------------

Official legalization back side

15

State of___________)
Country of_________) SS:

On the ____ day of __________, 19__, before me personally came ______________, to me known, who, being by me duly sworn, did depose and say that he resides in ________________________________; that he is the ___________________ of Avoba, Inc., the corporation described in and which executed the above instrument; and that he signed his name thereto by authority of the board of directors of said corporation.


Notary Public

State of New York )
County of Columbia) SS:

On the 13th day of May, 1999, before me personally came Stan Apkowski, to me known, who, being by me duly sworn, did depose and say that he resides in Ghent, New York; that he is the President of American BioMedica, the corporation described in and which executed the above instrument; and that he signed his name thereto by authority of the board of directors of said corporation.

/s/ Bonnie S. Baker
------------------------------
Notary Public comm-ex. 2/24/01

16

EXHIBIT 10.8

LEASE

THIS LEASE ("Lease") entered into between Whitesell Enterprises ("Landlord") and American BioMedica Corporation ("Tenant").

W I T N E S S E T H:

In consideration of the mutual covenants herein set forth, and intending to be legally bound hereby, the parties hereto covenant and agree as follows:

1. LEASE TERMS. The parties agree that the following defined terms and provisions, as used in this Lease, shall have the meanings and shall be construed as set forth below.

(a)  Date of Lease:      Aug 1, 1999

(b)  Landlord:           Whitesell Enterprises

     Address:            One Underwood Court, P.O. Box 1605
                         Delran, New Jersey 08075

(c)  Tenant:             American BioMedica Corporation

     Address:            603 Heron Drive, Unit 3
                         Bridgeport, New Jersey 08014

     Type of Entity:     Limited Partnership
     (check one)                                   --------
                         General Partnership
                                                   --------
                         Corporation                   X
                                                   --------
                         Sole Proprietorship
                                                   --------
                         Limited Liability Company
                                                   --------

State of Organization: New York

(d) Guarantor: Yes No X

Name:

(c) Approximate Number of Employees: Offices: 15

Warehouse:

(f) Approximate Number of Trucks/Trailers per day: 2

(g) Tenant's SIC Number: 2835

(h) Premises: 603 Heron Drive, Bridgeport, New Jersey 08014

Unit Number: 3

Approximate Rentable Square Footage: 3,929 square feet

(i) Building:

Street Address: 603 Heron Drive, Bridgeport, New Jersey 08014

Lot & Block Number: Lot 3.08/Block; 46

Approximate Rentable/Square Footage: 43,233 square feet

(j) Tenant's Pro Rata Share: 9.1%

(k) Term: Three (3) Years

Lease Commencement Date:  August 1, 1999

Expiration Date:          August 31, 2002

Rent Commencement Date:   August 1, 1999


(1-1)  Base Rent:     $6.80 per square foot net
                      $2,226.43 monthly
                      $26,717.20 yearly

(1-2) Initial Estimate of Additional Rent: $1.00 per square foot See Article 5 on page 3 for definitions.

(m) Security Deposit: $5,000.00

(n) Permitted Use: _______________

(o) Renewals: Non Applicable

(p) Broker: Non Applicable

(q) Tenant's Lease Execution Date Requirements:

                                         Amount       Received
                                         ------       --------
(i)     initial payment (1st month's     $7,296.43
        rent plus security deposit)

(ii)    insurance certificates per
        Article 18

2. DEMISE OF PREMISES. Landlord, for and in consideration of the Rent (as hereinafter defined) to be paid and the covenants and agreements to be performed by Tenant as hereinafter set forth, does hereby lease, demise and let unto Tenant for the Term the Premises, together with the non-exclusive right to use in common with the other tenants in the Building all common parking spaces located adjacent to the Building, walks, access roads and land surrounding the Building and the common areas in the Building (collectively the "Property").

3. USE OF PREMISES. (a) Tenant covenants and agrees to use the Premises for the Permitted Use, and for no other purpose or purposes. No machinery, equipment or other thing that could cause vibration, noise, odor or fumes which could unreasonably disturb other tenants of the Building shall be installed or placed therein. Tenant shall not subject any portion of the floor to greater loading than that portion of the Premises is designated to carry. Tenant agrees that all outside storage of any kind is prohibited. Parking of inoperable vehicles, non-motorized vehicles or trailers in or about the Premises is prohibited.

(b) Tenant shall, in the use and occupancy of the Premises and the conduct of Tenant's business or profession therein, at all times and at Tenant's expense comply with, and conform the Premises to the following requirements (the "Requirements"): all applicable laws, ordinances, orders, notices and regulations of the federal, state and municipal governments, or any of their departments and the regulations of the insurers of the Premises and Building and the rules and regulations attached hereto as Exhibit "B". Without limiting the generality of the foregoing, Tenant shall: (i) obtain, at Tenant's expense, before engaging in Tenant's business or profession within the Premises, all necessary licenses and permits including (but not limited to) state and local use or occupancy and business licenses or permits; and (ii) remain in compliance with and keep in force at all times all licenses, consents and permits necessary for the lawful conduct of Tenant's business or profession at the Premises. Tenant shall pay all personal property taxes, income taxes and other taxes which are or may be assessed, levied or imposed upon Tenant and which, if not paid, could be liened against the Premises or against Tenant's property therein or against Tenant's leasehold estate. Tenant agrees to promptly furnish Landlord with a copy of any notice that it receives that it is in violation of any Requirements.

(c) Tenant shall indemnify, protect, defend and save harmless Landlord with regard to any non-compliance or alleged non-compliance by Tenant with any Requirements. If Landlord is named as defendant or a responsible party with respect to any alleged violation or non-compliance by Tenant as aforesaid, Landlord also may require, by notice to Tenant as aforesaid, that the matters or conduct giving rise thereto be discontinued by Tenant unless and until the alleged violation or non-compliance is resolved in Tenant's favor.

4. POSSESSION. In no event shall Landlord be liable to Tenant for any actual or consequential damages in the event the Landlord is unable to deliver possession of the Premises on the Lease Commencement Date. If the Lease Term does not commence upon the Lease Commencement Date, Landlord and Tenant shall, by separate writing, set forth the revised Lease Commencement Date and Expiration Date (which shall be extended accordingly).

5. RENT. (a) The Base Rent shall be paid without notice in equal monthly installments on or prior to the first day of each month. Tenant shall pay to Landlord all Rent without demand, setoff or

2

deduction. The first month's rent shall be payable upon the execution of this Lease. If the Rent Commencement Date is other than the first day of a calendar month or if the Expiration Date is other than the last day of a calendar month, Rent for such partial month shall be prorated.

(b) In addition to the Base Rent, Tenant shall pay to Landlord its Pro Rata Share of all real estate taxes and assessments (collectively "Taxes") incurred during each tax year (pro rated where appropriate) during the Term of this Lease. The Taxes shall be estimated by Landlord from time to time and Tenant shall pay to Landlord monthly, in addition to the Basic Rent and on the same day provided in Article 5(a), 1/12 thereof. Landlord shall have the right, but not the obligation to appeal or contest any Taxes and Tenant shall pay its Pro Rata Share of Landlord's costs for the contest or appeal which costs, shall in no case ever exceed any tax savings.

(c) In addition to the Base Rent and Taxes, Tenant shall pay to Landlord its Pro Rata Share of all operating costs (the "Costs") incurred during each calendar year (pro rated where appropriate) during the Term of this Lease. The Cost shall be estimated by Landlord from time to time and Tenant shall pay to Landlord monthly, in addition to the Basic Rent and Taxes and on the same day provided in Article 5(a), 1/12 thereof. The Costs shall include any and all costs incurred (whether internal to Landlord or paid to a third party) in the maintenance, repair, upkeep, replacement, servicing, securing and operation of the Building and Property (less any charges invoiced directly to other tenants in the Building) and shall include but not be limited to:

(i) All costs and expenses directly related to the operation of the Building and Property including lighting, cleaning, maintaining and painting the Building exterior, fire suppression and alarm systems (including monitoring), removing snow, ice and debris and maintaining all landscape areas, (including replacing and replanting flowers, shrubbery and trees), maintaining and repairing all other exterior improvements (including without limitation parking areas, drives and sidewalks) on the Property and all repairs and compliance costs (including storm water runoff etc., if applicable) required of Landlord. Landlord's obligation to provide snow removal services shall be limited to the parking areas and Tenant shall be responsible for its entrance ways and sidewalks.

(ii) If the Property is located in an industrial park, Tenant shall pay any applicable owners' association dues and fees and its pro rata share of maintenance and repair of any common areas in the industrial park including, but not limited to drainage systems, lighting, trash removal, snow removal, landscaping and association fees or dues, if applicable.

(iii) Administrative fee of three (3%) percent of the Base Rent plus legal fees which are applicable to the overall operation of the Building. It is expressly understood that legal fees incurred in an action against an individual Tenant shall not be deemed includable as an operating expense pursuant to this provision.

(iv) All costs and expenses incurred by Landlord for environmental testing, sampling or monitoring necessary except any cost or expenses incurred in conjunction with the spilling or depositing of any hazardous substance for which any other Tenant is legally liable.

(v) All costs for insurance carried by Landlord.

(vi) Capital expenditures and the costs of preparing any other unit for rental shall not be included as operating expenses. However in the event that Landlord incurs any capital expense for an improvement required by virtue of any governmental statute, ordinance or regulation then Landlord shall be permitted to recover on an amortized basis (not to exceed five (5) years) the portion of the capital costs applicable to the Term of this Lease including any renewal or extension. Similarly should Landlord make any capital improvement which reduces the operating expenses payable hereunder then Landlord shall be permitted to recover the amortized costs as aforesaid but in no case shall the expense allocated exceed the cost savings achieved by the capital improvement. With the exclusion of snow removal and taxes these costs shall not exceed an increase of ten percent (10%) a year.

(d) Within 120 days following the end of each calendar year and/or tax year, as the case may be, Landlord shall send to Tenant a statement of actual Costs and/or Taxes, as the case may be, incurred for such year as appropriate, showing the Pro Rata Share due from Tenant. In the event the amount paid by Tenant as Additional Rent for such period pursuant to this Article 5 exceeds the amount that was actually due based upon actual year end cost, then Landlord shall issue a credit to Tenant in an amount equal to the overcharge which credit Tenant may apply to future rent payments until Tenant has been fully credited with the overcharge. If the credit due to Tenant is more than the aggregate total of future rental payments, Landlord shall pay to Tenant the difference between the credit in such aggregate total. In the event Landlord has undercharged Tenant, then Landlord shall send Tenant an invoice with the additional amount due which amount shall be paid in full by Tenant within ten (10) days of receipt.

Tenant shall have the right to review all invoices and other information on which the calculation of the Costs chargeable to Tenant were based by written notice to Landlord within thirty (30) days following Tenant's receipt of the Costs statement from Landlord. Upon receipt of such notice from Tenant, Landlord shall make such information available to Tenant or Tenant's authorized representative at

3

Landlord's location (or, at Landlord's option, Landlord may provide copies of such information to Tenant). Tenant shall have a period of thirty (30) days following the date on which Landlord notifies Tenant that such information is available for Tenant's review to advise Landlord of any discrepancy discovered by Tenant with respect to the Costs charged to Tenant whereupon Landlord and Tenant shall use their best efforts to resolve any such discrepancy discovered by Tenant with respect to the Costs charged to Tenant whereupon Landlord and Tenant shall use their best efforts to resolve any such discrepancy, and if they are unable to do so, Tenant shall be free to pursue any remedies available to Tenant by law. If Tenant does not notify Landlord of its wish to review the Costs information within thirty (30) days of Tenant's receipt from Landlord of its Costs statement or if Tenant does so notify Landlord, but does not, within thirty (30) days following the date when such information is made available to Tenant, notify Landlord of a discrepancy in the Costs charged to Tenant with respect to the applicable calendar year and to tax year, as the case may be, Tenant shall be deemed to have waived any right to make any claim against Landlord with respect to the applicable Costs statement.

(e) All Taxes, Costs and other sums other than Base Rent payable by Tenant to Landlord under this Lease shall be deemed additional rent ("Additional Rent") and Landlord shall have all rights with respect to the non-payment of Additional Rent as for Base Rent. Base Rent and Additional Rent are sometimes herein together called "Rent".

6. LATE PAYMENT. For each payment of Rent received after the first day following the due date therefor, Tenant shall pay to Landlord an initial late charge of ten (10%) percent of the payment due plus one and one-half (1-1\2%) percent for each additional month such payment is late, which charge must accompany the late payment. An additional charge will be made for checks returned for insufficient funds.

7. SECURITY DEPOSIT. Tenant does herewith deposit with Landlord the Security Deposit to be held as security for the full and faithful performance by Tenant of Tenant's obligations under this Lease and for the payment of damages to the Premises. Except for such sum as shall be applied by Landlord to satisfy claims against Tenant arising from defaults under this Lease or by reason of damages to the Premises, and further provided that Tenant is not then in default hereunder and has complied with all obligations for surrender and redelivery of the Premises to Landlord (including without limitation all obligations contained in Article 15(c)), the Security Deposit shall be returned to Tenant without interest within thirty (30) days of the expiration of the Term of this Lease or any renewals or extensions thereof. It is understood that no part of any Security Deposit is to be considered as the last rental due under the Term of the Lease. Notwithstanding any law to the contrary, Landlord shall not be required to pay any interest to Tenant on account of the holding of the Security Deposit and need not maintain this deposit in a separate account but may co-mingle and use these funds as its own. In the event of the sale or transfer of Landlord's interest in the Building, Landlord shall have the right to transfer the Security Deposit to such purchaser or transferee, in which event Tenant shall look only to the new landlord for the return of the Security Deposit and Landlord shall thereupon be released from all liability to Tenant for the return of the Security Deposit. In the event Landlord applies any portion of the Security Deposit to satisfy claims against Tenant arising from defaults under this Lease or by reason of damages to the Premises, within ten (10) days of receipt of written notice from Landlord, Tenant shall replenish the Security Deposit by the amount withdrawn therefrom by Landlord.

8. SIGNS. No sign, advertisement or notice shall be affixed to or placed upon any part of the Premises, Building or Property by Tenant or anyone acting under Tenant. At any time Landlord may put upon the Premises a suitable "for sale" sign and for six (6) months prior to the expiration of the current Term, Landlord or it agents may place the usual "to let" signs thereon. Landlord shall provide Landlord's standard signage identifying Tenant on Building pylon and at suite entrance.

9. SERVICES AND UTILITIES. Tenant shall pay all costs and charges for utilities and services including security deposits and minimum fees. The utilities shall be deemed to include without limitation the cost of heating, air conditioning if applicable, electricity, water, gas, sprinkler stand-by fee, sewer service and septic fee if applicable. Landlord shall not be liable for any interruption or delay in any of the above services for any reason. Upon demand, Tenant shall promptly furnish to Landlord payment or evidence of payment of charges for utilities and services. To the extent that Landlord is making available any electric or other utilities, Landlord shall have the sole right to select the provider of such utilities.

10. CONDITION OF PREMISES. (a) If Landlord has agreed to complete any work in the Premises prior to occupancy by Tenant, then the specifications for such construction shall be as set forth on the construction documents initialed by the parties and incorporated by reference into this Lease on Exhibit "C". Landlord shall be deemed to have delivered possession of the Premises to Tenant when such work has been substantially completed, except for (i) minor items of finishing and construction of a nature which are not necessary to make the Premises reasonably tenantable for the permitted use; and (ii) items then not completed because of delay by Tenant in furnishing any drawings, plans or approvals required for Landlord to complete any such work or because of any changes or additions thereto requested by Tenant. The taking of possession of the Premises by Tenant shall conclusively establish that the

4

Premises and the Building were at such time in satisfactory condition, order and repair, subject to any punchlist items.

(b) Landlord shall undertake the warranty work in Exhibit "D" (if any) and except as set forth therein Tenant is leasing the Premises in their "as-is" condition.

11. SURRENDER. Tenant shall at the expiration of the Term hereof, peaceably surrender possession of the Premises in as good and marketable order and condition as existed at the inception of this Lease, reasonable wear and tear of the finishing elements and carpeting and damage by fire, elements or casualty excepted, and will, at the expiration of said Term, or any continuation thereof, deliver the keys at the office of said Landlord. Within the final fifteen (15) days of the Term, the systems shall be inspected by a reputable electrical, mechanical or plumbing contractor designated by Landlord at the sole cost and obligation of Tenant. All mechanical, electrical, plumbing, heating and air conditioning systems shall be in good operating order at the termination of this Lease and Tenant shall perform a thorough cleaning of the Premises immediately prior to surrender, including without limitation shampoo and repairs of all carpeted areas of the Premises. Any property or fixtures which remain upon the Premises after the expiration of the Lease shall be deemed abandoned by Tenant and Landlord may take possession of same and dispose of same in any reasonable manner without any further liability of Landlord to Tenant. Any costs associated with the removal of such property shall be payable by Tenant.

12. REPAIRS AND MAINTENANCE. (a) Except as specifically otherwise provided in subsection (d) of this Article 12, Tenant, at its sole cost and expense throughout the Term of this Lease, shall keep and maintain the Premises including without limitation hot water heaters, roof fans, plumbing and electrical systems and fixtures, Tenants improvements, betterments and other special equipment attached to the Premises, glass, overhead doors, loading dock bumpers and levelers and carpeting in good order and condition, free of dirt and rubbish, and shall promptly make all repairs necessary to keep and maintain such good order and condition, whether such repairs are ordinary or extraordinary, foreseen or unforeseen. When used in this Article 12, the term "repairs" shall include replacements and renewals when necessary. All repairs made by Tenant shall utilize materials and equipment which are at least equal in quality and usefulness to those originally used in constructing the Building and the Premises. Tenant shall also repair and maintain any openings in the roof or walls specifically installed by or for Tenant with Landlord's prior written consent.

(b) Tenant shall pay Landlord's costs to service, repair and maintain HVAC equipment, any fire suppression system (including alarm monitoring) and any other service which pertains to the Premises. Tenant shall have the option to purchase and maintain its own service contract on the HVAC equipment so long as Landlord has given its prior written consent to the service agreement.

(c) All repairs required pursuant to this subsection shall be completed within thirty (30) days after written notice from Landlord. If Tenant does not complete these repairs within thirty (30) days, Landlord has the right to make the repairs and charge Tenant for same.

(d) Landlord, throughout the Term of this Lease shall make all necessary repairs to the footings and foundations, roof, external walls and structural steel columns and girders forming a part of the Premises (excluding doors, windows and other apertures); provided, however, that Landlord shall have no responsibility to make any repair unless and until Landlord receives written notice of the need for such repair from Tenant. Tenant shall pay the cost of any repairs made pursuant to this paragraph as same are occasioned by the act, omission or negligence of Tenant, its employees or invitees.

13. ALTERATIONS AND TRADE FIXTURES. (a) Tenant shall not make any alterations, additions, or improvements (collectively "Alterations") to the Building or Property and shall not make any Alteration to the Premises without Landlord's prior written consent. All Alterations made by either of the parties hereto upon the Premises, except moveable and detached or detachable office furniture, partitions, and machinery and equipment put in at Tenant's expense, shall be the property of Landlord, and shall remain upon and be surrendered with the Premises, as part thereof at the termination of this Lease or at the option of Landlord, said Alterations shall be removed by Tenant at Tenant's sole cost and expense (failing which, Landlord may remove such alterations and invoice Tenant for such work, which amount shall be Additional Rent immediately due hereunder). Any damages caused by or arising from Tenant's removal of any Alterations shall be restored or repaired at Tenant's expense. Tenant shall be solely responsible for removing all telephone, telefax, computer and other communications wiring, cabling and equipment and shall repair all damages caused by or arising from such removal at Tenant's expense.

(b) All labor and materials furnished by or on behalf of Tenant under or pursuant to this Lease shall be first class, not less than the caliber and quality which exists in the Premises and by contractors approved in writing by Landlord and shall be accomplished at times so as not to disturb the business of other tenants. Tenant shall not install any Alterations in such a manner as to compromise the structural integrity or impair the economic value or marketability of the Premises or any part thereof. The labor and materials shall be installed in complete conformity to all applicable statutes, codes, ordinances and regulations.

5

(c) Landlord agrees that it will not unreasonably withhold or delay its consent to any interior nonstructural Alterations to the Premises which do not affect any Building systems. Tenant agrees that it will submit to Landlord sealed plans and specifications along with the name and address of the proposed contractor and all subcontractors as part of any request made hereunder. Prior to commencing the work, Tenant will furnish Landlord with copies of all governmental permits, certificates establishing that its contractor and subcontractors have adequate insurance coverages naming Landlord (and any property manager) and Landlord's mortgagee as additional insureds. If Landlord has installed a master lock system Tenant agrees that under no circumstances will it change any of the exterior locks thereby making it impossible for Landlord to gain access with its master key.

14. ACCESS TO PREMISES. Landlord, its employees and agents shall have the right to enter the Premises at all reasonable times for the purpose of examining or inspecting the same, showing the same to prospective purchasers, mortgagees or tenants of the Building, and making such alterations, repairs, improvements or additions to the Premises or to the Building as may be necessary. If representatives of Tenant shall not be present to open and permit entry into the Premises at any time when such entry by Landlord is necessary or permitted hereunder, Landlord may enter by means of a master key (or forcibly in the event of an emergency) without liability to Tenant and without such entry constituting an eviction of Tenant or termination of this Lease.

15. ENVIRONMENTAL COMPLIANCE. (a) Tenant represents and warrants that Tenant's SIC (Standard Industrial Classification) number as designated in the Standard Classification Manual prepared by the Office of Management and Budget, and as set forth in Article 1(g) hereof, is correct. Tenant recognizes that for purposes of the Industrial Site Recovery Act (formerly known as the Environmental Cleanup Responsibility Act), N.J.S.A. 13:1K-6 et.seq. ("ISRA"), Tenant will acquire the SIC number of any entity for which it provides all or substantially all of its services or products. Tenant represents that the specific activities intended to be carried on in the Premises are in accordance with Article 1(n) and Tenant covenants and agrees that it will not do or suffer anything which will cause its SIC number (or that of any assignee or subtenant) to change so as to fall within any of the following "major group" classifications of SIC numbers during the Term or exercised renewal term hereof: 22 through 39 inclusive, 46 through 49 inclusive, 51 and 76 (together the "Covered Numbers"). Tenant further covenants and agrees to notify Landlord at least thirty days (30) prior to any change of facts which would result in the change of Tenant's SIC number from its present number to any of the Covered Numbers. Upon such notice, Landlord shall have the right, at its option, to terminate this Lease within thirty (30) days of receipt of such notice by notifying Tenant in writing.

(b) Tenant shall not engage in operations at the Premises which involve the unlawful generation, manufacture, refining, transportation, treatment, storage, handling or disposal of "hazardous substances" or "hazardous waste" as such terms are defined under ISRA. Tenant further covenants that it will not cause or permit to exist any Discharge (as such term is defined under ISRA) on or about the Premises.

(c) If Tenant's operations on the Premises now or hereafter constitute an "Industrial Establishment" subject to the requirements of ISRA, then prior to: (i) any sale or transfer of the Premises, (ii) Closing operations or Transferring ownership or operations of Tenant at the Premises (as defined under ISRA), (iii) the expiration or sooner termination of this Lease, or (iv) any assignment of this Lease or any subletting of any portion of the Premises; Tenant shall, at its expense, comply with all requirements of ISRA pertaining thereto. Without limitation of the foregoing, Tenant's obligations shall include (i) the proper filing of an initial notice under N.J.S.A. 13:1K-9(a) to the New Jersey Department of Environmental Protection ("NJDEP"), and (ii) the performance of all remediation and other requirements of ISRA, including without limitation all requirements of N.J.S.A. 13:1K-9(b) through and including (i). Upon written request of Landlord, Tenant shall cooperate with Landlord in obtaining evidence of compliance with ISRA or any other law, regulation, or order of any governmental authority, which cooperation shall include, without limitation, providing affidavits, reports, or responses to questions.

(d) The parties acknowledge and agree that, pursuant to the provisions of Section 20(c) of ISRA, Tenant shall be, and is hereby, designated the party responsible (the "Party Responsible") to comply with the requirements of ISRA (P.L. 1983, c.330), and that as a result of DEP shall compel Tenant to so comply. In addition, any failure of Tenant to provide any information and submission as required under Section 20(a) and Section 20(c) of ISRA shall constitute a default under this Lease. Any assignee or subtenant of Tenant shall be deemed to have, and by entering into such assignment or sublease, and/or by entering into possession of the Premises, does hereby, acknowledge that they shall be the Party Responsible, jointly and severally with Tenant, under the provisions of this Lease.

(e) In the event of Tenant's failure to comply in full with this Article 15, Landlord may, at its option, perform any and all of Tenant's obligations as aforesaid and all costs and expenses incurred by Landlord in the exercise of this right shall be deemed to be Additional Rent payable on demand and with interest at the Rate until payment.

6

(f) In the event Tenant is obligated, under this Article or otherwise, to perform and/or cooperate in performing any ISRA obligations and/or obtain and/or cooperate in obtaining any ISRA approval, by way of a non-applicability letter, " negative declaration", the performance of an approved remedial action work plan, the obtaining of a no further action letter, the performance under a remediation agreement and/or otherwise (collectively the "ISRA Obligations") and, prior to fully performing such ISRA Obligations, there occurs the scheduled expiration of the Term of this Lease or any other termination of this Lease (collectively, a "Lease Termination"), Tenant shall, following such Lease Termination, pay, at the time and in the manner Base Rent payments were due during the Term, an amount equal to: (i) Base Rent at twice the rate in effect immediately prior to such Lease Termination; and (ii) Additional Rent as provided under the Lease; until such time as all such ISRA Obligations have been fully completed.

(g) Tenant shall promptly provide Landlord with all documentation and correspondence, reports, notices and submissions: (i) provided to NJDEP pursuant to the Worker and Community Right to Know Act, N.J.S.A. 34:5A-1 et seq. and the regulations promulgated thereunder ("Right to Know Act"); (ii) pursuant to the Hazardous Substance Discharge-Reports and Notices Act, N.J.S.A. 13:1K-1 5 et seq. and the regulations promulgated thereunder ("Reports and Notices Act"); (iii) to NJDEP, the United States Environmental Protection Agency (EPA), the United States Occupational Safety and Health Administration (OSHA), or any other local, state or federal authority which requires submission of any information concerning environmental matters or hazardous wastes or substances. Should the Property be located in a state other than the state of New Jersey then the provisions of subparagraphs (i) and (ii) shall be deemed to pertain to the applicable laws of the state in which the Property is located (e.g. if located in Pennsylvania, the Pennsylvania Worker and Community Right to Know Act, 35 P.S. Section 7301 et seq.) The copies and notices required by this paragraph to be submitted to Landlord shall only pertain to the Property and not to any other site or location where Tenant may occupy another facility.

(h) Tenant shall indemnify, defend and save harmless Landlord from and against any and all fines, suits, proceedings, claims and/or actions of any kind and any and all losses, costs, damages and expenses (including, without limitation, attorney's fees) arising out of or in any way connected with any
(i) spills, releases or discharges of hazardous material at the Premises which occur during the Term of this Lease (including any renewal periods); (ii) Tenant's failure to provide all information, make all submissions and take all actions required by any governmental authority; (iii) Tenant's failure to comply with all requirements of ISRA (as required herein); (iv) violation of any environmental law; and/or (v) breach of any provision of this Article 15. Notwithstanding anything provided herein to the contrary, in no event shall Tenant's indemnification, defense and hold harmless obligation apply with respect to, nor shall Tenant have any responsibility for, any spills, releases or discharges of hazardous material at the Premises which occurred prior to the Term of this Lease (unless actually caused by Tenant, its contractors, agents or invitees).

(i) In the event that the Premises are located in Pennsylvania all reference to definitions contained in ISRA or any other New Jersey statutory references shall be changed to mean the Pennsylvania Solid Waste Management Act (35 P.S. Section 6018.101 et seq.), Pennsylvania Worker and Community Right to Know Act (35 P.S. Section 7301 et seq.) or other applicable Pennsylvania Statutes.

(j) This Article shall survive the expiration or sooner termination of this Lease.

16. ASSIGNMENT AND SUBLETTING. (a) Tenant shall have no right to assign or sublet by operation of law or otherwise, all or any part of the Premises without the prior written approval of Landlord.

(b) In the event Tenant desires to sublet the Premises or assign the Lease, Tenant shall give to Landlord written notice of Tenant's intended subtenant or assignee in order to secure Landlord's written consent. Within thirty (30) days of receipt of said notice, Landlord shall have the right: (i) to terminate this Lease by giving Tenant not less than thirty (30) days notice in the case of an assignment of the entire Lease or a subletting of more than fifty percent (50%) of the Premises or (ii) to terminate this Lease and simultaneously to enter into a new Lease with Tenant for that portion of the demised Premises Tenant may desire to retain upon the same terms, covenants and conditions of the existing Lease as applicable to the space retained. If Landlord exercises its right to terminate this Lease, Tenant agrees that Landlord shall have access to all or a portion of the demised Premises sixty
(60) days prior to the effective termination date for remodeling or redecorating purposes.

(c) On any approved subletting or assignment of all or any part of the Premises, (i) Landlord shall receive from Tenant all rent in excess of those defined herein and other profits relating to the premises derived by Tenant from the assignment or subletting; (ii) Tenant shall remain liable under all terms and conditions of this Lease; (iii) Landlord shall have the right to approve the subtenant or assignee and the sublease or assignment documents (and any assignee or subtenant must agree therein to assume all terms, conditions and obligations of the Lease) and (iv) Tenant shall be solely responsible for obtaining, at Tenant's cost, any certificate of occupancy or other permits required for occupancy of the Premises by and permitted subtenant or assignee. In the event of default by Tenant under the terms and conditions of this Lease at such time that all or part of the Premises are then sublet, Landlord may collect

7

directly from the subtenant(s) all rents becoming due to Tenant under the Sublease(s) and apply such rents against any sums due to Landlord by Tenant under this Lease, and Tenant hereby authorizes and directs such subtenant(s) to make such payment of rent to Landlord upon receipt of notice from Landlord. Such collection of rent by Landlord shall not constitute a novation or a release of Tenant from its liability under the terms and conditions of this Lease.

(d) The written approval of Landlord to one or more sublettings or assignments shall not operate as a waiver of Landlord's right to approve any further sublettings and assignments.

(e) Tenant shall not (i) mortgage, pledge or otherwise encumber its interest in this Lease or (ii) grant any license, concession or other right of occupancy of any portion of the Premises, without the prior written consent of Landlord.

(f) As a condition precedent to Tenant's right to sublease the Premises or to assign this Lease, Tenant shall, at Tenant's own expense, comply with ISRA. Tenant shall promptly furnish to Landlord true and complete copies of all documents, submissions and correspondence provided by Tenant to the New Jersey Department of Environmental Protection (NJDEP) and all documents, reports, directives and correspondence provided by the NJDEP to Tenant. Tenant shall also promptly furnish to Landlord true and complete copies of all sampling and test results obtained from samples and tests taken at and around the Premises. As a condition precedent to Tenant's right to sublease the Premises or to assign the Lease, Tenant shall have received from the NJDEP either (i) a non-qualified approval of Tenant's negative declaration or (ii) a non-applicability letter, for which Tenant shall promptly apply pursuant to ISRA. If this condition shall not be satisfied, then Landlord shall have the right to withhold consent to sublease or assignment.

(g) Nothing herein to the contrary withstanding, Landlord's written consent shall not be required for any sublease or assignment of this Lease to any other entity which controls or is controlled by Tenant provided that Tenant shall continue to remain liable in such instance. Tenant shall be required to give Landlord thirty (30) days written notice in advance of any such subleasing or assignment.

(h) Tenant agrees that any subleasing or assignment to any person, firm, partnership or corporation which is not an actual user of the Premises is absolutely prohibited and nothing herein shall require Landlord to consent to any such assignment. In addition, subleases or assignments are absolutely prohibited to any person, firm, entity or corporation which (i) at such time is a tenant in any building owned by Landlord or any affiliate of Landlord or (ii) is currently or has within six (6) months prior to the date of the proposed sublease or assignment actively been discussing a proposed lease with Landlord or any affiliate of Landlord.

17. MECHANICS' LIENS. If any mechanics' or other lien shall be filed against the Property, Premises or the Building for labor or material furnished or to be furnished at the request of Tenant, then Tenant shall at its expense cause such lien to be discharged of record by payment, bond or otherwise, within ten (10) days after the filing thereof. If Tenant shall fail to cause such lien to be discharged of record within such ten (10) day period, Landlord may cause such lien to be discharged by payment, bond or otherwise, without investigation as to the validity thereof or as to any offsets or defenses thereto. The cost to Landlord for removal of such lien will be charged to Tenant as Additional Rent and payable on the first day of the month next following the payment by Landlord together with interest until payment at a rate (the "Rate") equal to four (4%) percent per annum over the then domestic prime rate (the base rate on corporate loans at large U.S. money center commercial banking) or equivalent rate as announced daily in The Wall Street Journal under the heading "Money Rates". Tenant shall indemnify and hold Landlord harmless against any and all claims, costs, damages, liabilities and expenses (including reasonable attorney fees) which may be brought or imposed against or incurred by Landlord by reason of any such lien or its discharge.

18. INDEMNIFICATION AND LIABILITY INSURANCE. (a) Tenant covenants and agrees that it shall, at its own cost and expense, indemnify and save harmless Landlord, any affiliate of Landlord, any property manager or agent for Landlord and all of their respective officers, directors, owners and employees (together the "Protected Parties") against and from, and the Protected Parties shall not be liable to Tenant for, any and all claims by or on behalf of any person, entity, firm or corporation arising in any manner whatsoever from, out of or in connection with (i) the use and occupancy of the Property by Tenant; (ii) failure to perform any of the terms or conditions of this Lease required to be performed by Tenant; (ii) failure to perform any of the terms or conditions of this Lease required to be performed by Tenant; (iii) any failure by Tenant to comply with any statutes, regulation, ordinances or orders of any governmental authority; or (iv) any accident, death, injury, or damage, loss or theft of property in or about the Property (whether involving property belonging to Tenant or any other person) resulting from any cause whatsoever, unless such accident, death, injury, damage, loss or theft is caused by the sole negligence of the Protected Parties, and from and against all costs, attorney fees, expenses and liabilities incurred in or as a result of any such claim or action or proceeding brought against the Protected Parties by reason of any such claim. Tenant, upon notice from the Protected Parties, covenants to resist or defend such action or proceeding by legal counsel reasonably satisfactory to the Protected Parties.

8

(b) During the Term of this Lease and any renewal thereof, Tenant shall obtain and promptly pay all premiums for commercial general liability insurance with respect to the Property, covering at least the hazards of "premises/operations", "independent contractors" and "contractual liability" with a per occurrence limit of not less than $1,000,000.00 combined bodily injury and property damage, and an aggregate limit of not less than $2,000,000.00. On or before the commencement date of the Term of this Lease, and thereafter not less than fifteen (15) days prior to the expiration dates of said policy or policies, Tenant shall provide copies of policies or certificates of insurance evidencing coverage required by this Lease.

(c) Landlord shall insure the Building of which the Premises are a part and any improvements constructed by Landlord in accordance with Article 10 and Tenant shall insure the trade fixtures, equipment (including but not limited to all equipment, machinery, furnishings and inventory) and any tenant improvements and/or Alterations constructed by Tenant against loss or damage by fire and such other risks as may be included in the broadest form of extended coverage insurance including sprinkler leakage.

(d) Tenant shall not engage in any activity or store any product or material in the Premises which will either cause an increase in the insurance on the entire Building or which will make the Building uninsurable. In the event Tenant engages in any activity or stores any product or material in the Premises which causes an increase in the insurance on the entire Building (nothing contained herein being intended to authorize or permit same) Tenant shall pay, on demand, as Additional Rent from time to time, all such increased cost of insurance.

(e) All Tenant's policies of insurance (and renewals) required to be carried hereunder shall (i) be with insurance companies with an "A.M. Best" rating of A or above; (ii) shall name Landlord, its property manager and any mortgagee as an additional insured, and Landlord as a loss payee; (iii) provide that no material change or cancellation of said policies shall be made without thirty (30) days prior written notice to Landlord; (iv) provide that any loss shall be payable notwithstanding any act or negligence of Landlord which might otherwise result in the forfeiture of said insurance; (v) provide that the insurance company issuing the same shall have no right of subrogation against Landlord; and (vi) provide that as to the interest of Landlord, the insurance afforded by the policy shall not be invalidated by any breach or violation by Tenant of any of the warranties, declarations or conditions in the policy.

(f) If, in Landlord's sole discretion, Landlord allows Tenant to self insure any of the coverage required under this Article 18, Tenant shall deliver to Landlord a certificate in the form of Exhibit "E" attached hereto.

19. WAIVER OF SUBROGATION. Tenant and Landlord, respectively, hereby release each other from any and all liability or responsibility to the other for anyone claiming by, through or under it or them by way of subrogation or otherwise for any loss or damage to property covered by any insurance then in force, even if such loss or damage shall have been caused by the fault or negligence of the other party or anyone for whom such party may be responsible; provided, however, that this release shall be applicable and in force and effect only with respect to any loss or damage occurring during such time as the policy or policies of insurance covering said loss shall contain a clause or endorsement to the effect that this release shall not adversely affect or impair such insurance or prejudice the right of the insured to recover thereunder. Landlord and Tenant each agree to use their best efforts to obtain such a waiver in all applicable insurance policies, failing which such party shall immediately notify the other of such inability to obtain a waiver and provide with such notice written evidence of all attempts to procure same and the written rejection of the insurers consulted.

20. WAIVER OF CLAIMS. Except to the extent resulting from the gross negligence or willful misconduct of the applicable Protected Party, the Protected Parties shall not be liable for, and Tenant hereby releases and relieves the Protected Parties from, all liability in connection with any and all loss of life, personal injury, damage to or loss of property, or loss or interruption of business occurring to Tenant, its agents, servants, employees, invitees, licensees, visitors, or any other person, firm, corporation or entity, in or about or arising out of the Premises, from, without limitation,
(a) any fire, other casualty, accident, occurrence or condition in or upon the Premises, Building and/or Property; (b) any defect in or failure of (i) plumbing, sprinkling, electrical, heating or air conditioning systems or equipment, telecommunication conduit, lines and equipment or any other systems and equipment of the Premises and the Building, and (ii) the elevators, stairways, railings or walkways of the Building and/or Property; (c) any steam, gas, oil, water, rain or snow that may leak into, issue or flow from any part of the Premises, Building and/or Property from the drains, pipes, roof, or plumbing, sewer or other installation of same, or from any other place or quarter; (d) the breaking or disrepair of any installations and equipment; (e) the falling of any fixture or any wall or ceiling materials; (f) damaged or broken interior or exterior glass; (g) latent or patent defects; (h) the exercise of any rights by Landlord under the terms and conditions of this Lease; (i) any acts or omissions of the other tenants or occupants of the Building or of nearby buildings; (j) any acts or omissions of other persons or requirements or restrictions of governmental entities; (k) any acts or omissions of the Protected Parties; and (l) theft, acts of God, public enemy, injunction, riot, strike, insurrection, war, court order or any order of any governmental authorities having jurisdiction over the Premises.

9

21. FIRE OR OTHER CASUALTY. (a) Subject to paragraphs (b), (c) and (d) of this Article 21 below, if the Premises are damaged by fire or other casualty, the damage shall be repaired by and at the expense of Landlord and the Rent until such repairs shall be made shall be apportioned from the date of such fire or other casualty according to the part of the Premises which is usable by Tenant. Landlord agrees to repair such damage within a reasonable period of time after receipt from Tenant of written notice of such damage, except that Tenant agrees to repair and replace its own furniture, furnishings, equipment and any alteration or improvement installed by Tenant. Landlord shall not be liable for any inconvenience or annoyance to Tenant or injury to the business of Tenant resulting from such damage or the repair thereof.

(b) If the Premises, in the opinion of Landlord's licensed architect or engineer, are (i) rendered substantially untenantable by reason of such fire or other casualty; or (ii) twenty (20)% percent or more of the Premises is damaged by said fire or other casualty and less than six (6) months would remain on the Lease Term or any renewal thereof upon completion of the repairs or reconstruction; or (iii) fifty (50%) percent or more on the Premises is damaged by said fire or other casualty; then in any such events Landlord shall have the right to be exercised by notice in writing delivered to Tenant within thirty
(30) days from and after said occurrence, to elect to terminate this Lease, and, in such event, this Lease and the tenancy hereby created shall cease as of the date of said occurrence, the Rent to be adjusted as of said date.

(c) If the Building, in the sole opinion of Landlord, shall be substantially damaged by fire or other casualty, regardless of whether or not the Premises were damaged by such occurrence, Landlord shall have the right, to be exercised by notice in writing delivered to Tenant within thirty (30) days from and after said occurrence, to terminate this Lease; and in such event, this Lease and the tenancy hereby created shall cease as of the date of said termination, the Rent to be adjusted as of the date of such termination.

(d) In the event that any mortgagee unilaterally refuses to make the proceeds of any policy of insurance available for restoration, Landlord shall have the right, to be exercise by notice in writing delivered to Tenant within thirty (30) days from notice of such refusal to terminate this Lease and in such event, this Lease and the tenancy hereby created shall cease as of the date of said termination, the Rent to be adjusted as of the date of such termination.

22. CONDEMNATION. (a) If the whole of the Premises shall be condemned or taken either permanently or temporarily for any public or quasi-public use or purpose, under any statute or by right of eminent domain, or by private purchase in lieu thereof, then in that event the Term of this Lease shall cease and terminate from the date when possession is taken thereunder pursuant to such proceeding or purchase. The rent shall be adjusted as of the time of such termination and any rent paid for a period thereafter shall be refunded. In the event more than fifteen (15%) percent of the Building containing same shall be so taken (or if more than fifty (50%) percent of the parking areas are taken and not promptly replaced with contiguous parking areas) then Landlord may elect to terminate this Lease from the date when possession is taken thereunder pursuant to such proceeding or purchase or, Landlord shall repair and restore, at its own expense, the portion not taken and thereafter the rent shall be reduced proportionately to the portion of the Premises taken.

(b) In the event of any total or partial taking of the Premises or the Building, Landlord shall be entitled to receive the entire award in such proceeding and Tenant may make a separate application for Tenant's fixtures, equipment and moving expenses under the then applicable New Jersey eminent domain code, but Tenant shall not make any claim that will detract from or diminish any award for which Landlord may make a claim.

(c) If the Premises or the Building are declared unsafe by any duly constituted authority having the power to make such determination, or are the subject of a violation notice or notice requiring repair or reconstruction which cannot be repaired by Landlord at its sole cost and expense within thirty
(30) days, then Landlord at its option, may terminate this Lease, and in such event, Tenant shall immediately surrender said Premises to Landlord and thereupon this Lease shall terminate and the rent shall be apportioned as of the date of such termination.

23. ESTOPPEL CERTIFICATE. Tenant shall, at any time and from time to time, within ten (10) days after written request by Landlord, execute, acknowledge and deliver to Landlord, or its mortgagee or trustee, a statement in writing duly executed by Tenant (a) certifying that this Lease is in full force and effect (if that be the case) without modification or amendment (or, if there have been any modifications or amendments, that this Lease is in full force and effect as modified and amended and setting forth the modifications or amendments); (b) certifying the dates to which Base Rent and Additional Rent have been paid; (c) either certifying that to the knowledge of Tenant no default exists under this Lease or specifying each such default; and (d) providing such other information as Landlords purchaser or mortgagee may reasonably request; it being the intention and agreement of Landlord and Tenant that any such statement by Tenant may be relied upon by a prospective purchaser or a prospective or current mortgagee of the Building, or by others, in any matter affecting the Premises.

10

24. TENANT'S DEFAULT. (a) The occurrence of any of the following shall constitute a material default and breach of this Lease by Tenant:

(i) failure of Tenant to accept possession of the Premises within thirty (30) days after the date of issuance of a certificate of occupancy;

(ii) a failure by Tenant to pay, within five (5) days after written notice, any installment of Rent hereunder or any Additional Rent or any such other sum herein required to be paid by Tenant;

(iii) if any representation or warranty of Tenant or guarantor, if any, set forth in any notice, certificate, demand, request or other instrument delivered pursuant to, or in connection with, this Lease shall prove to be either false or misleading in any respect as of the time when the same shall have been made;

(iv) a failure by Tenant to observe and perform any other provisions or covenants of this Lease to be observed or performed by Tenant, where such failure continues for thirty (30) days after written notice thereof from Landlord to Tenant provided, however, that if the nature of the default is such that the same cannot reasonably be cured within such thirty (30) day period, Tenant shall not be deemed to be in default if Tenant shall within such period commence such cure and thereafter diligently prosecute the same to completion (but in no event shall such cure period exceed an additional thirty
(30) days).

(b) Upon the occurrence of any such event of default set forth above:

(i) Landlord may (but shall not be required to) perform for the account of Tenant any such default of Tenant and immediately recover as Additional Rent any expenditure made and the amount of any obligations incurred in connection therewith, plus interest at the Rate (as defined in Article 17 hereof) from the date of such expenditure;

(ii) Landlord may at its option accelerate all Rent and Additional Rent due for the balance of the Term of this Lease and declare the same to be immediately due and payable as liquidated damages;

(iii) Landlord, at its option, may serve notice upon Tenant that this Lease and the then unexpired Term hereof and all renewal options shall cease and expire and become absolutely void on the date specified in such notice, to be not less than five (5) days after the date of such notice without any right on the part of Tenant to save the forfeiture by payment of any sum due or by the performance of any terms, provision, covenant, agreement or condition broken; and, thereupon and at the expiration of the time limit in such notice, the Lease and the Term hereof granted, as well as the right, title and interest of Tenant hereunder, shall wholly cease and expire and become void in the same manner and with the same force and effect (except as to Tenant's liability) as if the date fixed in such notice were the date herein granted for expiration of the Term of this Lease. Thereupon, Tenant shall immediately quit and surrender to Landlord the Premises, and Landlord may enter into and repossess the Premises by summary proceedings, detainer, ejectment or otherwise and remove all occupants thereof and, at Landlord's option, any property thereon without being liable to indictment, prosecution or damages therefor. No such expiration or termination of this Lease shall relieve Tenant of its liability and obligations under this Lease, whether or not the Premises shall be relet;

(iv) Landlord may, at any time after the occurrence of any event of default, re-enter and repossess the Premises and any part thereof and attempt in its own name, as agent for Tenant if this Lease not be terminated or in its own behalf if this Lease be terminated, to relet all or any part of such Premises for and upon such terms and to such persons, firms or corporations and for such period or periods as Landlord, in its sole discretion, shall determine, including the term beyond the termination of this Lease; and Landlord shall not be required to accept any tenant offered by Tenant or observe any instruction given by Tenant about such reletting. For the purpose of such reletting, Landlord may make repairs and alterations as necessary in Landlord's judgment to relet the Premises; and the cost of such repairs and alterations shall be charged to and be payable by Tenant as Additional Rent hereunder, as well as any reasonable brokerage and legal fees expended by Landlord; and any sums collected by Landlord from any new tenant obtained on account of Tenant shall be credited against the balance of the Rent due hereunder as aforesaid. Landlord shall be entitled to recover from Tenant all damages and losses incurred by Landlord pursuant to the laws of the state of New Jersey and this subparagraph including, but not limited to (a) the loss of all Rent and Additional Rent until the Premises is released and any anticipated loss of future Rent to the end of the Term of this Lease if the Rent and Additional Rent payable by any new tenant is less than the amount which would have been payable by Tenant until the end of the Term; (b) an amount equal to any rental concessions received by Tenant; and
(c) an amount equal to the unamortized cost of the improvements furnished and installed by Landlord under this Lease;

11

(v) Landlord shall have the right of injunction, in the event of a breach or threatened breach by Tenant of any of the agreements, conditions, covenants or terms hereof, including the actual or threatened failure to vacate the Premises at the end of the Term, to restrain the same and the right to invoke any remedy allowed by law or in equity, whether or not other remedies, indemnity or reimbursements are herein provided. Landlord shall have the right of distraint upon Tenant's goods pursuant to N.J.S.A. 2A:33-1 et seq. upon adequate notice consistent with due process. The right and remedies given to Landlord in this Lease are distinct, separate and cumulative remedies; and no one of them, whether or not exercised by Landlord, shall be deemed to be in exclusion of any of the others;

(vi) In the event Tenant fails to vacate the Premises upon the expiration of this or any extended Term hereunder or upon termination of this Lease, Tenant shall pay to Landlord double the Rent and Additional Rent due and payable for the month in which this Lease expired or terminated and for the two
(2) subsequent months of any holdover by Tenant, and triple the Rent and Additional Rent for any period beyond two months, but such payment shall not preclude Landlord's right to seek eviction of Tenant nor constitute a consent by Landlord to such holdover by Tenant;

(vii) In addition to all remedies provided herein or by law, Tenant shall pay to Landlord reasonable attorneys fees and court costs incurred as a result of such breach;

(viii) Should Tenant fail to pay any sum required hereunder within any applicable grace period or should Tenant fail to perform or commit any other act which would enable Landlord to declare a default, in lieu of the declaration of default, Landlord shall have the option to suspend, without any liability to Tenant, any maintenance, repair or other service which it is required by the terms of this Lease to supply until such time as Tenant has paid to Landlord the delinquent payment or otherwise cured any event which would enable Landlord to declare the Lease in default;

(ix) Landlord may, but shall not be obligated to, without prejudice and in addition to any other rights it may have in law or equity, after giving Tenant written notice of such default and after failure by Tenant within thirty (30) days of the receipt of such notice to correct or to undertake and diligently pursue correction of said default(s) (which notice and/or opportunity to cure shall not be required in case Landlord shall determine that an emergency exists requiring prompt action), cure such default(s) on behalf of Tenant; and Tenant shall reimburse Landlord on demand for all costs incurred by Landlord in that regard plus interest thereon from the date(s) of expenditure at the Rate (as defined in Article 17 hereof) which shall be deemed Additional Rent payable hereunder.

(x) No right or remedy herein conferred upon or reserved to Landlord is intended to be exclusive of any other right or remedy, and each and every right and remedy shall be cumulative and in addition to any other right or remedy given hereunder or now or hereafter existing at law or in equity or by statute. The failure of Landlord to insist at any time upon the strict performance of any covenant or agreement or to exercise any option, right, power or remedy contained in this Lease shall not be construed as a waiver or a relinquishment thereof for the future. A receipt by Landlord of any Rent, any Additional Rent or any other sum payable hereunder with knowledge of the breach of any covenant or agreement contained in this Lease shall not be deemed a waiver of such breach, and no waiver by Landlord of any provision of this Lease shall be deemed to have been made unless expressed in writing and signed by Landlord. In addition to other remedies provided in this Lease, Landlord shall be entitled, to the extent permitted by applicable law, to injunctive relief in case of the violation, or attempted or threatened violation, of any of the covenants, agreements, conditions or provisions of this Lease, or to decree compelling performance of any of the covenants, agreements, conditions or provisions of this Lease, or to any other remedy allowed to Landlord at law or in equity;

(xi) Tenant hereby waives and surrenders for itself and all those claiming under it, including creditors of all kinds, (i) any right or privilege which it or any of them may have under any present or future constitution, statute or rule of law to redeem the Premises or to have a continuance of this Lease for the Term hereby demised after termination of Tenant's right of occupancy by order or judgment of any court or by any legal process or writ, or under the terms of this Lease or after the termination of the Term of this Lease as herein provided, and (ii) the benefits of any present or future constitution, statute or rule of law which exempts property from liability for debt or for distress for rent.

25. REQUIREMENT OF STRICT PERFORMANCE. The failure or delay on the part of either party to enforce or exercise at any time any of the provisions, rights or remedies in the Lease shall in no way be construed to be a waiver thereof, nor in any way to affect the validity of this Lease or any part hereof, or the right of the party to thereafter enforce each and every such provision, right or remedy. No waiver of any breach of this Lease shall be held to be a waiver of any other or subsequent breach. The receipt by Landlord of rent at a time when the rent is in default under this Lease shall not be construed as a waiver of such default. The receipt by Landlord of a lesser amount than the rent due shall not be construed to be other than a payment on account of the rent then due, nor shall any statement on Tenant's check or any letter accompanying Tenant's check be deemed an accord and satisfaction, and Landlord may accept such payment without prejudice to Landlord's right to recover the balance of the rent due or to pursue any other remedies provided in this Lease. No act or thing done by Landlord or Landlord's agents

12

or employees during the Term of this Lease shall be deemed an acceptance of a surrender of the Premises, and no agreement to accept such a surrender shall be valid unless in writing and signed by Landlord.

26. RELOCATION OF TENANT. Landlord, at its sole expense, on at least sixty (60) days prior written notice, may require Tenant to move from the Premises to another unit of comparable size and decor in order to permit Landlord to consolidate the Premises with other adjoining space leased or to be leased to another tenant in or coming into the Building provided, however, that in the event of receipt of any such notice, Tenant by written notice to Landlord within ten (10) days of the giving of Landlord's notice may elect not to move to the other space and in lieu thereof to terminate this Lease. In the event of any such relocation, Landlord will pay all the expenses of preparing and decorating the new premises so that they will be substantially similar to the Premises and the expense of moving Tenant's furniture and equipment to the relocated premises. Occupancy of the new Premises shall be under and pursuant to the terms of this Lease.

27. SUBORDINATION; RIGHTS OF MORTGAGEE. (a) This Lease shall be subject and subordinate at all times to the lien of any mortgages now or hereafter placed upon the Property, Premises or the Building without the necessity of any further instrument or act on the part of Tenant to effectuate such subordination. Tenant further agrees to execute and deliver upon demand such further instrument or instruments evidencing such subordination of this Lease to the lien of any such mortgage and such further instrument or instruments of attornment as shall be desired by any mortgagee or proposed mortgagee or by any other person. Notwithstanding the foregoing, any mortgagee may at any time subordinate its mortgage to this Lease, without Tenant's consent, by notice in writing to Tenant, and thereupon this Lease shall be deemed prior to such mortgage without regard to their respective dates of execution and delivery and in that event such mortgagee shall have the same rights with respect to this Lease as though it had been executed prior to the execution and delivery of the mortgage.

(b) In the event Landlord shall be or is alleged to be in default of any of its obligations owing to Tenant under this Lease, Tenant agrees to give to the holder of any mortgage (collectively the "Mortgagee") now or hereafter placed upon the Premises or the Building and the Land, notice by registered mail of any such default which Tenant shall have served upon Landlord, provided that prior thereto Tenant has been notified in writing (by way of Notice of Assignment of Rents and/or Leases or otherwise) of the name and address of any such Mortgagee. Tenant shall not be entitled to exercise any right or remedy as there may be because of any default by Landlord without having given such notice to the Mortgagee; and Tenant further agrees that if Landlord shall fail to cure such default: (i) the Mortgagee shall have an additional thirty (30) days (measured from the later of the date on which the default should have been cured by Landlord or the Mortgagee's receipt of such notice from Tenant) within which to cure such default, provided that if such default be such that the same could not be cured within such thirty (30) day period and the Mortgagee is diligently pursuing the remedies necessary to effectuate the cure (including but not limited to foreclosure proceedings if necessary to effectuate the cure), then the Mortgagee shall have such additional time as may be necessary for effectuating the cure within which to cure such default; and (ii) Tenant shall not exercise any right or remedy as there may be arising because of Landlord's default, including but not limited to termination of this Lease as may be expressly provided for herein or available to Tenant as a matter of law, if the Mortgagee either has cured the default within such thirty (30) day period or, as the case may be, has initiated the cure of same within such thirty (30) day period and is diligently pursuing the cure of same as aforesaid. Mortgage shall not be liable to Tenant for the return of any Security Deposit unless and to the extent actually received by such Mortgagee.

(c) In the event the Mortgagee acquires title to the Property, Premises or the Building by foreclosure, deed in lieu of foreclosure or pursuant to the exercise of any remedy provided in the mortgage held by such Mortgagee such Mortgagee shall not be (i) liable for any debt or omission of Landlord,
(ii) subject to any offset or deficiencies which Tenant might be entitled to assert against Landlord, (iii) bound by any payment of Rent made by Tenant to Landlord for more than one month in advance or (iv) bound by any agreement (other than this Lease) made by Tenant with Landlord without the prior written consent of the Mortgagee.

(d) No rights are to be conferred upon Tenant until this Lease has been signed by Landlord, approved by the Mortgagee if necessary and an executed copy of the Lease has been delivered to Tenant. No acceptance or deposit by Landlord or any payment called for hereunder shall bind Landlord until or unless it executes this Lease and returns a fully executed copy to Tenant. Tenant agrees that it will consent to the modification of any provision of this Lease requested by Landlord's current or future Mortgagees except in no case shall any such modification increase the amount of Rent payable hereunder or the amount of any other charge payable by Tenant pursuant to this Lease, or otherwise materially alter the rights or obligations of Landlord or Tenant under this Lease.

28. BANKRUPTCY AND INSOLVENCY. (a) In addition to the occurrences set forth in Article 24 herein, the following events shall constitute a default under this Lease: (i) Tenant admits in writing its inability to pay its debts as they mature; (ii) Tenant makes an assignment for the benefit of creditors or takes any other similar action for the protection or benefit of creditors; (iii) Tenant gives notice to any governmental body of insolvency or pending insolvency, or suspension or pending

13

suspension of operations; (iv) Tenant files a voluntary petition in bankruptcy or has an involuntary petition filed against him, her or it; (v) Tenant files any petition or answer seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution or other similar relief under any present or future bankruptcy statute, regulation or law; (vi) a court of competent jurisdiction enters an order, judgment or decree approving a petition filed against Tenant seeking any relief described in the preceding subparagraph
(v) and such order, judgment or decree shall remain unvacated and unstayed for an aggregate of thirty (30) days from the date of entry thereof; (vii) a trustee, receiver, conservator or liquidator of Tenant or of all or any substantial part of its property or its interest in the Premises is employed or appointed and such receivership remains undissolved for thirty (30) days; or
(viii) this Lease or any estate of Tenant hereunder is levied upon under any writ of attachment or execution, and such writ shall remain unvacated and unstayed for ten (10) days.

(b) Upon the filing of a petition by or against Tenant under the United States Bankruptcy Code, Tenant, as debtor in possession, and any Trustee who may be appointed agree to:

(i) Perform each and every obligation of Tenant under this Lease until such time as this Lease is either rejected or assumed by order of the United States bankruptcy Court;

(ii) Pay Rent in the manner and at the time provided hereunder as reasonable compensation for use and occupancy for the Premises;

(iii) Reject or assume this Lease within sixty (60) days of the filing of such petition under Chapter 7 of the Bankruptcy Code or within one hundred twenty (120) days (or such shorter term as Landlord, in its sole discretion, may deem reasonable so long as notice of such period is given) of the filing of a petition under any other Chapter;

(iv) Give Landlord at least forty-five (45) days prior written notice of any abandonment of the Premises, any such abandonment to be deemed a rejection of this Lease; and

(v) Do all other things of benefit to Landlord otherwise required under the Bankruptcy Code.

Tenant, as debtor in possession, and any such trustee shall be deemed to have rejected this Lease in the event of the failure to comply with any of the above requirements and to have consented to the entry of an order by an appropriate Bankruptcy Court providing all of the above, waiving all rights to notice of the entry of such order.

29. BROKERS. Tenant represents and warrants to Landlord that Tenant has had no dealings, negotiations or consultations with respect to the Premises or this transaction with any broker or finder other than the Broker, if any; and that otherwise no broker or finder called the Premises to Tenant's attention for lease or took any part in any dealings, negotiations or consultations with respect to the Premises or this Lease. Tenant agrees to indemnify and hold harmless Landlord from and against all liability, cost and expense, including attorney's fees and court costs, arising out of any misrepresentation or breach of warranty by Tenant under this Article 29.

30. LANDLORD'S OBLIGATIONS/LIABILITY. Landlord's obligations hereunder shall be binding upon Landlord only for the period of time that Landlord is in ownership of the Building; and, upon termination of that ownership, Tenant, except as to any obligations which have then matured, shall look solely to Landlord's successor in interest in the Building for the satisfaction of each and every obligation of Landlord hereunder. Landlord shall have no liability under any of the terms, conditions or covenants of this Lease and Tenant shall look solely to the equity of Landlord in the Building of which the Premises form a part for the satisfaction of any claim, remedy or cause of action accruing to Tenant as a result of the breach of any action of this Lease by Landlord.

31. LANDLORD'S SIGNS. Landlord shall have the right to display a "for sale" or "for rent" sign on the Premises or the property of which the Premises is a part, as the case may be, but any "for rent" sign shall not be displayed prior to six (6) months in advance of the end of the Term hereof.

32. QUIET ENJOYMENT. Tenant, upon the payment of all Rent and other charges provided for herein and upon the performance of all of the terms of this Lease, shall at all times during the Term hereof peacefully and quietly enjoy the Premises without any disturbance from Landlord or any person claiming through Landlord, subject, however, to the reservation and conditions of this Lease and any mortgage or encumbrance to which this Lease is subordinate.

33. TENANT'S AUTHORITY. Tenant warrants and represents that: (a) if it is a corporation it is in good standing organized and existing under the laws of its state of incorporation and that it is duly qualified to do business in the state in which the premises is located, that all corporate action necessary to authorize the execution of this Lease has been taken by the Board of Directors and that the President, and Secretary, have been authorized to execute and attest respectively this Lease; and (b) if is a partnership it is in good standing organized and existing under the laws of its state of

14

organization and that it is duly qualified to do business in the state in which the premises is located, that all partnership action necessary to authorize the execution of this Lease has been taken and the person or persons executing this Lease are authorized by the partnership agreement to bind the partnership. Tenant for good and valuable consideration shall indemnify and hold Landlord harmless from and against any and all claims, suits, proceedings, damages, obligations, liabilities, counsel fees, costs, losses, expenses, orders and judgments imposed upon, incurred by or asserted against Landlord by reason of the falsity or error of this aforesaid warranty.

34. NOTICES. Wherever in this Lease it shall be required or permitted that notice or demand be given or served by either party to this Lease to or on the other party, such notice or demand shall be deemed to have been duly given or served if in writing and either personally served or forwarded by nationally recognized overnight delivery service or Certified Mail, postage prepaid, to the address set forth in Article 1 (b) or (c), as applicable. Each such mailed notice shall be deemed to have been given to or served upon the party to which addressed two (2) days after the date the same is deposited in the United States Certified Mail, postage prepaid, and properly addressed to the addresses set forth in Articles 1 (b) and (c) of this Lease in the manner above provided, or one day after delivered to a nationally recognized overnight delivery service. Either party hereto may change its address to which said notices shall be delivered or mailed by giving written notice of such change to the other party hereto as herein provided.

LANDLORD: WHITESELL ENTERPRISES        TENANT: AMERICAN BIOMEDICA CORPORATION
          PO BOX 1605                          603 HERON DRIVE, UNIT 3
          DELRAN,NJ 08075-0117                 BRIDGEPORT, NJ, 08014

35. MISCELLANEOUS PROVISIONS.

A. Successors. The respective rights and obligations provided in this Lease shall bind and inure to the benefit of the parties hereto, their legal representatives, heirs, successors and assigns; provided, however, that no rights shall inure to the benefit of any successors of Tenant unless Landlord's written consent for the transfer to such successor has first been obtained as provided in Article 16 hereof.

B. Governing Law. This Lease shall be construed, governed and enforced in accordance with the laws of the state in which the Premises are located.

C. Severability. If any provisions of this Lease shall be held to be invalid, void or unenforceable, the remaining provisions hereof shall in no way be affected or impaired and such remaining provisions shall remain in full force and effect.

D. Captions. Marginal captions, titles or exhibits and riders and the table of contents in this Lease are for convenience and reference only, and are in no way to be construed as defining, limiting or modifying the scope of intent of the various provisions of this Lease.

E. Gender. As used in this Lease, the word "person" shall mean and include, where appropriate, an individual, corporation, partnership or other entity; the plural shall be substituted for the singular, and the singular for the plural, where appropriate; and the words of any gender shall mean to include any other gender.

F. Entire Agreement. This Lease, including the Exhibits and any Riders hereto (which are hereby incorporated by this reference, except that in the event of any conflict before the printed portions of this Lease and any Exhibits or Riders, the term of such Exhibits or Riders shall control), supersedes any prior discussions, proposals, negotiations and discussions between the parties and the Lease contains all the agreements, conditions, understandings, representations and warranties made between the parties hereto with respect to the subject matter hereof, and may not be modified orally or in any manner other than by an agreement in writing signed by both parties hereto or their respective successors in interest. Without in any way limiting the generality of the foregoing, this Lease can only be extended pursuant to the due exercise of an option (if any) contained herein or a formal agreement signed by both Landlord and Tenant specifically extending the terms. No negotiations, correspondence by Landlord or offers to extend the terms shall be deemed an extension of the termination date for any period whatsoever.

G. Counterparts. This Lease may be executed in any number of counterparts, each of which shall be deemed to be one and the same instrument.

H. Telefax Signatures. The parties acknowledge and agree that notwithstanding any law or presumption to the contrary a telefaxed signature of either party whether upon this Lease or any related document shall be deemed valid and binding and admissible by either party against the other as if same were an original ink signature.

15

36. WAIVER OF TRAIL BY JURY. LANDLORD AND TENANT WAIVE THE RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING BASED UPON, OR RELATED TO, THE SUBJECT MATTER OF THIS LEASE. THIS WAIVER IS KNOWINGLY, INTENTIONALLY, AND VOLUNTARILY MADE BY TENANT AND TENANT ACKNOWLEDGES THAT NEITHER LANDLORD NOR ANY PERSON ACTING ON BEHALF OF LANDLORD HAS MADE ANY REPRESENTATIONS OF FACT TO INDUCE THIS WAIVER OF TRIAL BY JURY OR IN ANY WAY TO MODIFY OR NULLIFY ITS EFFECT. TENANT FURTHER ACKNOWLEDGES THAT IT HAS BEEN REPRESENTED (OR HAS HAD THE OPPORTUNITY TO BE REPRESENTED) IN THE SIGNING OF THIS LEASE AND IN THE MAKING OF THIS WAIVER BY INDEPENDENT LEGAL COUNSEL, SELECTED OF ITS OWN FREE WILL, AND THAT IT HAS HAD THE OPPORTUNITY TO DISCUSS THIS WAIVER WITH COUNSEL. TENANT FURTHER ACKNOWLEDGES THAT IT HAS READ AND UNDERSTANDS THE MEANING AND RAMIFICATIONS OF THIS WAIVER PROVISION AND AS EVIDENCE OF SAME HAS EXECUTED THIS LEASE.

IN WITNESS WHEREOF, the parties hereto have duly executed this Lease and have initialed the Exhibits and any Riders hereto as of the day and year first above written.

WITNESS OR ATTEST:                       LANDLORD: WHITESELL ENTERPRISES

                                         By:
----------------------------                -----------------------------------
                                                  THOMAS R. WHITESELL

                                         TENANT: AMERICAN BIOMEDICA CORPORATION

                                         By: /s/ Douglas Casterlin
----------------------------                -----------------------------------
                                                 DOUGLAS CASTERLIN
                                                 V.P. & General Manager
                                                 American Biomedica Corporation

16

EXHIBIT 23.1

INDEPENDENT AUDITORS' CONSENT

We consent to the incorporation by reference in the Registration Statements of American Bio Medica Corporation (the "Company") on Form S-3 (File No. 333-16535), Form S-8 (File No. 333-91025) and Form S-8 (File No. 333-19203) of our report dated June 9, 2000 (with respect to the last paragraph of Note G July 20, 2000, the first and third paragraph of Note K[4](d), July 24, 2000, and the last paragraph of Note E, August 2, 2000) on our audit of the financial statements of the Company as of April 30, 2000 and for the years ended April 30, 2000 and 1999 which report is included in this Annual Report on Form 10-KSB. We also consent to the reference to our firm under the caption "Experts" in the Registration Statement on Form S-3.

Richard A. Eisner & Company, LLP

New York, New York
August 9, 2000


ARTICLE 5
This schedule contains summary financial information extracted from financial statements for the year ended April 30, 2000 and is qualified in its entirety by reference to such financial statements.


PERIOD TYPE 12 MOS
FISCAL YEAR END APR 30 2000
PERIOD END APR 30 2000
CASH 1,207,000
SECURITIES 74,000
RECEIVABLES 1,231,000
ALLOWANCES (81,000)
INVENTORY 1,332,000
CURRENT ASSETS 3,809,000
PP&E 611,000
DEPRECIATION (223,000)
TOTAL ASSETS 5,038,000
CURRENT LIABILITIES 1,793,000
BONDS 0
PREFERRED MANDATORY 0
PREFERRED 0
COMMON 180,000
OTHER SE 3,031,000
TOTAL LIABILITY AND EQUITY 5,038,000
SALES 7,653,000
TOTAL REVENUES 7,653,000
CGS 3,602,000
TOTAL COSTS 6,128,000
OTHER EXPENSES 38,000
LOSS PROVISION 0
INTEREST EXPENSE 21,000
INCOME PRETAX (2,136,000)
INCOME TAX 0
INCOME CONTINUING (2,136,000)
DISCONTINUED 0
EXTRAORDINARY 0
CHANGES 0
NET INCOME (2,136,000)
EPS BASIC (0.15)
EPS DILUTED (0.15)